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50 ABSTRACT
51 Objectives: To investigate the effectiveness of a complex behavioural intervention, ProLife, on 
52 tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking. 
53 Design: Multicentre, individual, randomised controlled trial where participants were assigned (1:1) 
54 to the ProLife intervention or usual care. 
55 Setting: 27 primary care clinics in South Africa.
56 Participants: 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or 
57 reported harmful/hazardous alcohol use.
58 Interventions: The intervention, delivered by lay health workers (LHWs), consisted of 3 brief 
59 motivational interviewing (MI) sessions, augmented with Short Message Service (SMS) messages, 
60 targeting medication adherence, alcohol use and tobacco smoking.
61 Outcome measures: The primary outcome was successful versus unsuccessful TB treatment at 6 to 9 
62 months, from TB records. Secondary outcomes were biochemically confirmed sustained smoking 
63 cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and 
64 antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 months by 
65 questionnaires; and cure rates in patients who had bacteriology-confirmed TB at baseline, from TB 
66 records.
67 Results: Between 15 November 2018 and 31 August 2019, 574 participants were randomised to 
68 receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not 
69 differ significantly between intervention (67.8%) and control (70.1%; OR=0.9 (95% CI: 0.64,1.27)). 
70 There was no evidence of an effect at 3- and 6-months respectively on continuous smoking 
71 abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication adherence 
72 (OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), OR=2.05 
73 (0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -2,1.91); 
74 and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)). 
75 Conclusions: Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs 
76 may not be an effective approach to improve TB outcomes.
77
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78 Trial registration: ISRCTN62728852, Registered on 13th April 2018.
79 Key words: Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral 
80 therapy, adherence
81
82 STRENGTHS AND LIMITATIONS OF THIS STUDY
83  The use of motivational interviewing combined with Short Text Messaging to address the 
84 effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis 
85 treatment outcomes is a novel and much needed intervention. 
86  Our study design was strong: this was a multi-site individually randomised controlled trial 
87 with a large sample size and a high follow up rate for the primary outcome.
88  We used validated measurement tools; furthermore, data analysis and primary outcome 
89 assessment were blinded, thereby limiting measurement bias. 
90  However, the study was underpowered for secondary outcomes, and low intervention 
91 uptake may have diluted any potential intervention effects.
92
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94 Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019, 
95 1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-
96 income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB 
97 burdens in the world; it is faced with high TB treatment interruption and loss to follow-up rates. It 
98 also has a high prevalence of human immunodeficiency virus (HIV) co-infection in patients with TB 
99 and a relatively high mortality in these co-infected patients.(1) Studies of interventions to advance 
100 the goal of ending the TB epidemic and improving treatment outcomes are therefore research 
101 priorities in South Africa and other LMICs.(2) 
102 Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly 
103 smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in 
104 patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients 
105 with TB and adherence to TB medication and anti-retroviral therapy (ART) in patients co-infected 
106 with TB and HIV, both of which may be negatively influenced by excessive alcohol use.(1) There is 
107 very limited research on how to concurrently tackle these three risk behaviours - namely smoking, 
108 harmful alcohol use and poor medication adherence - in patients with TB, particularly in LMICs. 
109 Motivational Interviewing (MI) has been shown to support reduced drinking, smoking cessation in TB 
110 patients and TB treatment and/or antiretroviral therapy (ART) medication adherence.(11–13) MI 
111 interventions can be effectively delivered by lay health workers (LHWs).(14) The more widespread 
112 use of LHWs and the increased use of mobile health (mHealth) digital technologies represent 
113 promising ways to increase the scalability of MI interventions. Indeed, the World Health 
114 Organisation (WHO) has called for researchers to capitalise on advances in mobile phone 
115 technology, network coverage and the increased use of common and widely available digital 
116 technologies (including the mobile phone short message service (SMS)) to improve TB care.(15) 
117 There is evidence that mHealth technologies can have modest beneficial effects on a range of health 
118 outcomes, including medication adherence.(16,17) Mobile phone messaging also shows a modest 
119 effect in improving TB treatment success rates.(18,19) The evidence is however stronger for two-
120 way messaging and interactive systems for which smart phones are required.(18) These are often 
121 not available to patients with TB in Africa.(20) 
122
123 A limitation of existing MI and mHealth interventions is that they have been studied in the context of 
124 modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more 
125 effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB, 
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126 there is a need for an intervention that has the flexibility to target multiple lifestyle factors as 
127 appropriate and in line with patient preferences. This could be achieved through increased 
128 integration of TB and non-communicable disease services.(23) 
129
130 Recent re-engineering of primary health care in South Africa has seen the introduction of municipal 
131 ward-based primary healthcare outreach teams of community health workers (CHWS). CHWs work 
132 in an integrated, team-based manner, supported by nurses, and take responsibility for health 
133 education and promotion, counselling and support for a range of health conditions.(24,25) Task 
134 shifting in this context has been shown to improve population health in LMICs (26) and these teams 
135 can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions 
136 could be implemented within this framework in a feasible and scalable way to improve outcomes for 
137 patients with TB across South Africa and beyond. 
138
139 Building on previous successes with MI and mHealth interventions, we developed a complex 
140 behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three 
141 lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption 
142 and poor medication adherence), and delivered by LHWs. We then conducted a randomised 
143 controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB 
144 treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence 
145 to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was 




150 Study design and participants
151 This was a prospective, two-arm, multicentre, individual RCT, which took place across 27 primary 
152 care clinics in 3 districts in South Africa (Lejweleputswa in the Free State province; Bojanala in the 
153 North West province; and Sedibeng in Gauteng province). Adult patients (18 years or older) were 
154 eligible for the study if they had drug-sensitive Pulmonary TB (PTB), and were initiating TB treatment 
155 or had been on TB treatment for less than a month for this treatment episode (both “new” and 
156 “retreatment patients”). They had to be tobacco smokers (defined as smoking daily or non-daily in 
157 the last four weeks on the Global Adult Tobacco Survey questionnaire)(28) and/or 
158 hazardous/harmful drinkers who were not alcohol dependent (Alcohol Use Disorders Identification 
159 Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20).(29) They also had to have access to a 
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160 mobile phone and understand one of the 4 languages used for the trial (English, IsiZulu, SeSotho and 
161 Setswana). Potential participants were recruited consecutively at the participating clinics between 
162 15 November 2018 and 31 August 2019. Trained field workers identified those interested in the 
163 study and screened them for eligibility. If eligible and willing to be enrolled into the trial, written 
164 informed consent was obtained. The RCT received ethics approval from the Research Ethics 
165 Committees of the five participating research institutions and the trial protocol was previously 
166 published.(30)
167
168 Randomisation and blinding
169 Patients were centrally randomised (1:1) to the ProLife intervention or control group using a 
170 randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation. 
171 We used block randomisation with varying block sizes stratified by clinic so as to achieve equal 
172 numbers in intervention and control groups within each clinic. Fieldworkers used sequentially 
173 numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife 
174 involved a complex behavioural intervention therefore LHWs and participants could not be blinded 
175 to the intervention. However, the determination of the primary outcome was done by the TB nurses 
176 who were blinded to the intervention status of the participants, based on routinely collected data. 
177 The statistician (MK) was blinded to the intervention or control arm allocation of participants during 
178 the analysis. 
179
180 Intervention and procedures
181 The ProLife intervention was developed based on a conceptual framework, following a review of 
182 pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful 
183 alcohol use and improved adherence to TB and HIV treatment would result in improved TB 
184 treatment outcomes.(30) The intervention consisted of 3 brief MI counselling sessions, lasting 15-20 
185 minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took 
186 place immediately or shortly after the randomisation and involved prioritisation and agenda setting, 
187 wherein the participant determined which factor should be prioritised (either a plan to quit tobacco 
188 smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication 
189 adherence). The second and third sessions built on the previous one until all relevant behavioural 
190 problems had been addressed. These sessions were reinforced with follow-up SMS text messages, 
191 twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven 
192 alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages 
193 were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the 
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194 feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after 
195 the first MI had taken place. Thereafter remaining messages were delivered even if the participant 
196 did not attend the second or third MI session.
197
198
199 Participants randomised to the ProLife intervention also received the same “usual care” as those in 
200 the control group. The control group received the usual care and routine treatment and support 
201 offered to patients with TB in South Africa, which varies by district but includes: health education; 
202 dietetic input; social support; point of care biochemical testing; and HIV testing with pre- and post-
203 test HIV test counselling. 
204
205 Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with 
206 mobile phones with the ProLife mobile data collection application (built with CommCare)(32) 
207 installed. They used a standardised electronic case report form (CRF) and followed standard 
208 operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage 
209 procedures have been reported elsewhere.(30)
210
211 Patient and public involvement
212 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination 




217 The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was 
218 recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful 
219 treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss 
220 to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated. 
221 It was measured using the routinely collected TB treatment outcomes in patients’ individual files. 
222
223 Secondary Outcomes
224 For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast 
225 bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of 
226 treatment (“cure rate”) was measured as a secondary outcome.(10) Continuous smoking abstinence 
227 was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers 
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228 at baseline. It was defined as having quit smoking completely and a self-report of not smoking more 
229 than 5 cigarettes from the start of the study, in addition to a negative biochemical test (exhaled 
230 Carbon Monoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the 
231 AUDIT questionnaire scores measured at 3- and 6-months follow-up in those participants who were 
232 hazardous/harmful drinkers at baseline. 
233 HIV positive participants were asked about ART status at baseline, 3- and 6-months using 
234 standardised questions on the CRF and change in ART status as measured at the 2 follow-up times. 
235 TB and ART medication adherence was measured using modified versions of the AIDS Clinical Trials 
236 Group Adherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35) 
237 Adherence was measured using an adherence index calculated by the formula (using the 4-day 
238 recall): [Total number of doses taken/Total number of doses prescribed] x 100. Patients with at least 
239 95% adherence were classed as having optimal adherence and those with less than 95% were 
240 classed as having low (or suboptimal) adherence. This was assessed at 3- and 6-months. 
241 During COVID-19 lockdown (in the second term of 2020) we switched to telephonic follow-up of 
242 participants using a shortened questionnaire whereby only strictly needed information for the 
243 measurement of outcomes was inquired about.
244 Training and Intervention Fidelity Monitoring
245 The training and intervention fidelity monitoring is described in more detail in previous 
246 papers.(30,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on 
247 counselling supervision underwent MI training over 5 days. LHWs completed a post-session semi-
248 structured form onto which they indicated the extent to which they implemented each element of 
249 MI, as well as their general qualitative impressions of that particular session. In addition, we 
250 assessed MI intervention fidelity based on ratings of the counsellors’ recorded MI sessions, as 




255 The ProLife intervention costs consisted of the costs of training and the delivery of the ProLife 
256 intervention, including relevant personnel involvement (trainers and LHWs), materials used, travel, 
257 accommodation and refreshments, and digital infrastructure for the intervention. These were 
258 estimated based on research team records. Usual care costs consisted of TB medication costs, 
259 biochemical investigations, and ART costs if applicable. These were estimated based on information 
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260 obtained through routine records. The country specific version of Euroqol with 5 dimensions and 3 
261 levels of response categories (EQ-5D-3L) for South Africa was administered to participants at 
262 baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)
263
264 Statistical analysis
265 The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference 
266 in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm 
267 with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the 
268 control group were based on actual success rates in patients with TB in the studied provinces 
269 obtained from TB managers at the time of the grant application for this study.
270 We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted 
271 statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the 
272 main outcome (TB treatment success rate) between the intervention and the usual care arm. Where 
273 treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment 
274 outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of 
275 bacteriological results did not permit us to verify the correctness of the nurse assessment. We 
276 carried out similar statistical analyses for the secondary outcomes with appropriate regression 
277 techniques. For the reduction in harmful or hazardous drinking, we used linear regression to 
278 estimate the difference in total AUDIT score between control and intervention groups accounting for 
279 the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed. 
280 For our main analyses we adjusted for baseline characteristics if these differed between trial arms at 
281 baseline. The covariates that we controlled for in each model are specified when a model is 
282 presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a 
283 P-value < 0.05 considered statistically significant. 
284 The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1) was 
285 used to assess MI intervention fidelity.(40) The coding entailed making ‘Global Ratings’ (on 4 
286 dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and 
287 ‘Behaviour’ counts (with respect to the items: giving information, persuade, persuade with 
288 permission, question, simple reflection, complex reflection, affirm, seeking collaboration, 
289 emphasising autonomy and confront). A score was assigned to each of these items and the scores 
290 compared against the competency and proficiency thresholds that are specified in the MITI manual. 
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292 For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data 
293 management system subscription. Results are presented in both ZAR and US dollar ($) using the 
294 2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was 
295 available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale, was used to 
296 derive utility values, because the GDP per capita in international dollars was the closest between the 
297 two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs) were derived from 
298 the utility values at the time points by calculating the area under the curve.(42) No missing data 





304 Participant enrolment and follow-up 
305 A total of 2099 patients with TB were screened for eligibility out of which 574 consenting and eligible 
306 participants were randomised: 291 to control and 283 to intervention. Trial recruitment was 
307 terminated on 31 August 2019 before the planned sample size was reached because of budget and 
308 time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1) 
309 session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was 
310 delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised 
311 to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253 
312 (89.4%) participants, respectively. (Figure 1)
313
314 Figure 1 Consort flow diagram
315
316 Baseline participant characteristics of the intervention and control arm
317 Socio-demographic; socio-economic and clinical characteristics
318 Baseline characteristics were distributed similarly in the intervention and control arms for most 
319 variables but with some imbalances in educational level. A total of 513 (91.3%) participants were 
320 new patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of 
321 Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the 
322 participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257 
323 (82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and 
324 co-morbidities are presented in Supplementary table 1.
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Table 1 Baseline descriptive socio-economic statistics and clinical characteristics by study arm
Control (N = 291)
n (%)*




Age in years: mean (SD) 39.37 (12.60) 38.56 (11.15)
Female Sex 69 (23.7) 60 (21.2) 129 (22.5)
Education
No education 7 (2.4) 5 (1.8) 12 (2.1)
Grades 1-5 23 (7.9) 20 (7.1) 43 (7.5)
Grades 6-7 32 (11.0) 35 (12.4) 67 (11.7)
Grades 8-11 96 (33.0) 128 (45.2) 224 (39.0)
Grade 12 87 (29.9) 70 (24.7) 157 (27.4)
Higher 24 (8.2) 8 (2.8) 32 (5.6)
Declined to answer** 22 (7.6) 17 (6.0) 39 (6.8)
TB Patient category
New patient 264 (92.3) 249 (90.2) 513 (91.3)
Relapse 10 (3.5) 9 (3.3) 19 (3.4)
Re-treatment after default 9 (3.1) 14 (5.1) 23 (4.1)
Re-treatment after failure 1 (0.3) 2 (0.7) 3 (0.5)
Other 2 (0.7) 2 (0.7) 4 (0.7)
TB Site of disease Pulmonary only (ICD-10 A15) 281 (98.9) 272 (98.9) 553 (98.9)
TB Sputum smear, Gene XPert, or culture result available N= 236 227 463
At least one Sputum smear, Gene XPert, or culture result positive 208 (88.1) 195 (85.9) 403 (87.0)
HIV status
Negative 118 (40.7) 125 (44.2) 243 (42.4)
Positive 163 (56.2) 142 (50.2) 305 (53.2)
Unknown 9 (3.1) 16 (5.7) 25 (4.4)
HIV positive patients
Using Cotrimoxazole 104 (63.8) 100 (67.1) 204 (65.4)
Using anti-retroviral 139 (85.3) 118 (79.2) 257 (82.4)
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326 * Frequencies and (percentages) are presented unless otherwise stated
327 **More variables with the option “declined to answer” are listed in the Supplementary table 1
328







In the past month, smoked tobacco
Not at all** 110 (37.8) 92 (32.5) 202 (35.2)
Daily 149 (51.2) 149 (52.7) 298 (51.9)
Less than Daily 32 (11.0) 42 (14.8) 74 (12.9)
Had a drink in the past 12-months 208 (71.5) 223 (78.8) 431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]† 12.27 (3.98) 13.02 (3.78) 12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19]† 11.32 (4.02) 10.98 (4.02) 11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined 
(Constructed)
Hazardous/harmful drinking Only‡ 110 (37.8) 92 (32.5) 202 (35.2)
Smoking Only 103 (35.4) 77 (27.2) 180 (31.4)
Smoking and hazardous/harmful drinking‡ 78 (26.8) 114 (40.3) 192 (33.4)
329 * Frequencies and (percentages) are presented unless otherwise stated
330 **Non-smokers were only included if they were harmful or hazardous drinkers
331 †Only hazardous/harmful drinkers and/or current smokers were included in the study. Therefore, patients with TB were excluded if they were non-current smokers and had an AUDIT score 
332 <7 (females) or <8 (males) or >19; however, they were included if they were smokers independent of whether they had a drink in the past year and therefore independent of the AUDIT 
333 score. These AUDIT scores are thus representative of the mean AUDIT scores in the entire study sample and differ from the AUDIT score in the harmful/hazardous drinkers whose change in 
334 AUDIT score was measured at 3 and 6-months follow-up
335 ‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20
336
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337 There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %) in 
338 the control arm were dual smokers and drinkers compared to 114 (40.3 %) in the intervention arm. 
339 In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were 
340 smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2) 
341 More details of smoking and drinking history, forms of tobacco use, addiction and quit attempts are 
342 presented in Supplementary Table 2.
343
344 Primary outcome 
345 Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or 
346 cured). The remainder either interrupted treatment, failed treatment, developed drug resistance, 
347 were transferred out or had an unknown treatment outcome.(Supplementary table 3) The 
348 percentage of successful TB treatment did not differ significantly between the control and 
349 intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI: 
350 (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs 
351 (Tables 3 and 4).
352
353 Secondary outcomes
354 Cure rates 
355 Among the 403 participants who had at least one positive bacteriological result at baseline, 168 
356 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to 
357 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the 
358 intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)
359
360 Continuous smoking abstinence 
361 Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-
362 report plus biochemical verification) to enable the identification of continuous abstinence at 6-
363 months of which 22 had continuously abstained from smoking. These were similarly distributed 
364 across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%) 
365 in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%) 
366 participants in the intervention arm compared to 27 (16.3%) in the control arm continuously 
367 abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)
368
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Control Intervention Total Control Intervention Total Control Intervention Total
TB treatment statusa
Successful** 204 (70.1) 192 (67.8) 396 (69.0)
Not Successful 87 (29.9) 91 (32.16) 178 (31.01)
Cured a, ***
Yes 83 (39.9) 85 (43.6) 168 (41.7)
No 125 (60.1) 110 (56.4) 235 (58.3)
Continuous smoking 
abstinenceb 
Yes 27 (16.3) 20 (11.2) 47 (13.6) 12 (7.2) 10 (5.6) 22 (6.4)
No 139 (83.7) 159 (88.8) 298 (86.4) 154 (92.8) 169 (94.4) 323 (93.6)
Harmful/hazardous 
drinkers!: N =
188† 206† 394† 141† 130† 271† 112† 127† 239†










































122† 83† 205† 100† 83† 183†
Taking ART 








91 (74.6) 58 (69.9) 149 (72.7) 80 (80.0) 74 (89.2) 154 (84.2)
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Optimal adherence 101 (99.0) 64 (98.5) 165 (98.8) 75 (97.4) 64 (97.0) 139 (97.2)
Suboptimal 
adherence
1 (1.0) 1 (1.54) 2 (1.2) 2 (2.6) 2 (3.0) 4 (2.8)
TB medication 
adherence
Optimal adherence 181 (92.3) 138 (90.8) 319 (91.7) 61 (89.7) 59 (90.8) 120 (90.2)
Suboptimal 
adherence
15 (7.6) 14 (9.2) 29 (8.3) 7 (10.3) 6 (9.2) 13 (9.8)
a: only assessed at 6-months
b: assessed at 3 and 6-months; this table refers to cigarette smokers only (other forms of tobacco smoking are excluded)
* Frequencies and (percentages) are presented unless otherwise stated
**Primary Outcome: This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or treatment interrupted 
for more than 2 months, or outcome not evaluated/unknown.
***Based on having a cured treatment outcome among those who were bacteriologically positive at baseline.
! hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20; *! Important distinction at baseline for eligibility purposes.
†Denominator for the mean (SD) or denominator for % 
‡ Information on HIV-positivity was obtained from information from TB records combined with patient self-report at baseline. True HIV-positivity rates may have been higher.
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TABLE 4 Regression analysis results for the primary and secondary outcomes at 6-months
Crude Odds Ratio
(95% CI)*





TB treatment status: Successful (Ref: Not successful) 0.90 (0.64,1.27) 0.548 0.86‡ (0.60,1.24) 0.421
Secondary outcomes
Cured (Ref: Not Cured) 1.16 (0.83,1.63) 0.374 1.07‡ (0.76,1.51) 0.684
Continuous smoking abstinence (Ref: No)*** 0.76 (0.35,1.63) 0.482
TB medication adherence (Ref: Optimal) 0.89 (0.26,3.07) 0.849
ART medication adherence (Ref: Optimal) 1.17 (0.14,9.94) 0.884
Taking ART medication (Ref: No) 2.05! (0.80,5.27) 0.136
AUDIT -0.04** (-2,1.91) 0.966 0.02!! (-1.55,1.6) 0.976
* Analyses accounted for potential clustering by centre.
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.
! Adjusting for art status at baseline
**Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.
!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.
***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, 
type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 
and 0.76 with similar confidence limits as for the crude estimate.
Page 19 of 155
















































For peer review only
18
TABLE 5 Regression analysis results for secondary outcomes measured at 3-months
Secondary outcome Crude Odds Ratio
(95% CI)*
P Value* Adjusted Odds Ratio
(95% CI)*
P Value*
Continuous smoking abstinence (Ref: No)** 0.65 (0.37,1.14) 0.135
TB medication adherence (Ref: Optimal) 1.22 (0.52,2.87) 0.641
ART medication adherence (Ref: Optimal) 1.58 (0.10,26.12) 0.750
Taking ART medication (Ref: No) 0.79! (0.38,1.65) 0.53 0.74‡ (0.35,1.58) 0.443
AUDIT 0.55† (-1.01,2.11) 0.474 0.74!! (-0.62,2.1) 0.273
*Analyses accounted for clustering.
! Adjusting for art status at baseline
‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.
†Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.
!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.
** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type 
of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 
0.66 with similar confidence limits as for the crude estimate.
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369 Change in harmful/hazardous drinking 
370 AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of 
371 the intervention.(Table 3) In the intervention arm, participants had, on average, a reduction of 0.04 
372 points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm 
373 controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was 
374 observed at 3-months. (Tables 4 and 5)
375
376 Medication adherence and ART uptake
377 At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the 
378 intervention arm to the control arm and controlling for ART baseline medication status; whereas it 
379 was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB 
380 medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months. 
381 Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87) 
382 comparing intervention arm to the control arm at 6-months and 3-months, respectively. The 
383 proportions of participants on ART who had optimal ART medication adherence were high at both 3-
384 months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication 
385 adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the 
386 intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)
387
388 Intervention fidelity
389 Motivational interviewing fidelity
390 The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms 
391 of the global ratings, the LHWs’ counselling sessions were above proficiency levels on all items, 
392 namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores 
393 were all above 2). In terms of the summary measures, the LHWs’ counselling sessions did not 
394 achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy) 
395 as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component 
396 (Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For 
397 behavioural counts, “Asking Questions” had the highest mean score (24.2; SD=10.42), followed by 
398 “Affirm” with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the 
399 following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions 
400 Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize 
401 Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade) 
402 statements per session. (Supplementary Table 4)
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405 Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were 
406 delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed 
407 the first MI, See Supplementary Table 5 for more details.
408
409 Costs and health related quality of life
410 Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental 
411 cost-utility ratios are not presented since the intervention was not clinically effective. The mean cost 
412 of the ProLife intervention was ZAR 2601 (SD 6) ($180.02 (SD $0.42)) per participant in the 
413 intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) ($47.13 (SD $24.71)) in 
414 the intervention arm (n=122) versus ZAR 706 (SD 302) ($48.86 (SD $20.90)) in the control arm 
415 (n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) ($227.37 (SD 
416 24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137 
417 intervention and 159 control arm participants. The mean QALYs estimated over six months were 
418 0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean 




423 This RCT did not provide evidence for improved TB treatment success rates in those receiving the 
424 ProLife intervention compared to those receiving usual care. We could also not demonstrate 
425 significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol consumption, 
426 medication adherence and ART initiation. To our knowledge there are no other published studies of 
427 similar complex interventions that aim to improve TB treatment outcomes in patients who smoke or 
428 drink to harmful or hazardous extent. Interventions evaluated by other studies were either complex 
429 interventions or SMS-based interventions aimed at improving TB outcomes through the pathway of 
430 increasing adherence, but without an alcohol or smoking intervention component (43,44) or focused 
431 on a single behaviour, namely smoking or drinking.(45,46). Of the latter studies, a brief smoking 
432 cessation intervention was effective in inducing smoking cessation in patients with TB but did not 
433 improve TB outcomes.(45) Conversely, in another study in India, intensive counselling for alcohol 
434 disorders led to significantly better TB treatment outcomes in the intervention group compared to 
435 the control group.(46) Smoking cessation also led to better TB treatment outcomes in a secondary 
436 analysis of a large tobacco cessation trial in patients with TB in Bangladesh and Pakistan.(47) Our 
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437 non-significant result for smoking-related outcomes is not consistent with findings from our previous 
438 TB study, which used a single MI session and found that the chance of sustained smoking cessation 
439 was twice as high in the MI intervention group compared to the control group,(14) albeit with a less 
440 stringent exhaled CO cut-off point. Evidence on the effectiveness of MI for smoking abstinence in 
441 non-TB settings has been equivocal.(48) Self-reported alcohol consumption decreased with about 4 
442 points in both intervention and control arms in our study at both follow-up times. Answering 
443 questions on drinking in brief intervention trials may alter subsequent self-reported behaviour: 
444 exposing non-intervention control groups to an integral component of the intervention may 
445 therefore underestimate the effect of the intervention.(49) There have been few previous studies 
446 looking at MI and SMS interventions for the modification of hazardous/harmful drinking in the 
447 context of TB. A previous trial of a brief counselling intervention to reduce alcohol consumption in 
448 patients with TB did not find a significant effect on alcohol reduction.(50) Outside a TB setting, 
449 results have been mixed. A meta-analysis showed a small but significant improvement in outcomes 
450 when MI was used in conjunction with cognitive behavioural therapy for co-morbid alcohol use and 
451 depression.(51) Self-reported TB and ART medication adherence was high overall in our study 
452 population, which is consistent with other studies conducted in South Africa.(52,53) It is possible 
453 that we did not find a difference in treatment adherence due to a ceiling effect.
454
455 There were several key strengths in this RCT. This was an individually RCT with a relatively large 
456 sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment 
457 was blinded. This was a novel intervention, which built on previous successes with both MI and 
458 mHealth interventions and was aligned with the WHO’s call to increase the use of digital 
459 technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire 
460 (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as 
461 self-reports tend to underreport drinking while overestimating adherence behaviour compared 
462 with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall, 
463 the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs 
464 trained as counsellors were more proficient in MI than during the feasibility stage, as observed by 
465 their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy. 
466 (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs 
467 during the trial and adapting the training based on feedback from the feasibility stage. Extra 
468 counsellors were also appointed to minimise travel distances to clinics. There were some limitations 
469 associated with this RCT. Trial recruitment had to be terminated before the planned sample size 
470 because of funding and time constraints. Nevertheless, the calculation of sample size was based on 
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471 an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes 
472 were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in 
473 primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however 
474 reduce the power to detect a difference for secondary outcomes for which the LTFU was much 
475 higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was 
476 the case for outcomes relating to smoking, drinking, ART and cure rates. In addition, due to COVID-
477 19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a 
478 shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB 
479 treatment outcomes. The low intervention uptake meant that half of the participants received only 
480 one or two MI sessions combined with SMS messages. SMS messages were only used for the first 
481 half of the study period, and one quarter of participants did not receive their messages, a commonly 
482 occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing 
483 text messages, the MI and associated text messages were not enough to keep participants focussed 
484 for the second three months of the trial. The 2-arm study design did not permit the untangling of the 
485 individual effects of SMS and MI. Understanding their separate effects could have important cost 
486 implications as SMS-communication would be cheaper and easier to organise than individual 
487 counselling. 
488
489 The lack of effectiveness of our intervention on the primary outcome (TB treatment success) can 
490 have a number of possible explanations. Although intervention uptake was high (80.2%) for the first 
491 counselling session, many participants did not return for the second (29.7%) and third (47%) 
492 sessions. As a result of this only about half of the intervention arm participants received all three MI 
493 sessions. Furthermore, about one quarter of all participants did not receive any SMS-messages. Low 
494 intervention uptake leads to a dilution of any potential effects. The lack of effectiveness on TB 
495 treatment success could perhaps also be explained by the complexity of the ProLife intervention 
496 itself: counsellors had to address multiple behaviours, namely medication adherence, tobacco 
497 smoking and hazardous/harmful drinking. Despite having established the feasibility and acceptability 
498 of this approach (31) and ongoing on site performance monitoring and feedback of counsellors, it is 
499 possible that MI for multiple behaviour change in the ProLife study was counterproductive as 
500 counsellors may have ended up not focusing on any of the behaviours at optimal levels. Similarly, 
501 patients might have found it difficult to change multiple behaviours simultaneously, especially 
502 because smoking and drinking are mutually reinforcing. This integrated approach was nevertheless 
503 adopted to avoid the need for multiple vertical counselling services (in addition to TB treatment and 
504 HIV treatment), to allow the different elements of the programme to reinforce one another, and to 
505 improve the affordability, feasibility and acceptability for a future roll-out of the programme. It is 
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506 also possible that sequential interventions may be better, at least for smoking cessation.(56) More 
507 intensive counselling (more sessions) or a modified counselling method may have been more 
508 appropriate, even more so since a recent review of reviews of MI casts doubt on its 
509 efficacy.(48,57,58) For example, more emphasis on increasing patient knowledge in addition to 
510 increasing self-efficacy may have been more effective.(59) The cause of the mobile health message 
511 delivery problems (such as poor network coverage, no electricity to charge phones) (60) would need 
512 to be investigated in order to increase the effectiveness of future mHealth interventions. Messages 
513 may also have to be intensified or modified to be more interactive and/or tailored to specific 
514 circumstances of each individual. This would improve the personal value of the intervention to the 
515 individual, which is likely to increase the chances of their participation in the intervention.(61) 
516 Consistent with the normalisation process theory,(62) cognitive participation in the intervention 
517 might have been higher had we been deliberate in the implementation to ensure the TB nurse who 
518 would have routinely seen the participants, provided additional support and motivated participants 
519 to attend MI sessions with the counsellor. In this way, the intervention would have gained 
520 ‘legitimacy’ but this would have led to unblinding of the nurses to the intervention arm. 
521
522 In conclusion, we could not demonstrate that the ProLife intervention was effective in improving TB 
523 treatment outcomes. This may be due to the lack of effect of the intervention, but the study may 
524 also have been underpowered for the intermediary secondary outcomes. Valuable lessons were 
525 learnt on challenges relating to training LHWs in MI counselling and delivery, SMS-delivery in a 
526 challenging socio-economic context and the reasons for loss to follow-up of TB participants with 
527 multiple health problems. Further research is needed to provide answers on how to increase 
528 intervention uptake in poor resource settings and whether our complex intervention should have 
529 been more intensive. Other important questions are whether another counselling method would 
530 have been more effective. Lastly, in the light of the already existing evidence of SMS and the costs 
531 and implementation challenges relating to MI, intervention studies limited to an mHealth 
532 intervention but using different intensities, duration and type of interventions (one-way, two-way, 
533 interactive) are needed. 
534
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Assessed for basic eligibility (n=2099)
Excluded  
Participants
• Not meeting inclusion criteria (862)
• Declined to participate (358)
Enrolment
Assessed for eligibility (n=879)
Excluded  
Participants
• Not meeting inclusion criteria (294)
• Declined to participate in screening (4)
• Did not consent to RCT (4)
• Did not complete baseline and randomization (3)
Allocated to intervention (n=283)
Received allocated intervention
• MI 1 (n=227)
• MI 2 (n=199)
• MI 3 (n=150)
• All SMS (99), 1% to 60% of SMS (34), 61% to 99% 
of SMS (75)
Did not receive allocated intervention:
• MI 1 (n=56): Unable to get hold of (n=18), 
Discontinued intervention (n=15), Working or 
relocated (n=6), Deceased (n=3), Other (n=14) 
• MI 2 (n=84): MI 1 Incomplete (n=56), Unable to get 
hold of (n=10), Working or relocated (n=3), 
Deceased (n=2), Other (n=13)
• MI 3 (n=133): MI 2 Incomplete (n=84), Unable to get 
hold of (n=19), Working or relocated (n=6), 
Discontinued intervention (n=6), Other (n=18)
• SMS (n=75)
Allocated to control (n=291)
• Received intervention
• MI 1 (n=0)
• MI 2 (n=0) 
• MI 3 (n=0)
• SMS (n=1)
Month 3 (n=168)
• Lost to follow-up (n=115): Unable to get hold 
of (n=34), Working or relocated (n=21), Deceased 
(n=10), Discontinued intervention (n=14), Other 
(n=36)
Month 6 (n=165)
• Lost to follow-up (n=118): Unable to get 
hold of (n=49), Working or 
relocated (n=20), Deceased (n=13), 
Discontinued intervention (n=10), Other (n=26)
Month 6-9 TB outcome (n=253)
Month 3 (n=213)
• Lost to follow-up (n=78): Unable to get hold of 
(n=36), Working or relocated (n=14), Deceased 
(n=5), Discontinued intervention (n=3), Other (n=20)
Month 6 (n=173)
• Lost to follow-up (n=118): Unable to 
get hold of (n=49), Working 
or relocated (n=16), Deceased 
(n=7), Discontinued intervention (n=14), Other (n=32)
Month 6-9 TB outcome (n=244)
Analysed  
TB treatment outcome (n=283) 
Analysed
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SUPPLEMENTARY TABLES  
 
Supplementary table 1 Detailed baseline descriptive statistics for socio-demographic, socio-
economic, and clinical characteristics by study arm  
 Control  
(N = 291) 
n (%)* 
Intervention 





Marital status    
Married or living together 102 (35.1) 95 (33.6) 197 (34.3) 
Divorced/separated 20 (6.9) 18 (6.4) 38 (6.6) 
Widowed 10 (3.4) 7 (2.5) 17 (3.0) 
Never married and never lived together 144 (49.5) 150 (53.0) 294 (51.2) 
Declined to answer 15 (5.2) 13 (4.6) 28 (4.9) 
Employment    
Self-employed (full-time) 30 (10.3) 36 (12.7) 66 (11.5) 
Employed full-time (30 hrs a week or more) 62 (21.3) 54 (19.1) 116 (20.2) 
Employed part-time (less than 30 hrs a week) 19 (6.5) 29 (10.2) 48 (8.4) 
Retired 17 (5.8) 16 (5.7) 33 (5.7) 
Unemployed (but able to work) 125 (43.0) 120 (42.4) 245 (42.7) 
Unable to work because of long-term disability 
or 
ill health 
9 (3.1) 8 (2.8) 17 (3.0) 
Full-time student 12 (4.1) 4 (1.4) 16 (2.8) 
Caring from my home and family/doing 
household work/housewife 
0 (0.0) 2 (0.7) 2 (0.3) 
Occasional work (“piece job”) 17 (5.8) 12 (4.2) 29 (5.1) 
Declined to answer 0 (0.0) 2 (0.7) 2 (0.3) 
Ever worked or spent time in mines    
No 244 (83.8) 237 (83.7) 481 (83.8) 
Yes 46 (15.8) 45 (15.9) 91 (15.9) 
Household items (Yes is displayed)    
A radio 249 (85.6) 234 (82.7) 483 (84.1) 
A television 255 (87.6) 255 (90.1) 510 (88.9) 
A landline telephone 21 (7.2) 22 (7.8) 43 (7.5) 
A desktop or laptop computer 67 (23.0) 48 (17.0) 115 (20.0) 
A refrigerator 248 (85.2) 240 (84.8) 488 (85.0) 
A vacuum cleaner or floor pol 49 (16.8) 35 (12.4) 84 (14.6) 
A microwave oven 198 (68.0) 189 (66.8) 387 (67.4) 
An electric or gas stove 254 (87.3) 238 (84.1) 492 (85.7) 
A washing machine 153 (52.6) 136 (48.1) 289 (50.3) 
Total number of assets: mean (SD) 5.14 (1.96) 4.94 (1.77) 5.04 (1.87) 
In the past month, number of days you or 
people in the household went to bed hungry 
because there was no food to eat 
   
0 days 244 (83.8) 238 (84.1) 482 (84.0) 
1-7 days 45 (15.5) 34 (12.0) 79 (13.8) 
More than 7 days 2 (0.7) 9 (3.2) 11 (1.9) 
Declined to answer 0 (0.0) 2 (0.7) 2 (0.3) 
Number of pre-treatment smear tests 
recorded? 
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One 197 (92.1) 169 (87.6) 366 (89.9) 
Two 17 (7.9) 24 (12.4) 41 (10.1) 
Number of Gene XPert results recorded    
One 225 (97.8) 210 (97.2) 435 (97.5) 
Two 5 (2.2) 6 (2.8) 11 (2.5) 
Number of culture results recorded on the TB 
Treatment record 
   
One 54 (94.7) 42 (97.7) 96 (96.0) 
Two 3 (5.3) 1 (2.3) 4 (4.0) 
Co-morbidities    
Hypertension 19 (6.93) 11 (4.1) 30 (5.54) 
Diabetes 5 (1.84) 4 (1.49) 9 (1.66) 
Epilepsy 3 (1.09) 4 (1.49) 7 (1.29) 
Mental illness 3 (1.09) 0 (0) 3 (0.55) 
Liver disease 1 (0.36) 1 (0.38) 2 (0.37) 
Renal insufficiency 1 (0.36) 1 (0.38) 2 (0.37) 
Allergies 2 (0.76) 0 (0) 2 (0.38) 
Other 1 (0.36) 1 (0.38) 2 (0.37) 
Depression score (CESD 10): mean (SD) 8.44 (4.38) 8.74 (4.8) 8.59 (4.59) 
*Counts and percentages unless otherwise indicated 
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Supplementary table 2 Detailed descriptive statistics for smoking history, alcohol history at 







Smoking History (current smokers only) N= 181 191 372 
On the days that you smoke, how soon after 
you wake up do you have your first cigarette? 
   
After 60 minutes 30 (16.6) 28 (14.7) 58 (15.6) 
31-60 minutes 24 (13.3) 16 (8.4) 40 (10.8) 
6- 30 minutes 60 (33.1) 65 (34.0) 125 (33.6) 
Within 5 minutes 67 (37.0) 82 (42.9) 149 (40.1) 












Age started smoking in years: mean (SD) 19.2 (6.3) 19.3 (6.3) 19.3 (6.3) 
Age started smoking in years: median (IQR) 18 (15-20) 18 (16-21) 18  
(15.5-20.5) 
Form of tobacco used    
Manufactured cigarettes (Yes) 166 (91.7) 179 (93.7) 345 (92.7) 
Number of days you smoked in the past 7days: 
mean (SD) 
5.3 (2.65) 5.53 (2.33) 5.42 (2.49) 
Average number of cigarettes smoked daily: 
mean (SD) 
6.18 (6.43) 6.48 (8.21) 6.34 (7.39) 
Hand-rolled cigarettes (Yes) 14 (7.7) 21 (11.0) 35 (9.4) 
Number of days you smoked in the past 7days: 
mean (SD) 
4.71 (2.84) 3.71 (2.95) 4.11 (2.91) 
Average number of handrolled cigarettes smoked 
daily: mean (SD) 
3.71 (3.97) 3.81 (2.82) 3.77 (3.27) 
Pipe (Yes) 4 (2.2) 2 (1.0) 6 (1.6) 
Number of days in the past 7days you smoked: 
median (IQR) 
1 (0, 2.5) 4.5 (2, 7) 2 (0, 3) 
Average number of daily sessions: median (IQR) 1 (0, 3.5) 3 (1, 5) 1.5 (0, 5) 




60 (30, 90) 90 (30, 90) 
Cigars, cheroots or cigarillos (Yes) 1 (0.55) 0 (0) 1(0.27) 
Water pipe (Yes) 3 (1.7) 2 (1.0) 5 (1.3) 
Other 10 (5.5) 4 (2.1) 14 (3.8) 
Heaviness of smoking index >= 4 134(74.03) 158(82.72) 292(78.49) 
Smoking inside your home restrictions    
Total: Not allowed 96 (53.0) 108 (56.5) 204 (54.8) 
Some rules: where/when it is allowed 61 (33.7) 58 (30.4) 119 (32.0) 
No rules 24 (13.3) 25 (13.1) 49 (13.2) 
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* Frequencies and (percentages) are presented unless otherwise stated 
 
Attempts to quit smoking (current smokers only)     
Ever attempted to quit in the past (Yes) 52 (28.7) 64 (33.5) 116 (31.2) 
Number of attempts to quit: mean (SD) 2.46 (2.98) 2.64 (1.62) 2.56 (2.32) 
Time elapsed since attempt to quit last time, in 
months: mean (SD) 
36.65 
(94.62) 
25.13 (37.91) 30.29 
(69.22) 
Longest duration abstinent in previous quit 
attempts: mean (SD) 
6.15 
(13.48) 
4.22 (8.9) 5.09 (11.18) 
Likelihood to TRY TO QUIT smoking completely 
and permanently in the next three months 
   
Definitely will not 6 (3.3) 5 (2.6) 11 (3.0) 
Probably will not 10 (5.5) 12 (6.3) 22 (5.9) 
Probably will 104 (57.5) 109 (57.1) 213 (57.3) 
Definitely will 61 (33.7) 65 (34.0) 126 (33.9) 
Likelihood that I WILL QUIT smoking completely 
and permanently in the next three months 
   
Definitely will not 6 (3.3) 5 (2.6) 11 (3.0) 
Probably will not 11 (6.1) 13 (6.8) 24 (6.5) 
Probably will 103 (56.9) 104 (54.5) 207 (55.6) 
Definitely will 61 (33.7) 69 (36.1) 130 (34.9) 
Ever used any methods to help you stop smoking 
tobacco in the past 3-months? (Yes) 
23 (12.7) 16 (8.4) 39 (10.5) 
Smokeless tobacco use (all participants)    
In the past month, have you used smokeless 
tobacco (Snuff) on a daily basis 
   
Not at all 275 (94.5) 275 (97.2) 550 (95.8) 
Daily 12 (4.1) 6 (2.1) 18 (3.1) 
Less than Daily 4 (1.4) 2 (0.7) 6 (1.0) 












Form of ST used (for SLT users)    
Snuff (by mouth) 2 (12.5) 0 (0.0) 2 (8.3) 
Snuff (by nose) 11 (68.8) 5 (62.5) 16 (66.7) 
Chewing tobacco leaves 0(0) 0(0) 0(0) 
Other 1 (6.3) 0 (0.0) 1 (4.2) 
Help to stop drinking (N= , had a drink in past 12 
months) 
208 223 431 
Ever used any methods to stop drinking alcohol 
in the past 3-months 
21 (11.2) 22 (10.7) 43 (10.9) 
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Supplementary table 3 Detailed descriptive statistics for primary outcome by study arm at 6-
months  






Cured 108 (37.1) 105 (37.1) 213 (37.1) 
Treatment completed 96 (33.0) 87 (30.7) 183 (31.9) 
Treatment interrupted > 2 months 15 (5.2) 29 (10.2) 44 (7.7) 
Treatment failure 5 (1.7) 2 (0.7) 7 (1.2) 
Acquired drug resistance 1 (0.3) 4 (1.4) 5 (0.87) 
Died 11 (3.8) 15 (5.3) 26 (4.5) 
Transfer out 8 (2.75) 11 (3.9) 19 (3.31) 
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Supplementary table 4 MI treatment fidelity scores of counselling sessions delivered by 17 lay 
health workers* 
Ratings Mean (SD) Range 
Global ratings**   
Cultivating change talk 3.2 (1.17) 1-5 
Softening sustain talk 3.4 (0.96) 1-4 
Partnership 3.4 (1.12) 2-5 
Empathy 2.9 (1.34) 1-5 
Behaviour counts&   
Giving information 4.8 (8.13) 0-5 
Persuade 0.8 (1.48) 0-5 
Persuade with permission 0.1 (0.24) 0-1 
Question 24.2 (10.42) 12-51 
Simple reflection 4.1 (3.21) 0-10 
Complex reflection 1.6 (2.69) 0-9 
Affirm 5.5 (3.47) 1-12 
Seeking collaboration 2.4 (1.46) 0-6 
Emphasising autonomy 1.4 (1.37) 0-4 
Confront 0.4 (0.74) 0-3 
Summary measures   
Total MI non-adherent † 1.2 (2.28) 0-7 
Total MI adherent† 9.3 (4.74) 1-16 
Technical global ratings** 3.3 (0.97) 1.5-4.5 
Relational global ratings** 3.1 (1.19) 1.5-5 
Reflec on to ques on ra o†† 0.23 (0.24) 0-0.83 
Percentage of complex reflections*** 20.4 (21.9) 0-67 
*The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In order to assess the fidelity of 
the counsellors’ delivery of motivational interviewing during the trial, we are used the validated Motivational Interviewing 
Treatment Integrity Coding Manual 4.2.1 (MITI) tool. The table shows the results of the fidelity assessment that was 
conducted by one rater who is proficient in English, seSotho and seTswana and in motivational interviewing. The rater 
listened to the recordings and coded a randomly selected 20-min portion of the written transcript. In the case of shorter 
counselling sessions, the entire recording was assessed.  
**The “global ratings” involve assessing, on a 5-point Likert scale (1 for low and 5 for high), how well or poorly the counsellor 
adheres to the MI practice. Ratings are conducted on four items, two each making up Technical Components (Cultivating 
change talk and Softening sustain talk) and Relational Components (Partnership and Empathy).  
**Scores on Cultivating Change Talk and Softening Sustain Talk are averaged to obtain the Technical global scores. 
***Scores on Partnership and Empathy are averaged to obtain Relational global scores. The basic competency threshold 
scores for fair and good proficiency are 3 and 4, respectively for Technical scores and 3.5 and 4, respectively for Relational 
scores.  
&The “behaviour counts” involve counting 10 verbal behaviours of the counsellor during the intervention.  
† “MI adherence” is determined by adding up the following verbal behaviours: Seeking Collaboration, Affirm and Emphasising 
autonomy. “MI non-adherence” is determined by summing instances of Confront and Persuade. No thresholds for MI 
adherence or non-adherence are specified in the MITI 4.2.1.  
††The Reflection-to-Question (R:Q) ratio is the total reflections divided by the total questions asked. One reflection to each 
question is considered a “fair” practice level while two reflections to each question is considered a “good” practice level. 
*** The Percentage of Complex Reflections (% CRs) is calculated by dividing the number of complex reflections by the sum 
of complex reflections and simple reflections. A fair and a good % CRs are 40% and 50%, respectively. 
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Supplementary table 5 SMS delivery 
 Intervention (N=283) Control (N=291) 
No. of participants who received ALL due IMB messages INDEPENDENT OF WHETHER they 
completed MI 1 
99/283 (35%) 1/291 (0.3%) 
Completion of first MI and initiation of SMS-sequence 
Completed first MI 227/283 (80.2%) 0/291 (0%) 
No. of participants who received ALL due messages after receipt of MI1 95/227 (41.9%) 0/0 (0%) 
SMS delivery for participants for whom the SMS-sequence was initiated (after receipt of first MI) 
 Mean (SD) Median (IQR) 
Range 
Mean (SD) Median (IQR) 
Range 
Average no. adherence messages received per participant (n=227) 7.9 (3.5) 10 (8-10) 
0-11 
0 0 
Average no. tobacco-related messages received (n=153) 5.4 (2.5) 7 (5-7) 
0-7 
0 0 
Average no. alcohol related messages received (n=171) 5.5 (2.5) 7 (5-7) 
0-7 
0 0 
Average no. IMB messages received (n= 227) 15.7 (7.3) 17 (13-22) 
0-25 
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Supplementary table 6 Unit costs used in the analysis (Presented in Rand as sources, $1=R14.448 in 2019) 
Item Unit costs 
Personnel LHWs: R3000/month, 160 hours/month, R18.75/hour; District coordinators: R7500/month, 160 hours/month, R46.88/hour; 
MRC appointed supervisor: R205.79/hour; Trainers: R373.17/hour; Administrative staff: R333.24/hour 
Materials Training manual: R3250; Printing: R3000; Additional printing & stationary: R500 
Accommodation / Travel 
/ Refreshments 
LHWs accommodation: R540 000; Trainers accommodation/travel: R36 000; Supervision accommodation/travel: R30 000; 
Refreshment: R12 500 
SMS system Monthly subscription at R433.44 ($30) for 3-months: R1300 
MI sessions Session 1 (17 minutes): R5.31; Session 2 (16 minutes): R5.00; Session 3 (17 minutes): R5.31 
Biochemical 
investigations 
Cost of TB smear microscopy: R28.37; culture: R79.22 and GeneXpert: R201.56 (Source: 2019/20 National Health Laboratory 
Service pricing schedule)* 
ART Atroiza: R3.78/dose; Dumiva: R5.55/dose; Tenemine: R2.34/dose; Zovilam: R1.72/dose; Kavimun: R1.89/dose; Ricovir: 
R1.36/dose; Zidomat: R1.38/dose; Lazena: R0.55/dose; Efrin:R0.63/dose; Efamat: R0.63/dose; Acriptaz: R0.61/dose (Source: 
Western Cape Department of Health. Antiretroviral and TB Stockmaster Worksheet. 2019) 
TB medication Month’s supply of RHZE (intensive) @ R65.80; RH (continuation) @ R55.56 (Source: Western Cape Department of Health. 






Page 43 of 155


















































Statistical Analysis Plan PROLIFE Trial Jan 2020 




Improving TB outcomes by modifying life-style behaviours through a brief motivational 
intervention followed by short text messages (Phase II) 
 
A multi-centre randomised controlled trial looking at the effect of a complex behavioural 










      Version date: 14 Feb 2020 25 Oct 2020 
Department of Health Sciences  Author(s): Mona Kanaan 
University of York     
York, YO10 5DD 
 
Principal Investigator: Olalekan Ayo-Yusuf and Kamran Siddiqi    
Trial Coordinator: Goedele M Louwagie 
 
Sponsor Olalekan Ayo-Yusuf, Sefako Makgatho 
University/ University of Pretoria 
Funder Newton Fund/MRC 
Funder Reference Number MRC-RFA-02: TB -05-2015 
 
 
Page 44 of 155
































































Statistical Analysis Plan PROLIFE Trial Jan 2020 






1. Definition of terms ........................................................................................................................ 4 
2. Trial Objectives ............................................................................................................................. 5 
3. Design ........................................................................................................................................... 6 
4. Sample Size ................................................................................................................................... 7 
5. Randomisation .............................................................................................................................. 7 
6. Outcomes ...................................................................................................................................... 8 
6.1 Primary outcome ........................................................................................................................ 8 
6.2 Secondary outcomes ................................................................................................................... 9 
6.2.1 Monitoring adverse events .................................................................................................. 9 
6.3 Trial assessment schedule ......................................................................................................... 11 
6.4 Other important information .................................................................................................... 12 
6.5 Fidelity of the intervention ....................................................................................................... 12 
7. Data ............................................................................................................................................ 13 
7.1 Data collection methods ........................................................................................................... 13 
7.2 Data management .................................................................................................................... 16 
8. Analysis ....................................................................................................................................... 17 
8.1 Participants Flow ....................................................................................................................... 18 
8.2 Baseline data ............................................................................................................................. 19 
8.3 Primary analysis ........................................................................................................................ 24 
8.3.1 Primary outcome definition: .............................................................................................. 24 
8.3.2 Primary outcome Analysis .................................................................................................. 24 
8.3.3 Primary outcome Analysis Results ..................................................................................... 25 
8.4 Secondary analyses ................................................................................................................... 26 
8.4.1 Secondary outcome definitions that involve defining a positive baseline test: ....... 27 
8.4.2 Continuous Abstinence ...................................................................................................... 29 
8.4.4 Change in harmful or hazardous drinking at month 3 and 6 follow-ups ............................ 32 
8.4.5 Proportion of ART uptake of HIV-positive participants at month 3 and 6 follow-ups . 34 
8.5 Subgroup analyses (See above analyses) .................................................................................. 35 
8.5 Sensitivity analyses ................................................................................................................... 35 
8.6 Adverse events .......................................................................................................................... 36 
8.7 Planned interim review and analyses........................................................................................ 36 
STATISTICAL ANALYSIS PLAN 
V1.2 
Page 45 of 155
































































Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 3 of 67 
 
8.8 List of Tables and Graphs .......................................................................................................... 37 
9. SAP amendment log .................................................................................................................... 38 
10. Signatures of approval ............................................................................................................ 38 
11. References .............................................................................................................................. 39 
12. Appendix A (Results tables)..................................................................................................... 40 
Table 1: ........................................................................................................................................... 40 
13. Appendix B (Scoring notes + ) ........................................................... Error! Bookmark not defined. 
13. Additional descriptive Statistics .............................................................................................. 65 
 
 
This analysis plan deals only with the statistical analysis of the trial.  
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ACTG AIDS Clinical Trials Group 
AE Adverse Event  
ART Anti-retroviral therapy 
AUDIT Alcohol Use Disorders Identification Test 
CI Confidence Interval 
CO Carbon monoxide 
CONSORT Consolidated Standards of Reporting Trials 
CRF  Case Report Form 
EPTB Extra-pulmonary TB 
HIV Human immunodeficiency virus 
LHW Lay health worker 
MI Motivational interviewing 
PTB Pulmonary TB 
SMS  Short Message Service 
SA South Africa 
SADHS South Africa Demographic and Health Survey 
SAE Serious Adverse Event  
SD Standard deviation 
SOPs Standard Operating Procedures  
TB Tuberculosis 
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2. Trial Objectives 
 
The PROLIFE model is a complex behavioural intervention comprised of a brief 
motivational interviewing (MI) counselling strategy augmented with subsequent SMS 
messaging. To be delivered in three brief sessions, the MI intervention will target three 
main areas, as appropriate:  
• Tobacco smoking  
• Alcohol drinking  
• Tuberculosis (TB) and Anti-retroviral therapy (ART) adherence or ART initiation  
 
Primary objective: 
● To assess the effectiveness of the PROLIFE model delivered by lay health 
workers (LWH) compared to usual care in improving Pulmonary TB (PTB) 
treatment outcomes 
 
Secondary objective: (this element will not be addressed in this SAP) 
● To estimate the cost-effectiveness of the PROLIFE model 
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This is a pragmatic, prospective, multicentre, two-arm, parallel, individual RCT taking place in 
27 purposively selected primary care clinics with the highest TB case-load in three districts in 
South Africa: Welkom in the Free State; Bojanala in the North West province; and Sedibeng 
in Gauteng province. The intervention will be delivered by LHWs and three district 
coordinators who will each cover 1–2 clinics. 
 
This is a pragmatic parallel superiority individually randomised controlled trial. There are two 
treatment arms: 
 
The control arm (Arm1): Intervention arm – participants will receive the PROLIFE 
programme;  
The intervention arm (Arm2): Control arm – participants will receive usual treatment and 
support provided to TB patients in TB treatment clinics in South Africa (‘usual care’). 
 
Full details of the background and design of the trial are presented in the protocol (version 
1.2 Prolife Protocol_15 Dec 17_with markup) and the published protocol in Moriarty et al 




The inclusion criteria for participants are: 
• adult patients (aged ≥ 18 years)  
• with drug-sensitive (bacteriologically or clinically confirmed) PTB; 
• initiating TB treatment or on TB treatment for < 1 month (these include both ‘new’ 
and ‘retreatment’ patients); 
• current smokers and/or 
•  hazardous/harmful drinkers who are not alcohol dependent (Alcohol Use Disorders 
Identification Test [AUDIT] score ≥ 8 for men or ≥ 7 for women but < 20); 
• access to a functional mobile phone; and 
• understand one of the four languages used for the trial (Sesotho, Setswana, Isizulu or 
English). 
Exclusion criteria: 
• alcohol-dependent participants (AUDIT score ≥ 20); 
• Extrapulmonary TB without PTB; or 
• Resistance to one or more TB drugs at baseline  
  
Page 49 of 155
































































Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 7 of 67 
 
4. Sample Size 
 
We will recruit 696 participants (348 per study arm).  The sample size calculations were 
based on the following assumptions: 
• Detection a 10% difference in TB treatment success rates (0.86 vs 0.76) in the 
ProLife group versus the control group  
• 80% power,  
• a significance level of 0.05, and  
• 25% attrition.  
The sample size per clinic was in the range of 14–74 participants per clinic with a median of 
24. The assumed success rates in the control group are based on actual success rates in TB 




Patients will be randomised using a randomised sequence generator performed by the trial 
statistician (MK) who will remain blind to the arm allocation. We will use block randomisation 
with varying block sizes stratified by the clinic to achieve equal numbers in intervention and 
control groups within each clinic. Allocation concealment will be done with consecutively 
numbered, sealed, opaque envelopes. 
 
Lay health workers delivering the intervention, field researchers, and participants cannot be 
blinded to the intervention. However, the determination of the primary outcome will be 
completed by TB nurses who are blinded to the intervention status of the participants based 
on routinely collected data.  
 
The statistician will be blinded to the intervention or control arm allocation of participants 
during the analysis stage.  
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6. Outcomes 
6.1 Primary outcome 
The primary outcome is TB treatment success at six to nine months of follow-up. This is a 
binary variable defined as  
• Success: cured or treatment completed  
• Failure: failed treatment, death, acquired drug resistance, loss to follow-up or 
‘default’, or not outcome evaluated.  





Cure Patient in whom baseline smear or culture was positive at beginning of 
treatment AND is smear/culture negative in the last month of treatment and 
on at least one previous occasion at least 30 days prior 
According to local protocol, a patient who is diagnosed using Gene Xpert and 
is sputum negative for TB at 11 and 23 weeks is considered ‘Cured’. 
Treatment 
completed 
Patient whose baseline smear or culture was positive at the beginning and 
has completed treatment but does not have a negative smear/culture in the 
last month of treatment and on at least one previous occasion > 30 days 
prior. Patients diagnosed with PTB whose baseline smear (or culture) result 
was negative and who started treatment based on clinical and radiological 
findings who have shown clinical improvement and completed the prescribed 
course of treatment. 
N.B. The smear examination may not have been done or the results may not 
be available at the end of treatment. 
Treatment 
failure 
Patient whose baseline smear or culture was positive and remains or 
becomes positive again at 5 months or later during treatment. 
Patients who were negative at baseline but were later found to be positive. 
N.B. This definition excludes those patients who are diagnosed with RR-TB or 
MDR-TB during treatment. 
Died Patient who dies for any reason during the course of TB treatment. 
Treatment 
default 
Patient whose treatment was interrupted for two consecutive months or 
more during the treatment period. 
Transfer 
out 
Patient who was referred to a facility in another district to continue 
treatment and for whom the treatment outcome is not known. 
Acquired 
resistance 
Participants who are subsequently referred for MDR treatment. 
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6.2 Secondary outcomes 
 
The following outcome measures will be recorded at the six-month follow-up: 
• sputum conversion at the end of treatment in the group of participants who had 
bacteriology confirmed PTB at baseline 1 
• continuous smoking abstinence for identified smokers at baseline2 
 
Whereas, the following will be assessed at three and six months follow-up: 
• reduction in harmful or hazardous drinking3 
• TB and ART medication adherence will be measured using a modified version of the 
AIDS Clinical Trials Group (ACTG) Adherence Questionnaire4; using an adherence 
index calculated by the formula (using the four-day recall table): 
 
[Total number of doses taken/Total number of doses prescribed] x 100 
 
Patients with at least 95% of adherence will be considered as having optimal 
adherence otherwise will be considered as having low (or suboptimal) adherence.  
• increase in proportion of HIV-positive participants on ART  at three  and six months  
from baseline using standardised questions on the CRF. 
 
 
6.2.1 Monitoring adverse events 
Adverse events (AE) and serious adverse events (SAE) will be defined apriori and relevant 
information will be collected.  
 
A Serious Adverse Event (SAE) is actually a special case of an adverse 
event where adverse outcomes are severe. It includes following events: Death of any of the 
participants associated with a clinical trial. Examples of events: Death, a life-
threatening adverse event, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant. 
 
An adverse event (AE) is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily 
have a causal relationship with this treatment. 
 
The events are reported to ethics committee within 72 hours  
 
1 i.e. cure rates in intervention group versus control group for participants who initially had sputum AFB-
positive, culture-positive or GeneXpert-positive PTB 
2 defined as a self-report of not smoking > 5 cigarettes six months from the start of the abstinence period, 
supported by a negative biochemical test CO < 7 ppm 
3 alcohol use will be measured using the AUDIT questionnaire. The questionnaire will be administered at 
screening (which will take place on the same day or shortly after the baseline assessment) and again at three months and six months.  
4 The questionnaire is a validated tool for measuring adherence specifically to ART and we will use an 
adapted version to also measure TB medication adherence [40]. 
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The following information were collected to report the events: 
Participants identification number, Gender, Age, Date of Enrollment, Arm (Control or 
intervention), Date of death notification to staff, Date of death , If death is related or not 
related to study. 
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6.3 Trial assessment schedule 
Table 2 details the trial assessment schedule 
 





















ELIGIBILITY        
Smoking status  X      
Smoking profile   X     
Alcohol profile  X      
Medical eligibility  X      
Eligible, consenting  X      
MEASURES        
Trial ID, visit date   X     
Socio-demographic history    X     
Depression screen   X  X X  
Clinical review of TB Treatment record 
for disease information 
  X    X 
Smoking history    X     
Smoking abstinence (self-report)     X X  
Exhaled CO     X X  
Record sputum culture or smear or 
Gene Expert  result 
  X X X X  
HIV Status   X     
ART Status (if HIV positive)   X  X X  
AUDIT  X   X X  
Modified ACTG (Follow up)     X X  
Economic evaluation   X  X X  
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6.4 Other important information 
 
In addition to the above, the following information was collected at baseline.  
Socio-demographic history included age, gender, marital status, education, 
employment status, and comorbidities. For details about these variables, see Table 3.   
 
6.5 Fidelity of the intervention 
  
The main fidelity analysis will be published somewhere else. Some descriptive statistics 
regarding  fidelity will be added here once the main analysis is completed and the 
statistician is unblinded to the treatment arm. 
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7. Data  
 
7.1 Data collection methods   
 
The fieldworkers will screen all TB patients for eligibility immediately after the TB nurse at 
the clinic has initiated TB treatment and opened the TB “blue card”. Consent will be obtained 
for this screening phase as the alcohol related questions are sensitive and the fieldworkers must 
gain insight in the patient files. 
 
Eligible and consenting patients will be enrolled in the trial and the baseline questionnaire and 
record review completed. Patients will be given a unique Trial Number that will be used on all 
research documents. Data will be collected and recorded by field workers equipped with 
Android phones with a mobile data collection application installed. 
Participants in the control arm will continue with the routine TB care. Intervention arm study 
participants will be referred by the fieldworker to the lay counsellor for motivational 
interviewing. The first MI session will be on the same day of the completion of the screening 
questionnaire, where possible (with a 2-week window period). The second and third MI session 
will be scheduled 4 weeks and 8 weeks from the first counselling session respectively each 
time with a 2-week window period. 
MI counselling and data collection will take place in a well-ventilated private area inside or 
outside the clinic, and audio-recorded after consent obtained. Fieldworkers and LHWs will be 
provided with high particulate respirator masks to minimise the risk of infection. 
Fieldworkers will follow-up all participants in both arms at 3 and 6 months within a window 
period of 2-weeks before and 2-weeks after the ideal 3 and 6-month visit. Participants will 
receive SMS reminders 3 days before each planned visit. Participants will also be in a position 
to send “please call me “messages to the fieldworkers or district coordinators, who will then 
call the participant to solve problems that may have arisen with the appointment. 
Patients who did not return for the planned 3 and 6 months visit will be contacted by 
telephone up to 3-times, as needed. Home visits will also be undertaken by existing clinic 
“tracer teams” or Community Based Outreach teams -where feasible - for participants who 
cannot be traced by telephone. The data collection process is illustrated in Table 3.  
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Table 3: Data Collection Process by time-point and details of data collection method 
Time-point Information required at time-point Data collection method 
Baseline 
interview 
1. Socioeconomic and demographic status (to 
include history of mine work) 
● Age 
● Gender 
● Marital status 
● Educational level achieved 
● Employment 
● Mine work/type of mine work 
 
2. Clinical information: 
● Patient category (First episode vs recurrence) 
● Site of disease  
● Results of sputum smear, culture and Gene 
Xpert 
● HIV status 
● ART information 
● Co-morbidities 
 
3. Current smoking status and quit history, 




4. Alcohol history  







CRF – Questions 






CRF – Questions 
to participant and 
information from 
the TB Treatment 
Record (as 

















3 months 1. ART information 
 
2. TB and ART medication adherence 
(modified ACTCG) 
 
3. Alcohol history (repeat AUDIT) 
 
4. Smoking history  
5. SLT use 
 
 









AUDIT score at 3 
month 
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6. Depression   
Follow-up 
questions as per 
Russell’s Standard 




6 months 1. TB treatment status (Primary outcome) 
 
 
2. Sputum smear or culture result 
 
3. ART information 
 
 
4. TB and ART medication adherence  
 
5. Alcohol history (repeat AUDIT) 
 
 








TB record on 








questionnaire at 6 
months 
 
AUDIT at 6 
months 
 
Questions as per 
Russell’s Standard 
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7.2 Data management  
 
Sefako Makgatho University (SMU) appointed a data manager who will utilise an electronic 
platform for data collection, ensuring data quality, and facilitating the SMS messages.  
 
Fieldworkers collecting research data will be equipped with Android mobile phones, which 
will have a mobile application installed on them to allow for data collection in areas with 
poor internet connectivity. The electronic data captured will be stored on secure and 
password protected storage servers and mobile phones, which ensure data privacy through 
only allowing authorised research staff access to the data. 
 
The electronic data collection system used for the study requires an SMS gateway to send and 
receive messages to the research participants. Consenting participants’ phone numbers, 
participant IDs, and associated SMS messages will be stored on the SMS gateway’s secured 
and password-protected server. 
 
Data quality will be ensured by providing fieldworkers with standard operating procedures 
(SOPs), training, and ongoing support on the importance of data quality, data collection, and 
data collection problem-solving. The data manager will continuously monitor the captured 
data for missing variables and inconsistencies in order to resolve any data problems.  
 
The data manager will export the data from the secured server, conceal the participants study 
arm allocation, and de-identify the data before sharing the data in STATA and R compatible 
formats.  The exported de-identified data will be stored in Dropbox, a secure cloud storage 
platform, for sharing with the lead trial statistician at the Universit  of York for analysis.  
 
All research data and documents referring to the PROLIFE trial will be stored and maintained 
in a secured storage space at SMU for a minimum of 15 years from the end of the PROLIFE 
trial. Study materials will be destroyed 15 years after the study. 
  
Page 59 of 155
































































Statistical Analysis Plan PROLIFE Trial Jan 2020 




The computer packages STATA 16 (StataCorp. 2019) and R 3.5.3 (ref) will be used.  
Significance tests will be two-sided and the significance level is set at 0.05.  The statistician 
will remain blind to allocation until results are finalised.  We will follow the CONSORT 
statement guidelines in reporting. 
 
Below, we detail the analyses that we will carry out for the data collected at baseline, the 
primary outcome, the secondary outcomes, and adverse events. We also list the sensitivity 
analyses that we might perform and subgroup analyses.  
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8.1 Participants Flow 
 




Assessed for eligibility (n=  ) 
Excluded   
Participants 
   Not meeting inclusion criteria ( ) 
   Declined to participate ( ) 
   Other reasons ( ) 
 
Analysed  (n= ) 
 
 Excluded from analysis (give reasons) (n= ) 
 
Month 3 
Lost to follow-up  (n= ) 
Discontinued intervention (give reasons)  (n= ) 
Month 6-9 (primary outcome assessed) 
Lost to follow-up  (n= ) 
Discontinued intervention (give reasons)  (n= )  
Allocated to intervention  
(n= ) 
 Received allocated intervention (n= ) 
-MI 1 (n=)  
-MI 2 (n=)  
-MI 3 (n=)  
 Did not receive allocated intervention (give 
reasons) (n= ) 
-MI 1 (n=) plus reasons 
-MI 2 (n=) plus reasons 
-MI 3 (n=) plus reasons 
Month 3 
Lost to follow-up  (n= ) 
Discontinued intervention (give reasons)  (n= ) 
Month 6-9 (primary outcome assessed) 
Lost to follow-up  (n= ) 
Discontinued intervention (give reasons)  (n= )  
Allocated to control  
(n= ) 
 Received allocated intervention (n= ) 
 Did not receive allocated intervention (give 
reasons) (n= ) 
-MI 1 (n=) plus reasons 
-MI 2 (n=) plus reasons 
-MI 3 (n=) plus reasons 
 
 
Analysed  (n= ) 
 








Figure 1 CONSORT DIAGRAM SHOWING FLOW OF PARTICIPANTS 
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8.2 Baseline data 
 
Baseline data Analysis Plan: 
Baseline data including demographic variables will be summarised 
descriptively by trial arm, but no formal statistical comparisons will be undertaken.  
Continuous measures will be reported as means and standard deviations (SD) while 
categorical data will be reported as counts and percentages, see Tables 1 to 4 in 
Appendix A.  For skewed continuous measures, we will also provide medians and 
interquartile ranges.  
 




In the control arm (Arm1) 286 gave written consent and 5 verbal consent for 
participation in the study and for access to their medical records 
In the intervention arm (Arm2) 279 gave written consent and 4 verbal consent for 






 It seems that for education there is imbalance between the two arms for Grades 8-
11/Grade 12/Higher; the control arm (Arm1) had a higher educated group the 
difference in percentage points 8.2% as opposed to 2.8% in the intervention arm, 
see Table 2 for further details. There are 9 participants who are not literate in the 




In the intervention arm, 223 (78.8%) had a drink in the past 12-months compared to 
208 (71.5%) in the control arm, see Table 3.  
In the control arm (Arm1), 110 (37.8%) were drinkers only, 83 (28.5%) were smokers 
only, and 98 (33.7%) were smokers and drinkers compared to 92 (32.5%), 60 (21.2%),  
and 131 (46.3%) in the intervention arm (Arm2), respectively.   
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The vast majority had a radio (84%), a television (89%), a refrigerator (85%), an 
electric or gas stove (86%), and a microwave (67%), however, only 50% had a 
washing machine. Furthermore, a minority had a landline telephone (7.5%), a 
desktop or laptop computer (20%:), and a vacuum cleaner or floor polisher (15%).  
Figure 2 is a boxplot of the total number of assets by study arm. The spread in the 
control arm (Arm1) is greater than that in the intervention arm (Arm2). However, the 
mean number of assets is similar across the two groups of 5 (SD: 1.87).  
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There were 305 (53.2%) HIV positive participants out of which   204 (65.38%) were 
using Cotrimoxazole and 257 (82.37%) were undergoing anti-retroviral therapy, see 
Table 2. 
TB History: The vast majority of participants were New TB patients 513(91.3%), with 
Pulmonary only (ICD-10 A15) being the site of disease for the vast majority 553 
(98.9%). Among those with results known, the majority had one pre-treatment smear 
result 366 (89.9%), one Gene XPert recorded 435 (97.5%), and one culture result 
recorded 96 (96%).  
Among those with results available, 220 (58.51%) had at least one positive smear 
result,362 (87.23%) had at least one positive Gene XPert result, and 35 (47.95%) 
at least one positive culture result.  
However, 85 (53.46%) in the control arm had at least one positive smear result 
within 60 days of the TB treatment start date compared to 96 (61.15%) in the 
intervention arm.  
In addition, only 34 had their culture results within 60 days from the TB start dates of 
which 21 had positive results; 11 in the control arm compared to 10 in the 
intervention arm.  
The vast majority of participants did not have any co-morbidities 525 (96.3%) and 
18 (3.3%) had one.  
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Baseline Smoking Related variables: 
 
Thirty five percent (202) did not smoke in the past month, whereas 52% smoked daily 
and the remaining 13% smoked in the past month but less frequently than on a daily 
basis, see Table 3.  
 
In the past 30 days, the vast majority were exposed to smoke for seven days or less 
at: home  462 (80.5%); cafes/restaurants 464 (80.8%); Shebeens, bars or clubs  432 
(75.3%); Bus/train/taxi/ vehicle 448 (78.0%); and Shops/shopping mall 461 (80.3%) 
and where applicable  at the workplace 173 (66.8%).  
Among those who smoked in the past month 372:  181 in the control arm (Arm1) vs 
191 in the intervention arm (Arm2),   
 
345 (92.7%) smoked manufactured cigarettes of which 225(65%) did so on a daily 
basis in the past seven days whereas 40 (11.6%) did not smoke in the past week. The 
mean number of days smoked was 5.42 days in the past week (SD: 2.49) with 6.34 
cigarettes (SD: 7.39) smoked daily on average.  
 
Hand-Rolled cigarettes were used by 35 participants of which 16 (45.7%) smoked 
daily in the past week. They smoked on average for 4.11 (SD:2.91) days in the past 
week and on average smoked 3.77 (SD: 3.27) hand-rolled cigarettes per day. 
 
There was only one person who exclusively smoked waterpipe, two who exclusively 
smoked pipe, and seven who exclusively used other formats of tobacco other than 
the ones that are listed here.  
 
For the vast majority the total number of cigarettes smoked is based on their answer 
to   manufactured cigarettes. In 27 cases, they supplemented this with other sources 
and 8 used only other forms to report the number smoked on average per day. 
 
Over the past 3 months, they spent on average 174.58 (SD: 181.61) Rands per week 
on tobacco products. 
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Smoking restrictions  
 
No smoking was allowed inside home for 204(54.8%) participants, whereas 
119(32.0%) had some rule where/when it is allowed and 49(13.2%) had no rules in 
place.  
 
Quit Attempts:  
 
Among smokers, 116 (31.2%) made an attempt to quit; the mean number of attempts 
to quit was 2.56 (SD: 2.32).  
 
Furthermore, 213 (57.3%) said they will probably try to quit smoking completely and 
permanently in the next three months and 126 (33.9%) said that they definitely will.  
 
Whereas, 207 (55.6%) said they will probably quit smoking completely and 
permanently in the next three months and 130 (34.9%) said that they definitely will. 
 
Only 39 (10.5%) have ever used any methods in the past 3 months to help them stop 
smoking tobacco. These spent on average 136.64 (SD:  205.36) Rands on methods 
to help you stop smoking in the past 3 months. 
 
Smokeless tobacco was used by only 24 participants (4.2%). They have been 
using ST for an average of 10.5 years (SD: 8.8) and have started using it at the age 
of 27 (SD: 11.33) years on average.  
 
Heaviness of smoking:  
 
In the control arm (Arm1), 67(37.0%) of smokers reported smoking within 5 minutes 
of waking up whereas 82(42.9%) did so in the intervention arm (Arm2).  
 
Among those who smoked and who reported the number of cigarettes/pipes/cigars 
they used on average per day, 134(74.03%) in the control arm (Arm1) and 
158(82.72%) in the intervention arm (Arm2) were considered as heavy smokers.  
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8.3 Primary analysis 
 
8.3.1 Primary outcome definition: 
 
As per section 6.1, we would define the primary outcome as those who had a 
successful treatment versus not.  Where successful treatment is considered if the 
patient is considered to have been cured or treatment completed; all other categories 
will be deemed as not successful.  The successful treatment5 categories are defined 
as follows:  
Cure Patient in whom baseline smear or culture was positive at beginning of 
treatment AND is smear/culture negative in the last month of treatment 
and on at least one previous occasion at least 30 days prior 
According to local protocol, a patient who is diagnosed using Gene 




Patient whose baseline smear or culture was positive at the beginning 
and has completed treatment but does not have a negative 
smear/culture in the last month of treatment and on at least one 
previous occasion > 30 days prior. Patients diagnosed with PTB whose 
baseline smear (or culture) result was negative and who started 
treatment based on clinical and radiological findings who have shown 
clinical improvement and completed the prescribed course of 
treatment. 
N.B. The smear examination may not have been done or the results 
may not be available at the end of treatment. 
 
 
8.3.2 Primary outcome Analysis 
 
For the primary outcome, we will conduct analysis on an intention-to-treat basis. We 
will use binary logistic regression to compare the main outcome between the 
 
5 Following  discussion with the team, we will take this at face value as it  is not possible 
to query some of the anomalies found in the recording of dates of tests. 
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intervention and the usual care arm. We will also investigate any potential clustering 
at the centre level and account for it.  We will present the results for this analysis in 
Table 6.   
 
We will also adjust for HIV status, sex, alcohol versus tobacco versus both, and 
district; if these differ between trial arms at baseline. 
 
8.3.3 Primary outcome Analysis Results 
 
 
Table 4 gives the descriptive statistics for the initial outcome and the derived -
dichotomised outcome; these indicate that overall, 69% were classified as successful 
treatment based on the medical professional assessment (cured/treatment 
completed).  This percentage was similar for the two arms with the control arm 
(Arm1) having a slightly higher percentage of success of 70.1% compared to 67.8% 
in the intervention arm (Arm2)6. Table 9 gives the distribution per centre by study 
arm. Generally, these are fairly balanced any imbalance observed is most probably 
due to the early termination of the study.  
 
For 203 participants, the TB treatment outcome date was not available, with those 
participants more likely to not have been cured (59% not cured), however, the 
percentage was similar across the two study arms for those with missing TB 
treatment outcome date.    
 
The odds of successful treatment is 0.9 (95% CI: (0.64,1.27)) in the intervention arm 
(Arm2) compared to the control arm (Arm1). This estimate is very similar to the 
estimate adjusting for district and drinking/smoking status. This is also the case if 
you further adjust for sex and HIV status at baseline where the OR is 0.86 (95% CI: 




6 Primary outcome Control: 204/291, 95% CI proportion  0.70 (0.64,0.75) 
Primary outcome Intervention:192/283, 95% CI proportion 0.68 (0.62,0.73) 
Page 68 of 155
































































Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 26 of 67 
 
8.4 Secondary analyses 
 
Secondary analyses plan 
 
In the group of participants who had bacteriology confirmed at baseline, we will use 
logistic regression to compare cured versus not cured, as indicated by the outcome 
at the end of treatment, between the two study arms.  We will also control for 
baseline characteristics and other covariates such as sex, alcohol use, HIV-status, 
district, and account for any potential clustering by centre.   
 
We will use a similar approach for the six-months continuous smoking abstinence 
outcome. This analysis will be performed on the group of participants who were 
current tobacco smokers at baseline. We will also control for baseline characteristics 
and other covariates such as age, duration of smoking, alcohol problem (hazardous, 
harmful, non-drinker/light drinker), heaviness of smoking index7, depression, and 
potentially HIV-status. 
 
For the reduction in harmful or hazardous drinking, we will use linear regression to 
measure difference in total AUDIT score between control and intervention groups 
accounting for the baseline AUDIT scores. Separate analyses for the AUDIT at 3 and 
6 months will be performed.   
 
The AUDIT is a 10-items questionnaire with a range between 0 and 40 where higher 
values indicate higher dependency.8  It is worth mentioning that a score of 8 or more 
 
7 [Goedele’s Comment on an earlier Version]Definitely a measure of severity of smoking and duration of 
smoking. For example Heaviness of Smoking Index which can be derived as follows: 
HSI=Heaviness of smoking index ≥ 4, calculated based on sum of time to first cigarette (0: 61+min, 1:31-60 min, 2: 6-30 
min, 3: ≤5 min) and number of cigarettes smoked per day (0: 0-10 cigarettes per day [CPD] 
Also: age, duration of smoking, alcohol problem (hazardous, harmful, non-drinker/light drinker), maybe HIV-status, (adding 
this may reduce your sample size too much, because of missing HIV-status, unless you include HIVstatus unknown as a 
category of HIV-status). Depression 
8 Scoring the audit  
Scores for each question range from 0 to 4, with the first response for each question (eg never) scoring 0, 
the second (eg less than monthly) scoring 1, the third (eg monthly) scoring 2, the fourth (eg weekly) 
scoring 3, and the last response (eg. daily or almost daily) scoring 4. For questions 9 and 10, which only 
have three responses, the scoring is 0, 2 and 4 (from left to right).  
A score of 8 or more is associated with harmful or hazardous drinking, a score of 13 or more in women, 
and 15 or more in men, is likely to indicate alcohol dependence.  
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is associated with harmful or hazardous drinking, a score of 13 or more in women, 
and 15 or more in men, is likely to indicate alcohol dependence. Eligibility criteria for 
our study is an AUDIT score ≥ 8 for men or ≥ 7 for women but <20. However, if 
assumptions of linear regression are not met we will either transform the data or use 
alternative regression analyses such as ordinal logistic regression.  
 
Adherence to TB and ART medication will be measured using an adherence index  
based on a modified version of the AIDS Clinical Trials Group (ACTG) Adherence 
Questionnaire; where patients with at least 95% of adherence will be considered as 
having optimal adherence otherwise will be considered as having low (or suboptimal) 
adherence.  We will use logistic regression to model patient’s characteristics (age, 
sex, alcohol, smoking status, depression) that might influence adherence at 6-month; 
we will also compare adherence between study arms.  Similar to the previous 
outcomes, we will account for any potential clustering by centre.  
 
We will also report the proportion of HIV-positive participants on ART at six months 
and compare these to the baseline using standardised questions on the CRF. 
 
8.4.1 Secondary outcome definitions that involve defining a positive baseline 
test: 
 
To operationalise the above we need to define how we determine if someone has a 
positive baseline smear or culture.  Each participant might have up to two tests of the 
following: smear test, GeneExpert test, and culture test.  
 
If a test was administered two times then to be considered negative both tests 
should be negative, otherwise it is considered positive.  If a test was administered 
only once, then the result of that instance is taken as is.  
 
 
1Saunders JB, Aasland OG, Babor TF et al. Development of the alcohol use disorders identification test 
(AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption — 
II. Addiction 1993, 88: 791–803 
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If for a patient more than one test was administered, then to be considered negative 
the result should be negative under both tests.  
 
This is illustrated in the following table.  
 
Baseline   P=+, N = -     
    XXXX Test at run 2 (Result 2)   
 XXXX Test run 1 (Result 1)   N  P                 
  N NN NP 
  P PN PP 
 XXXX=Smear or Culture or GeneXpert       
Smear test at baseline  N1 NN   
  P1 NP, PN, PP   
        
Genexpert N2 NN   
  P2 NP, PN, PP   
        
culture N3 NN   
  P3 NP, PN, PP   
        
Positive at baseline  PB P1 or P2 or P3   
Negative at baseline  NB N1 and N2 and N3   
 
To define a conversion among those who were positive at baseline, we used the 
primary outcome response category cured  to indicate a negative result at month 6 per 
the nurse’s assessment.  
 
Among the 403 participants who were positive at baseline 168(41.69%) were recorded 
as cured by 6-month of these 83 (39.9%) in the control arm compared to 85 (43.59%) 
see Table 4. The odds ratio of conversion is 1.16 (95% CI: (0.83,1.63)) comparing the 
intervention arm to the control arm.  When adjusting for district, sex, and 
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8.4.2 6-months Continuous Abstinence  
 
For this outcome, those who smoked cigarettes at baseline were considered as the 
analytic sample. In addition, those where the following could not be ascertained:  
self-report of not smoking > 5 cigarettes six months from the start of the abstinence 
period and supported by a negative biochemical test CO < 7 ppm were considered 
as smokers for the analysis of this variable. The number of participants who 
identified as cigarette smokers at baseline were 345 (60.1%)9.   
 
23 (85.19%) out of 27 with three measurements available10 managed to abstain 
continuously for six months.  These were similarly distributed across the two study 
arms, see Table 4.  Among those who identified as cigarette smokers, 10 (5.59%) 
participants in the intervention arm continuously abstained. In the control arm there 
were 12 (7.23%) who continuously abstained for 6-months.  
 
The crude odds of 6-months continuous abstinence is 0.76 (95% CI: (0.35,1.63)) in 
the intervention arm compared to the control arm among baseline cigarette smokers.  
Given the limited number of those who were identified as continually abstained, we 
were only able to adjust for one additional variable at a time. Adding one of  the 
following variables: heaviness of smoking, type of drinker at baseline, age when 
started smoking, and the duration of smoking at baseline, the adjusted odds ratio of 
continuous abstinence comparing the intervention to the control arm did not differ 
much from the crude estimate of 0.76. The adjusted estimate for the various models 
ranged between 0.73 and 0.76 with similar confidence limits as for the crude 
estimate.  Furthermore, we did not have evidence that any of the adjusting variables 
were statistically significantly correlated to continuous abstinence in these models.  
 
We carried an additional analysis where those who died and were smokers at 
baseline, 22 in total, 20 were cigarette smokers and were removed from the 
analytical sample for the continuous abstinence outcome.  This resulted in a crude 
 
9 Any type of tobacco smoking at baseline 372 (64.8%).  The numbers reflect those who used manufactured 
cigarettes which were the vast majority. 
10 We had only 27 participants who had self-report of not smoking at 3 months,  6 months and a  carbon 
monoxide reading at 6 months. Continuous abstinence was defined as a self-report of not smoking > 5 
cigarettes six months from the start of the abstinence period and supported by a negative biochemical test CO 
< 7 ppm 
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OR of 0.78 which is similar to the OR when the larger analytic sample was 
considered; this was also the case for the associated 95% CI. Similar estimates were 
observed when adjusting for the aforementioned variables.  
 
We carried an additional analysis where the analytic sample was all those who were 
smokers regardless of the type used. There were a total of 372 that identified as 
smokers. The crude odds ratio in this case changes to 0.86 (95% CI: (0.38,1.95)). 
The 95% CI is similar to that of the smaller analytic sample. When adjusting for the 
heaviness of smoking, type of drinker at baseline, age when started smoking, and 
the duration of smoking at baseline, the adjusted odds ratio of continuous abstinence 
comparing the intervention to the control arm did not differ much from the crude 
estimate. 
 
3-months Continuous Abstinence 
 
Among those who identified as cigarette smokers, 20 (11.17%) participants in the 
intervention arm continuously abstained for 3-months while in the control arm there 
were 27 (16.27%) who continuously abstained for 3-months.  
 
The crude odds of 3-months continuous abstinence is 0.65 (95% CI: (0.37,1.14)) in 
the intervention arm compared to the control arm among baseline cigarette smokers.  
Given the limited number of those who were identified as continually abstained, we 
were only able to adjust for one additional variable at a time. Adding one of  the 
following variables: heaviness of smoking, type of drinker at baseline, age when 
started smoking, and the duration of smoking at baseline, the adjusted odds ratio of 
continuous abstinence comparing the intervention to the control arm did not differ 
much from the crude estimate of 0.65. The adjusted estimate for the various models 
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Point Abstinence  
 
There were 57 participants who indicated that they stopped smoking tobacco 
completely at the 3-month follow-up, of which one had more than 5 cigarettes in the 
past 3 months.  There were 81 participants who indicated that they stopped smoking 
tobacco completely at the 6-month follow-up, of which three had more than 5 
cigarettes in the past 3 months. Only 30 participants had information for the entirety 
of the 6-month period, of which none consumed more than 5 cigarettes over the past 
6-month period.  Of these, 23 had a confirmed CO < 7 ppm, 4 had these levels >= 7, 
and 3 were missing.     
 
182 responded that they continued smoking either as usual or at a reduced rate but 
regularly at month 3; whereas 133 done so at month 6 of these we had 97 that had 
measurements at  both time points thus resulting  in a total of 218 where they  have 
smoked on a regular basis over the past 6 month period.  11 had responded as not 
smoking in the past three months at month 6 but had missing information for the first 
three months; 9 of these had carbon monoxide readings available at month 6. Of 
these nine, two had their CO >= 7 (in fact these were 10 & 10.1).   
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8.4.4 Change in harmful or hazardous drinking at month 3 and 6 follow-ups 
 
 
Alcohol use was measured using the AUDIT questionnaire. We will assess whether 
there has been a reduction in alcohol consumption three months and six months 
following recruitment.  This analysis will be performed on the group of participants 
who were harmful or hazardous drinkers at baseline. Figure YYY provides 
histograms of the AUDIT score at baseline, 3-months and 6-months, respectively, 
among those who were considered as hazardous or harmful drinkers.  It also 
presents scatterplots of the 3-months and 6-months scores versus the baseline 
scores for this group by trial arm, respectively. 
 
Among those who were harmful or hazardous drinkers at baseline those in the 
intervention arm had on average a reduction of 0.04 points (95% CI: (-2,1.91)) on the 
AUDIT score at 6-months compared to those in the control arm controlling for their 
baseline score, see Table 6.  However, when additionally adjusting for district, sex, 
and smoking/drinking status (which effectively flags smokers/non-smokers who are 
also drinkers) and HIV status at baseline; the intervention arm had an average 
increase of 0.02 points on the AUDIT score (95% CI: (-1.55,1.6)) compared to the 
control arm.  It is worth noting that of the variables in the adjusted model; the only 
statistically significant result is for the district variable. It seems that those in district 
“S”  score on average 5.8 points less than  those in “B” (95% CI: (-11.26,-0.35)); 
similarly those in “L” score 5 points less than  those in “B” on AUDIT  but  we do not 
have evidence that this difference is statistically significant  (95% CI: (-10.35,0.26)), 
see Table 6 for further details. 
 
At 3-month, the estimates were  an average increase of 0.55  (95% CI: (-1.01,2.11)) 
on the AUDIT score in the intervention arm compared to the control arm when only 
accounting for the baseline scores; whereas it increased to 0.74 (95% CI: (0.62,2.1)) 
when adjusting for other covariates in the model, for further details see Table 7.   
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Figure YYY:  Graphs (a), (b), and (c) are histograms of the AUDIT score at baseline, 3-months and 6-
months, respectively, among those who were considered as hazardous or harmful drinkers.  (d) and 
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8.4.5 Proportion of ART uptake of HIV-positive participants at month 3 and 6 follow-ups 
  
We will assess whether there has been an increase in proportion of HIV-positive 
participants on ART at three and six months from baseline using standardised 
questions on the CRF. 
 
There were 171 HIV-positive participants whose baseline ART medication status 
was known and whose ART medication status was known as well at 6-months. Of 
these, 123 remained on their medication, 19 took up medication at 6-months 
compared to not taking medication at baseline, whereas 29 stopped taking their 
medication at 6-months but were on medication at baseline, see Table 6 for further 
details.  
 
There were 10 who had an unknown status in terms of medication at baseline and 
no information was available about them at 6-months, 12 who were initially of 
unknown medication status who took up medication at 6-months (these were equally 
distributed between the two arms). Furthermore, there were 10 who were not taking 
medication at baseline and 102 who were taking medication at baseline whose 6-
months medication status was not recorded.  
 
At 6-months, the odds ratio of taking medication at 6-months was 2.05 (95% CI: 
(0.80,5.27)) in the intervention arm compared to the control arm, controlling for ART 
baseline medication status. 
 
There were 188 HIV-positive participants whose baseline ART medication status 
was known and whose ART medication status was known as well at 3-months. Of 
these, 122 remained on their medication, 16 took up medication at 3-months 
compared to not taking medication at baseline, whereas 50 stopped taking their 




There were 9 who had an unknown status in terms of medication at baseline and no 
information was available about them at 3-months, 11 who were initially of unknown 
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medication status who took up medication at 3-months, and two who were initially of 
unknown medication status who were not taking medication at 3-months. 
Furthermore, there were 9 who were not taking medication at baseline and 82 who 
were taking medication at baseline whose 3-months medication status was not 
recorded.  Furthermore, there were 4 who carried on not taking medication at 3-
months.     
 
At 3-months, the odds ratio of taking medication at 6-months was 0.79 (95% CI: 
(0.38,1.65)) in the intervention arm compared to the control arm, controlling for ART 




At 3-months 165 (98.8%) of 167 participants had optimal ART medication 
adherence, whereas 139(97.2%) of 143 had optimal ART medication adherence. 
These were similar across the two arms.  
 
Similarly, at 3-months 319(91.67%) of 348 participants had optimal TB medication 
adherence, whereas 120(90.23%) of 133 had optimal TB medication adherence. 
These were similar across the two arms.  
 
 
8.5 Subgroup analyses (See above analyses) 
We will conduct subgroup analyses to determine whether TB treatment outcomes differ 
between subgroups, as follows: HIV-positive versus HIV-negative participants; participants 
with an alcohol problem only versus smokers only versus participants who are conjoint 
smokers and drinkers; and participants who were GeneXpert positive versus participants 
who were GeneXpert negative at baseline. 
8.5 Sensitivity analyses 
 
In case of missing data, multiple imputations and appropriate sensitivity analyses will be 
conducted. As it is likely that more than one variable will have missing data we will use 
multiple imputations using chained equations (MICE). A minimum of 10 imputations will be 
performed; however, the final number of imputations will depend on the missing in the data. 
We will report the decisions that we make with regard to the number of imputations and the 
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variables we use in the imputations. We will also conduct a sensitivity analysis to explore the 
implications of the missing at random assumption [21p,22p]. 
 
8.6 Adverse events 
 
Analysis of adverse events and serious AE will explore whether these differ by treatment arm 
using Chi-square tests. 
8.7 Planned interim review and analyses 
 
No interim analysis is planned. The main analyses will be completed after three months of the 
data closing.  
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8.8 List of Tables and Graphs 
 
Measures of central tendency and percentages will be reported to two decimal places 
whereas measures of variability and p-values will be reported to three decimal places.   
 
 
The following is a list of suggested tables and graphs; the templates are included in Appendix 
A.  
 
TABLE 1: Numbers in the study at Baseline and follow-ups at month 3, and 6 by centre and  
study arm.  
TABLE 2:  Descriptive statistics for socio-demographic and socio-economic characteristics at 
baseline and as analysed by study arm. Frequencies and (percentages) are presented unless 
otherwise stated 
TABLE 3:  Descriptive statistics for smoking history, alcohol history, clinical characteristics 
and depression score at baseline and as analysed by study arm. Frequencies and 
(percentages) are presented unless otherwise stated. 
TABLE 4: Descriptive statistics for primary and secondary outcomes by study arm at baseline 
(where available), 3 month (where available) and 6 month. Frequencies and (percentages) 
are presented unless otherwise stated. 
TABLE 5:  Number and type of adverse events at month 2, 3, and 6 by centre and study arm. 
TABLE 6:   Regression analysis results for the primary and secondary outcomes at 6 month.  
Estimates presented with corresponding 95% CI.  Crude and adjusted estimates are 
provided.  
TABLE 7: Regression analysis results for the secondary outcomes that are measured at 3 
month.  Estimates presented with corresponding 95% CI.  Crude and adjusted estimates are 
provided.  
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9. SAP amendment log 
 
Amendment/addition to SAP and reason for change New version number, 
name and date 
SAP completed and signed-off V1.0,   




10. Signatures of approval 
Sign-off of the final approved version of the Statistical Analysis Plan by the principle 
investigator and trial statistician(s) (can also include Trial Manager/Co-ordinator) 
 
Name Trial Role Signature Date 
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12. Appendix A (Results tables) 
 
Table 1: Numbers in the study at Baseline and follow-ups at month 3 and 6 by centre and  study arm. (SEE FLOWCHART) 
 
TABLE 1: NUMBERS IN THE STUDY AT BASELINE AND FOLLOW-UPS AT MONTH 3 AND 6 BY CENTRE AND  STUDY ARM. 
Centre  Baseline Month 3 Month 6  
 Intervention  Control  Intervention  Control  Intervention  Control  
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
       
         
         
         
Total         
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TABLE 2:  Descriptive statistics for socio-demographic, socio-economic,  and clinical characteristics at baseline by study arm. Frequencies and (percentages) 
are presented unless otherwise stated 
 
TABLE 2:  DESCRIPTIVE STATISTICS FOR SOCIO-DEMOGRAPHIC, SOCIO-ECONOMIC,  AND CLINICAL CHARACTERISTICS AT BASELINE AND AS ANALYSED BY STUDY ARM. FREQUENCIES AND 
(PERCENTAGES) ARE PRESENTED UNLESS OTHERWISE STATED 
  Baseline 
 N1/N2 Control Intervention  Total 
  Arm 1 Arm 2  
     
Age in years: mean (SD) 291/283 39.37 (12.60) 38.56 (11.15)  
Age in years: median (IQR)     
Gender     
Female   69 (23.7) 60 (21.2) 129 (22.5) 
Male  222 (76.3) 223 (78.8) 445 (77.5) 
Do not want to disclose     
Marital status     
Married or living together  102 (35.1) 95 (33.6) 197 (34.3) 
Divorced/separated  20 (6.9) 18 (6.4) 38 (6.6) 
Widowed  10 (3.4) 7 (2.5) 17 (3.0) 
Never married and never lived together  144 (49.5) 150 (53.0) 294 (51.2) 
Declined to answer  15 (5.2) 13 (4.6) 28 (4.9) 
Education     
No education  7 (2.4) 5 (1.8) 12 (2.1) 
Grades 1-5  23 (7.9) 20 (7.1) 43 (7.5) 
Grades 6-7  32 (11.0) 35 (12.4) 67 (11.7) 
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Grades 8-11  96 (33.0) 128 (45.2) 224 (39.0) 
Grade 12  87 (29.9) 70 (24.7) 157 (27.4) 
Higher  24 (8.2) 8 (2.8) 32 (5.6) 
Declined to answer  22 (7.6) 17 (6.0) 39 (6.8) 
Employment     
Self-employed (full-time)  30 (10.3) 36 (12.7) 66 (11.5) 
Employed full-time (30 hrs a week or more)  62 (21.3) 54 (19.1) 116 (20.2) 
Employed part-time (less than 30 hrs a week)  19 (6.5) 29 (10.2) 48 (8.4) 
Retired  17 (5.8) 16 (5.7) 33 (5.7) 
Unemployed (but able to work)  125 (43.0) 120 (42.4) 245 (42.7) 
Unable to work because of long-term disability or 
ill health 
 
9 (3.1) 8 (2.8) 17 (3.0) 
Full-time student  12 (4.1) 4 (1.4) 16 (2.8) 
Caring from my home and family/doing 
household work/housewife 
 
0 (0.0) 2 (0.7) 2 (0.3) 
Occasional work (“piece job”)  17 (5.8) 12 (4.2) 29 (5.1) 
Declined to answer  0 (0.0) 2 (0.7) 2 (0.3) 
     
     
     
Ever worked or spent time in mines     
No  244 (83.8) 237 (83.7) 481 (83.8) 
Yes  46 (15.8) 45 (15.9) 91 (15.9) 
     
     
Socioeconomic status     
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Household items (Yes is displayed)     
A radio  249 (85.6) 234 (82.7) 483 (84.1) 
A television  255 (87.6) 255 (90.1) 510 (88.9) 
A landline telephone  21 (7.2) 22 (7.8) 43 (7.5) 
A desktop or laptop computer  67 (23.0) 48 (17.0) 115 (20.0) 
A refrigerator  248 (85.2) 240 (84.8) 488 (85.0) 
A vacuum cleaner or floor pol  49 (16.8) 35 (12.4) 84 (14.6) 
A microwave oven  198 (68.0) 189 (66.8) 387 (67.4) 
An electric or gas stove  254 (87.3) 238 (84.1) 492 (85.7) 
A washing machine  153 (52.6) 136 (48.1) 289 (50.3) 
Total number of assets: mean (SD)  5.14 (1.96) 4.94 (1.77) 5.04 (1.87) 
In the past month,  number of days you or people in 
the household went to bed hungry because there 
was no food to eat 
    
0 days  244 (83.8) 238 (84.1) 482 (84.0) 
1-7 days  45 (15.5) 34 (12.0) 79 (13.8) 
More than 7 days  2 (0.7) 9 (3.2) 11 (1.9) 
Declined to answer  0 (0.0) 2 (0.7) 2 (0.3) 
     
     
     
TB and medical history     
TB history     
Patient category     
New patient  264 (92.3) 249 (90.2) 513 (91.3) 
Relapse  10 (3.5) 9 (3.3) 19 (3.4) 
Re-treatment after default  9 (3.1) 14 (5.1) 23 (4.1) 
Re-treatment after failure  1 (0.3) 2 (0.7) 3 (0.5) 
Other   2 (0.7) 2 (0.7) 4 (0.7) 
Site of disease     
Pulmonary and Extra Pulmonary (ICD-10 A17-A19)   3 (1.1) 3 (1.1) 6 (1.1) 
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Pulmonary only (ICD-10 A15)  281 (98.9) 272 (98.9) 553 (98.9) 
Number of pre-treatment smear results      
One  197 (92.1) 169 (87.6) 366 (89.9) 
Two  17 (7.9) 24 (12.4) 41 (10.1) 
Smear result N = 196 180 376 
At least one positive smear result  111 (56.63) 109 (60.56) 220 (58.51) 
Number of Gene XPert results recorded     
One  225 (97.8) 210 (97.2) 435 (97.5) 
Two  5 (2.2) 6 (2.8) 11 (2.5) 
Gene XPert result  N = 211 204 415 
At least one positive Gene XPert result  184 (87.2) 178 (87.25) 362 (87.23) 
Number of culture results recorded on the 
TB Treatment record 
    
One  54 (94.7) 42 (97.7) 96 (96.0) 
Two  3 (5.3) 1 (2.3) 4 (4.0) 
Culture result  N = 41 32 73 
At least one positive culture result  20 (48.78) 15 (46.88) 35 (47.95) 
Co-morbidities     
Hypertension  19 (6.93) 11 (4.1) 30 (5.54) 
Diabetes  5 (1.84) 4 (1.49) 9 (1.66) 
Epilepsy  3 (1.09) 4 (1.49) 7 (1.29) 
Mental illness  3 (1.09) 0 (0) 3 (0.55) 
Liver disease  1 (0.36) 1 (0.38) 2 (0.37) 
Renal insufficiency  1 (0.36) 1 (0.38) 2 (0.37) 
Allergies  2 (0.76) 0 (0) 2 (0.38) 
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Other  1 (0.36) 1 (0.38) 2 (0.37) 
Total Number of comorbidities      
0  265 (96.0) 260 (96.7) 525 (96.3) 
1  10 (3.6) 8 (3.0) 18 (3.3) 
2  0 (0.0) 1 (0.4) 1 (0.2) 
5  1 (0.4) 0 (0.0) 1 (0.2) 
HIV status     
Negative  118 (40.7) 125 (44.2) 243 (42.4) 
Positive  163 (56.2) 142 (50.2) 305 (53.2) 
Unknown  9 (3.1) 16 (5.7) 25 (4.4) 
HIV positive patients     
          CD4 Count: mean(SD)     
            Using Cotrimoxazole  104 (63.8) 100(67.11) 204 (65.38) 
          Using anti-retroviral   139 (85.28) 118 (79.19) 257 (82.37) 
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TABLE 3:  Descriptive statistics for smoking history, alcohol history and depression score at baseline by study arm. Frequencies and (percentages) are 
presented unless otherwise stated. 
 
TABLE 3:  Descriptive statistics for smoking history, alcohol history and depression score at baseline and as analysed by study arm. Frequencies and (percentages) are 
presented unless otherwise stated. 
 Baseline 
 Control Intervention  Total 
 Arm 1 Arm 2 Total 
    
In the past month, smoked tobacco     
Not at all  110 (37.8) 92 (32.5) 202 (35.2) 
Daily 149 (51.2) 149 (52.7) 298 (51.9) 
Less than Daily 32 (11.0) 42 (14.8) 74 (12.9) 
    
Had a drink in the past 12-months 208 (71.5) 223 (78.8) 431 (75.1) 
AUDIT Score (males): mean (SD) [max :19] [min = 8 if drinkers only] 12.27 (3.98) 13.02 (3.78) 12.66 (3.89) 
AUDIT Score (females): mean (SD) [max :19] [min = 7 if drinkers only] 11.32 (4.02) 10.98 (4.02) 11.15 (4) 
    
Drinking and Smoking Combined (Constructed)    
Drinkers Only 110 (37.8) 92 (32.5) 202 (35.2) 
Smokers Only 83 (28.5) 60 (21.2) 143 (24.9) 
Smokers and Drinkers 98 (33.7) 131 (46.3) 229 (39.9) 
    
    
    
    
    
Page 89 of 155
















































For peer review only
Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 47 of 67 
 
 Arm 1 Arm 2 Total 
    
Smoking History (current smokers only) 181 191 372 
On the days that you smoke, how soon after you wake up do you have your first cigarette?    
After 60 minutes 30 (16.6) 28 (14.7) 58 (15.6) 
31-60 minutes 24 (13.3) 16 (8.4) 40 (10.8) 
6- 30 minutes 60 (33.1) 65 (34.0) 125 (33.6) 
Within 5 minutes 67 (37.0) 82 (42.9) 149 (40.1) 
Duration of smoking in months: mean (SD) 212.09 (134.03) 224.93 (127.82) 218.68 (130.86) 
Duration of smoking in months: median (IQR) 186 (110, 282) 206 (135, 294) 200.5 (123, 287) 
Age started smoking in years: mean (SD) 19.2 (6.3) 19.3 (6.3) 19.3 (6.3) 
Age started smoking in years: median (IQR) 18 (15-20) 18 (16-21) 18 (15.5-20.5) 
    
Form of tobacco used    
    
Manufactured cigarettes (Yes) 166 (91.7) 179 (93.7) 345 (92.7) 
Number of  days in the past 7days you smoked: mean (SD) 5.3 (2.65) 5.53 (2.33) 5.42 (2.49) 
Average number of cigarettes smoked daily: mean (SD) 6.18 (6.43) 6.48 (8.21) 6.34 (7.39) 
Hand-rolled cigarettes (Yes) 14 (7.7) 21 (11.0) 35 (9.4) 
Number of  days in the past 7days you smoked: mean (SD) 4.71 (2.84) 3.71 (2.95) 4.11 (2.91) 
Average number of handrolled cigarettes smoked daily: mean (SD) 3.71 (3.97) 3.81 (2.82) 3.77 (3.27) 
Pipe (Yes) 4 (2.2) 2 (1.0) 6 (1.6) 
Number of  days in the past 7days you smoked: median (IQR) 1 (0, 2.5) 4.5 (2, 7) 2 (0, 3) 
Average number of daily sessions: median (IQR) 1 (0, 3.5) 3 (1, 5) 1.5 (0, 5) 
Length  of one session (on average) in minutes: median (IQR) 90 (60, 107.5) 60 (30, 90) 90 (30, 90) 
Cigars, cheroots or cigarillos  (Yes) 1 (0.55) 0 (0)  1(0.27) 
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Water pipe (Yes) 3 (1.7) 2 (1.0) 5 (1.3) 
Other 10 (5.5) 4 (2.1) 14 (3.8) 
    
Heaviness of smoking index >= 4 134(74.03) 158(82.72) 292(78.49) 
    
Smoking inside your home restrictions    
Total: Not allowed 96 (53.0) 108 (56.5) 204 (54.8) 
Some rules: where/when it is allowed 61 (33.7) 58 (30.4) 119 (32.0) 
No rules 24 (13.3) 25 (13.1) 49 (13.2) 
    
Attempts to quit smoking (current smokers only) (Yes)    
Ever attempted to quit in the past    
Yes 52 (28.7) 64 (33.5) 116 (31.2) 
No 129 (71.3) 127 (66.5) 256 (68.8) 
Number of attempts to quit:  mean (SD) 2.46 (2.98) 2.64 (1.62) 2.56 (2.32) 
Time elapsed since attempt  to quit last time in months:  mean (SD) 36.65 (94.62) 25.13 (37.91) 30.29 (69.22) 
Longest duration abstinent in previous quit attempts:  mean (SD) 6.15 (13.48) 4.22 (8.9) 5.09 (11.18) 
    
Likelihood to TRY TO QUIT smoking completely and permanently in the next three months    
definitely will not 
6 (3.3) 5 (2.6) 11 (3.0) 
probably will not 
10 (5.5) 12 (6.3) 22 (5.9) 
probably will 
104 (57.5) 109 (57.1) 213 (57.3) 
definitely will 
61 (33.7) 65 (34.0) 126 (33.9) 
    
 Control Intervention   
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 Arm 1 Arm 2 Total 
Likelihood that I WILL QUIT smoking completely and permanently in the next three months    
definitely will not 
6 (3.3) 5 (2.6) 11 (3.0) 
probably will not 
11 (6.1) 13 (6.8) 24 (6.5) 
probably will 
103 (56.9) 104 (54.5) 207 (55.6) 
definitely will 
61 (33.7) 69 (36.1) 130 (34.9) 
    
Ever used any methods to help you stop smoking tobacco in the past 3 months? (Yes) 23 (12.7) 16 (8.4) 39 (10.5) 
    
Out of your pocket spend (in Rands) on methods to help you stop smoking in the past 3 
months: mean (SD) 
134.87 (237.58) 139.19 (155.07) 136.64 (205.36) 
Average spend per week on cigarettes over the past 3 months: mean (SD) 168.77 (178.15) 180.29 (185.27) 174.58 (181.61) 
Smokeless tobacco use (all participants)    
In the past month, have you used smokeless tobacco (Snuff) on a daily basis    
Not at all 
275 (94.5) 275 (97.2) 550 (95.8) 
Daily 12 (4.1) 6 (2.1) 18 (3.1) 
Less than Daily 4 (1.4) 2 (0.7) 6 (1.0) 
Duration of using ST in months: mean(SD) 113.69 (112.7) 152 (91.16) 126.46 (105.61) 
Age started using ST in years: mean (SD) 27.56 (10.57) 25.88 (13.43) 27 (11.33) 
Form of ST used (for SLT users)    
Snuff (by mouth) 2 (12.5) 0 (0.0) 2 (8.3) 
Snuff (by nose) 11 (68.8) 5 (62.5) 16 (66.7) 
Chewing tobacco leaves 0(0) 0(0) 0(0) 
Other 1 (6.3) 0 (0.0) 1 (4.2) 
 Arm 1 Arm 2 Total 
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 Control Intervention   
Tobacco smoke exposure: number of days in the past 30 days, you were in a place where 
someone smoked close to you (all participants?) 
   
Home    
7 days or less 
233 (80.1) 229 (80.9) 462 (80.5) 
More than 7 days 
58 (19.9) 54 (19.1) 112 (19.5) 
Workplace (Missing 315; probably Not Applicable)    
7 days or less 
84 (65.6) 89 (67.9) 173 (66.8) 
More than 7 days 
44 (34.4) 42 (32.1) 86 (33.2) 
Cafes/restaurants    
7 days or less 
230 (79.0) 234 (82.7) 464 (80.8) 
More than 7 days 
61 (21.0) 49 (17.3) 110 (19.2) 
Shebeens, bars or clubs    
7 days or less 
219 (75.3) 213 (75.3) 432 (75.3) 
More than 7 days 
72 (24.7) 70 (24.7) 142 (24.7) 
Bus/train/taxi/ vehicle    
7 days or less 
229 (78.7) 219 (77.4) 448 (78.0) 
More than 7 days 
62 (21.3) 64 (22.6) 126 (22.0) 
Shops/shopping mall    
7 days or less 
235 (80.8) 226 (79.9) 461 (80.3) 
More than 7 days 
56 (19.2) 57 (20.1) 113 (19.7) 
 
   
 
   
 
   
 Arm 1 Arm 2 Total 
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Had a drink in the past 12-months 208 (71.5) 223 (78.8) 431 (75.1) 
Help to stop drinking (drinkers only)    
Ever used any methods to stop drinking alcohol in the past 3 months 21 (11.2) 22 (10.7) 43 (10.9) 
Average spend in Rands per week on alcohol over the past 3 months: mean (SD) 363.76 (531.56) 337.03 (387.94) 349.79 (461.66) 
    
Depression: CESD 10 how often you felt or behaved this way during the 
past week 
   
I was bothered by things that usually don’t bother me.    
Rarely or None of the Time (Less than 1 day) 
180 (61.9) 159 (56.2) 339 (59.1) 
Some or a Little of the Time (1-2 days) 
71 (24.4) 78 (27.6) 149 (26.0) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
24 (8.2) 31 (11.0) 55 (9.6) 
Most or All of the Time (5-7 days) 
16 (5.5) 15 (5.3) 31 (5.4) 
I had trouble keeping my mind on what I was doing.    
Rarely or None of the Time (Less than 1 day) 
150 (51.5) 136 (48.1) 286 (49.8) 
Some or a Little of the Time (1-2 days) 
93 (32.0) 85 (30.0) 178 (31.0) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
31 (10.7) 38 (13.4) 69 (12.0) 
Most or All of the Time (5-7 days) 
17 (5.8) 24 (8.5) 41 (7.1) 
I felt depressed.    
Rarely or None of the Time (Less than 1 day) 
152 (52.2) 171 (60.4) 323 (56.3) 
Some or a Little of the Time (1-2 days) 
94 (32.3) 70 (24.7) 164 (28.6) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
37 (12.7) 30 (10.6) 67 (11.7) 
Most or All of the Time (5-7 days) 
8 (2.7) 12 (4.2) 20 (3.5) 
I felt that everything I did was an effort.    
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Rarely or None of the Time (Less than 1 day) 
140 (48.1) 117 (41.3) 257 (44.8) 
Some or a Little of the Time (1-2 days) 
77 (26.5) 87 (30.7) 164 (28.6) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
38 (13.1) 43 (15.2) 81 (14.1) 
Most or All of the Time (5-7 days) 
36 (12.4) 36 (12.7) 72 (12.5) 
I felt hopeful about the future.    
Rarely or None of the Time (Less than 1 day) 
85 (29.2) 84 (29.7) 169 (29.4) 
Some or a Little of the Time (1-2 days) 
78 (26.8) 70 (24.7) 148 (25.8) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
53 (18.2) 56 (19.8) 109 (19.0) 
Most or All of the Time (5-7 days) 
75 (25.8) 73 (25.8) 148 (25.8) 
I felt fearful.    
Rarely or None of the Time (Less than 1 day) 
175 (60.1) 159 (56.2) 334 (58.2) 
Some or a Little of the Time (1-2 days) 
82 (28.2) 79 (27.9) 161 (28.0) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
25 (8.6) 32 (11.3) 57 (9.9) 
Most or All of the Time (5-7 days) 
9 (3.1) 13 (4.6) 22 (3.8) 
My sleep was restless.    
Rarely or None of the Time (Less than 1 day) 
142 (48.8) 135 (47.7) 277 (48.3) 
Some or a Little of the Time (1-2 days) 
95 (32.6) 89 (31.4) 184 (32.1) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
31 (10.7) 33 (11.7) 64 (11.1) 
Most or All of the Time (5-7 days) 
23 (7.9) 26 (9.2) 49 (8.5) 
I was happy.    
Rarely or None of the Time (Less than 1 day) 
85 (29.2) 74 (26.1) 159 (27.7) 
Some or a Little of the Time (1-2 days) 
70 (24.1) 65 (23.0) 135 (23.5) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
73 (25.1) 86 (30.4) 159 (27.7) 
Most or All of the Time (5-7 days) 
63 (21.6) 58 (20.5) 121 (21.1) 
I felt lonely.    
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Rarely or None of the Time (Less than 1 day) 
158 (54.3) 161 (56.9) 319 (55.6) 
Some or a Little of the Time (1-2 days) 
89 (30.6) 83 (29.3) 172 (30.0) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
23 (7.9) 26 (9.2) 49 (8.5) 
Most or All of the Time (5-7 days) 
21 (7.2) 13 (4.6) 34 (5.9) 
I could not get “going”.    
Rarely or None of the Time (Less than 1 day) 
168 (57.7) 174 (61.5) 342 (59.6) 
Some or a Little of the Time (1-2 days) 
78 (26.8) 69 (24.4) 147 (25.6) 
Occasionally or a Moderate Amount of the Time (3-4 days) 
35 (12.0) 29 (10.2) 64 (11.1) 
Most or All of the Time (5-7 days) 
10 (3.4) 11 (3.9) 21 (3.7) 
Total CESD 10: mean (SD) 8.44 (4.38) 8.74 (4.8) 8.59 (4.59) 
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Table 4:  Descriptive statistics for primary and secondary outcomes by study arm at baseline (where available), 3 month (where available) and 6 month. 
Frequencies and (percentages) are presented unless otherwise stated 
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TABLE 4:  DESCRIPTIVE STATISTICS FOR PRIMARY AND SECONDARY OUTCOMES BY STUDY ARM AT BASELINE (WHERE AVAILABLE), 3 MONTH (WHERE AVAILABLE) AND 6 MONTH. FREQUENCIES AND 
(PERCENTAGES) ARE PRESENTED UNLESS OTHERWISE STATED. 
 Baseline Follow-up 3-month Follow-up 6-month 
 Control Intervention  Total Control Interventio
n  
Total Control Intervention  Total 
 Arm1 Arm2 Total Arm1 Arm2 Total Arm1 Arm2 Total 
TB treatment status  detailed          
Cured       108 (37.11) 105 (37.1) 213 (37.11) 
Treatment completed       96 (33.0) 87 (30.74) 183 (31.88) 
Treatment default       15 (5.2) 29 (10.25) 44 (7.67) 
Treatment failure       5 (1.7) 2 (0.7) 7 (1.2) 
Acquired drug resistance       1 (0.34) 4 (1.41) 5 (0.87) 
Died       11 (3.78) 15 (5.30) 26 (4.53) 
Transfer out       8 (2.75) 11 (3.89) 19 (3.31) 
Unknown       42 (14.43) 25 (8.83) 67 (11.67) 
Missing       5 (1.72) 5 (1.77) 10 (1.74) 
TB treatment status binary (Primary 
outcome**) 
         
Not Successful       87 (29.9) 91 (32.16) 178 (31.01) 
Successful       204 (70.10) 192 (67.84) 396 (68.99) 
          
At least one positive smear result 
85 (53.46) 96 (61.15) 
181 
(57.28) 
      
At least one positive Gene XPert result 
184 (87.20) 178 (87.25) 
362 
(87.23) 
      
At least one positive culture result 11 (57.89) 10 (66.67) 21 (61.76)       
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Sputum smear, Gene XPert, or culture 
result 
         
Negative 29 (12.45) 32 (14.16) 61 (13.29)       
Positive 204 (87.55) 194 (85.84) 398 (86.71)       
          
Conversion from positive to 
negative*** 
         
Yes       83(39.9) 85(43.59) 168(41.69) 
No       125(60.1) 110(56.41) 235(58.31) 
          
Continuous smoking abstinence 
among cigarette smokers at baseline 
         
Yes    27(16.27) 20(11.17) 47(13.62) 12(7.23) 10(5.59) 22(6.38) 
No    139(83.73) 159(88.83) 298(86.38) 154(92.77) 169(94.41) 323(93.62) 
          
Harmful or hazardous drinking1          
Had a drink in the past 12-months 208 (71.5) 223 (78.8) 431 (75.1)       
AUDIT score: mean (SD) 12.03 (4) 12.53 (3.93) 12.29 (3.96)       
Harmful or hazardous drinkers out of those 
who had a drink in the past 12-months at 
baseline (%) 
188(90.38) 206(92.38) 394(91.42) 141 130 271 112 127 239 
AUDIT Score (males): mean (SD)  
[max :19; min = 8]*! 
13.14 (3.31) 13.61 (3.29) 13.39 (3.31) 8.20(6.08) 9.08(4.97) 8.63(5.58) 9.21(6.58) 8.24(5.41) 8.69(5.99) 
AUDIT Score (females): mean (SD)  
[max :19; min = 7]*! 
11.73 (3.52) 11.55 (3.6) 11.64 (3.54) 8.5(6.52) 8.15(6.44) 8.33(6.44) 7.67(6.84) 9.97(6.79) 8.89(6.86) 
AUDIT score: mean (SD) 12.76 (3.42) 13.12 (3.47) 12.94 (3.45) 8.28(6.18) 8.84(5.38) 8.55(5.81) 8.79(6.66) 8.70(5.83) 8.74(6.22) 
Difference from baseline    -4.61 (6.26) -4.07(5.33) -4.35(5.83) -4.25(6.56) -4.17(6.61) -4.21(6.57) 
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Taking ART medication among HIV 
Positive patients 
[163 (56.2)] [142 (50.2)] [305 (53.2)] [122] [83] [205] [100] [83] [183] 
Yes 139 (85.28) 115 (80.99) 254 (83.28) 91 (74.6) 58 (69.9) 149 (72.7) 80 (80.0) 74 (89.2) 154 (84.2) 
          
ART medication adherence           
          
Optimal adherence    101(99.02) 64(98.46) 165(98.8) 75(97.4) 64(96.97) 139(97.2) 
Suboptimal adherence    1(0.98) 1(1.54) 2(1.2) 2(2.6) 2(3.03) 4(2.8) 
          
TB medication adherence          
          
Optimal adherence    181(92.35) 138(90.79) 319(91.67) 61(89.71) 59(90.77) 120(90.23) 
Suboptimal adherence    15(7.65) 14(9.21) 29(8.33) 7(10.29) 6(9.23) 13(9.77) 
          
          
1 hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20 
**Primary Outcome:  in the published protocol paper "This is a binary variable defined as either successful treatment (cured or treatment completed) or failed 
treatment, death, acquired drug resistance, loss to follow-up or ‘default’, or not outcome evaluated. 
*** Conversion from positive to negative: this was based on having a cured treatment outcome among those who were positive at baseline.  
*! Important distinction at baseline for eligibility purposes.  
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TABLE 5:  Number and type of adverse events at month 2, 3, and 6 by centre and study arm (see other document) 
 
TABLE 5:  Number and type of adverse events at month 2, 3, and 6 by centre and study arm 
Centre   Month 2 Month 3  Month 6 
 TYPE  Intervention  Control  Intervention  Control  Intervention  Control  
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
  
Page 101 of 155
















































For peer review only
Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 59 of 67 
 
TABLE 6:   Regression analysis results for the primary and secondary outcomes at 6 months.  Estimates presented with corresponding 95% CI.  Crude and 
adjusted estimates are provided. 
TABLE 6:   Regression analysis results for the primary and secondary outcomes at 6 months.  Estimates presented with corresponding 
95% CI.  Crude and adjusted estimates are provided. 
 Crude Odds Ratio 
(95% CI)* 
P Value* Adjusted Odds 




Primary outcome      
TB treatment status: Successful 
(Ref: Not successful) 
0.9 (0.64,1.27) 
 
0.548 0.86 (0.60,1.24) 0.421  
      
Secondary outcomes      
      
Sputum smear or culture result: 
converted from positive to negative 
(Ref: Not converted) 
1.16 (0.83,1.63) 0.374 1.07‡ (0.76,1.51) 0.684  
      
Six-month continuous smoking 
abstinence among cigarette smokers at 
baseline (Ref: No) 
0.76 (0.35,1.64) 0.482    
      
Taking ART medication among HIV 
positive patients!! 
2.05 (0.80,5.27) 0.136    
      
TB medication adherence 
(Reference: Optimal) 
0.89 (0.26,3.07) 0.849    
      
ART medication adherence 
(Reference: Optimal) 
1.17 (0.14,9.94) 0.884    
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AUDIT for those who were harmful or 
hazardous drinkers at baseline**: 
-0.04 (-2,1.91) 0.966 0.02! (-1.55,1.6) 0.976  
      
 
*  analyses accounted for potential clustering by centre. 
† Number of participants whose outcome was treatment successful among the total number in the group. 
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline 
**Controlling for the AUDIT baseline values.  
! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline 
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TABLE 7:   Regression analysis results for secondary outcomes measured at 3-months.  Estimates presented with corresponding 95% CI.  Crude and adjusted 
estimates are provided. 
TABLE 7:   Regression analysis results for secondary outcomes measured at 3-months.  Estimates presented with corresponding 95% CI.  
Crude and adjusted estimates are provided. 
 Crude Odds 
Ratio 
(95% CI) 
P Value Adjusted Odds 
Ratio 
(95% CI) 
P Value  
Secondary outcome      
3-months continuous smoking 
abstinence among cigarette smokers 
at baseline 
0.65 (0.37,1.14) 0.135    
      
Taking ART medication among HIV 
positive patients!! 
0.79 (0.38,1.65) 0.53 0.74‡ (0.35,1.58) 0.443  
      
TB medication adherence 
(Reference: Optimal) 
1.22 (0.52,2.87) 0.641    
      
ART medication adherence 
(Reference: Optimal) 
1.58 (0.10,26.12) 0.750    
      






AUDIT for those who were harmful 
or hazardous drinkers at baseline**: 
0.55 (-1.01,2.11) 0.474 0.74 (-0.62,2.1) 0.273  
 
*   analyses accounted for clustering. 
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline 
**Controlling for the AUDIT baseline values.  
! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline 
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Variable Intervention (N= ….) (=no. of 
participants allocated to 
intervention group, for 
example 245) 
 
Control (N=…)  (=no. 
participants allocated to 
control group, for example 
248) 
No. of participants 
who received ALL 
due IMB messages 
INDEPENDENT OF 
WHETHER they 
completed MI 1 
(i.o.w this is ITT 
analysis) 
For example 
120/245 (49 %) 
For example 2/248 (…%) 
Completion of first MI and initiation of SMS-sequence 
Completed first MI n/N (%) 
(=No. who completed first MI 
in intervention arm/ no. 
participants allocated to 
intervention arm [%] 
For example 170/245 [69%]) 
n/N (%) 
(=No. who completed first MI in 
control/ no. participants 
allocated to control [%] 
For example 2/248) 
No. of participants 
who received ALL 
due messages after 
receipt of MI1 and 
SMS sequence was 
generated (this is a 
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denominator limited 
to those who had 
MI1) 
SMS delivery for participants for whom the SMS-sequence was initiated (after receipt of 
first MI) 
 Mean (SD) Median (IQR) 
Range 




per participant  (n=…) (n = the no. of 
participants who 
completed first MI, 







Expected to be 
0 or close to it 
Expected to be 
0 or close to it 
Average no. 
tobacco-related 
messages received  (n=…) (n=no of 
participants who 
completed first MI 
AND were current 









Expected to be 
0 or close to it 
Expected to be 
0 or close to it 
Average no. alcohol 
related messages 
received (n=…) (n=no. 
participants who 







Expected to be 
0 or close to it 
Expected to be 
0 or close to it 
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AND were drinkers at baseline=….for 
example 100) 
Average no. IMB 
messages received 
(n= total no who 







Expected to be 
0 or close to it 
Expected to be 





Other variables not yet analysed: 
 
CESD at 3 and 6-month FU 
Other smoking related questions at 3 and 6 month (quit intentions etc) but also SLT use at 3 and 6 month. (important because 
participants may have switched from tobacco smoking to SLT) 
Other non-HE questions not yet analysed 
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13. Additional descriptive Statistics 
 
TABLE 8:   Additional Descriptive statistics for   characteristics at baseline by study arm. Frequencies and (percentages) are presented unless otherwise stated 
 
 
  Baseline 
 N1/N2 Intervention  Control  Total 
  Arm 1 Arm 2  
TYPE OF MINE WORK 46/45    91 
Coal  7 (15.2) 3 (6.7) 10 (11.0) 
Diamond  3 (6.5) 1 (2.2) 4 (4.4) 
Gold  13 (28.3) 17 (37.8) 30 (33.0) 
Platinum and palladium  24 (52.2) 17 (37.8) 41 (45.1) 
Chromium  11 (23.9) 12 (26.7) 23 (25.3) 
Uranium  1 (2.2) 1 (2.2) 2 (2.2) 
Manganese  0(0) 0(0) 0(0) 
Other  0(0) 0(0) 0(0) 
     
Total Types of Mines worked 
in  
 
   
1 73    
2 12    
3 3    
4 1    
     
Page 108 of 155
















































For peer review only
Statistical Analysis Plan PROLIFE Trial Jan 2020 
Page 66 of 67 
 
Exact Distribution for number 
smoked in the past seven days 
 
   
0  24 (14.5) 16 (8.9) 40 (11.6) 
1  4 (2.4) 4 (2.2) 8 (2.3) 
2  4 (2.4) 3 (1.7) 7 (2.0) 
3  5 (3.0) 13 (7.3) 18 (5.2) 
4  13 (7.8) 8 (4.5) 21 (6.1) 
5  5 (3.0) 17 (9.5) 22 (6.4) 
6  1 (0.6) 3 (1.7) 4 (1.2) 
7  110 (66.3) 115 (64.2) 225 (65.2) 
new_a_positive_TB     
0  29 (11.98) 33 (14.35) 62 (13.14) 
1  122 (50.41) 104 (45.22) 226 (47.88) 
2  80 (33.06) 81 (35.22) 161 (34.11) 
3  11 (4.55) 12 (5.22) 23 (4.87) 
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No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 




2a Scientific background and explanation of rationale 4-5 
2b Specific objectives or hypotheses 5-7 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5-6 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons NA 
Participants 4a Eligibility criteria for participants 5 
4b Settings and locations where the data were collected 5 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
6 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
7-8 
6b Any changes to trial outcomes after the trial commenced, with reasons NA 
Sample size 7a How sample size was determined 8 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 6 




9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
6 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
6  
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 6 
Page 111 of 155
















































For peer review only
CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions NA 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 9 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
10, Figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons 10, Fig 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 5-6 
14b Why the trial ended or was stopped 10,21 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group Table 1 and 
2, Supp Table 
1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Fig 1, Table 3 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
Table 3,4,5 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended Only relative 
effect 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
Table 4, 5 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) No harms 
reported  
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 21-22 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings NA, no effect 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 21 
Other information  
Registration 23 Registration number and name of trial registry 2 
Protocol 24 Where the full trial protocol can be accessed, if available Published 
paper 
referenced 
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Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 23 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
Page 113 of 155



















































1 Effect of a brief motivational interview and text message intervention targeting tobacco smoking, 
2 alcohol use, and medication adherence to improve tuberculosis treatment outcomes in adult 
3 patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in 
4 South Africa
5 Goedele Maria Louwagie1, 2, Mona Kanaan3, Neo Keitumetse Morojele4, 5, André van Zyl1, Andrew 
6 Stephen Moriarty3, Jinshuo Li3, Kamran Siddiqi3, Astrid Turner2, Noreen Dadirai Mdege3, Olufemi 
7 Babatunde Omole6, John Tumbo1, Max Oscar Bachmann7, Steve Parrott3, Olalekan Ayo-Yusuf1, 2
8 Correspondence to Goedele Maria Louwagie; goedele.louwagie@up.ac.za
9
10 1Goedele Maria Louwagie, Sefako Makgatho Health Sciences University and 2School of Health 
11 Systems and Public Health, University of Pretoria , RSA; goedele.louwagie@up.ac.za
12
13 3Mona Kanaan, Department of Health Sciences, University of York, UK; mona.kanaan@york.ac.uk
14
15 4Neo Keitumetse Morojele, Department of Psychology, University of Johannesburg and 5Alcohol, 
16 Tobacco and Other Drug Research Unit, South African Medical Research Council, RSA; 
17 nmorojele@uj.ac.za
18
19 1André van Zyl, Sefako Makgatho Health Sciences University, RSA; drevanzyl@gmail.com 
20
21 3Andrew Stephen Moriarty, Department of Health Sciences and the Hull York Medical School, 
22 University of York, UK; andrew.moriarty@york.ac.uk
23
24 3Jinshuo Li, Department of Health Sciences, University of York, UK; jinshuo.li@york.ac.uk
25
26 3Kamran Siddiqi, Department of Health Sciences and the Hull York Medical School, University of York, 
27 UK; kamran.siddiqi@york.ac.uk
28
29 2Astrid Turner, School of Health Systems and Public Health, University of Pretoria, RSA; 
30 astrid.turner@up.ac.za
31
32 3Noreen Dadirai Mdege, Department of Health Sciences, University of York, UK; 
33 noreen.mdege@york.ac.uk
34
35 6Olufemi Babatunde Omole, Department of Family Medicine, University of Witwatersrand, RSA; 
36 Olufemi.Omole@wits.ac.za
37
38 1John Tumbo, Department of Family Medicine, Sefako Makgatho Health Sciences University, RSA; 
39 tumbo@lantic.net
40
41 7Max Oscar Bachmann, Norwich Medical School, University of East Anglia, UK; 
42 m.bachmann@uea.ac.uk
43
Page 114 of 155

































































44 3Steve Parrott, Department of Health Sciences, University of York, UK; steve.parrott@york.ac.uk
45
46 1Olalekan Ayo-Yusuf, Africa Centre for Tobacco Industry Monitoring & Policy Research, Sefako 
47 Makgatho Health Sciences University, and 2School of Health Systems and Public Health, University of 
48 Pretoria, RSA; lekan.ayo-yusuf@smu.ac.za
49
50 ABSTRACT
51 Objectives: tto investigate the effectiveness of a complex behavioural intervention, ProLife, on 
52 tuberculosis (TB) treatment success, medication adherence, alcohol use and tobacco smoking. 
53 Design:  mmulti-centre, individual, randomised controlled trial where participants were assigned 
54 (1:1) to the ProLife intervention or usual care. 
55 Setting: 27 primary care clinics in South Africa.
56 Participants: 574 adults starting treatment for drug-sensitive pulmonary TB who smoked tobacco or 
57 reported harmful/hazardous alcohol use.
58 Interventions: The intervention, delivered by lay health workers (LHWs), consisted of 3 brief 
59 motivational interviewing (MI) sessions , augmented with Short Message Service (SMS) messages, 
60 targeting medication adherence, alcohol use and tobacco smoking.
61 Outcome measures: the primary outcome was successful versus unsuccessful TB treatment at 6 to 9 
62 months, from TB records; secondary outcomes: biochemically confirmed sustained smoking 
63 cessation, reduction in the Alcohol Use Disorder Identification Test (AUDIT) score, improved TB and 
64 antiretroviral treatment (ART) adherence and ART initiation, each measured at 3 and 6 months by 
65 questionnaires; cure rates in patients who had bacteriology-confirmed TB at baseline, from TB 
66 records.
67 Results: Between 15 November 2018 and 31 August 2019, 574 participants were randomised to 
68 receive either the intervention (n=283) or usual care (n=291). TB treatment success rates did not 
69 differ significantly between intervention (67.8%) and control (70.1%) (OR=0.9 (95% CI: 0.64,1.27)). 
70 There was no evidence of an effect at 3- and 6-months respectively  on continuous smoking 
71 abstinence (OR=0.65 (95% CI: 0.37,1.14); OR=0.76 (95% CI: 0.35,1.63)), TB medication adherence 
72 (OR=1.22 (95%CI: 0.52,2.87); OR=0.89 (95%CI: 0.26,3.07)), taking ART (OR=0.79 (0.38,1.65), OR=2.05 
73 (0.80,5.27)) or AUDIT scores (mean score difference 0.55 (95% CI: -1.01,2.11); -0.04 (95% CI: -2,1.91); 
74 and adjusting for baseline values. Cure rates were not significantly higher (OR=1.16 (0.83,1.63)). 
75 Conclusions:  Simultaneous targeting of multiple health risk behaviours with MI and SMS using LHWs 
76 may not be an effective approach to improve TB outcomes.
77
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78 Trial registration: ISRCTN62728852, Registered on 13th April 2018.
79 Key words: Tuberculosis, smoking, alcohol, motivational interviewing, mHealth, anti-retroviral 
80 therapy, adherence
81
82 STRENGTHS AND LIMITATIONS OF THIS STUDY
83  The use of motivational interviewing combined with Short Text Messaging to address the 
84 effect of multiple risk behaviours (smoking, drinking and poor adherence) on tuberculosis TB 
85 treatment outcomes is a novel and much needed intervention. 
86  Our study design was strong: this was a multi-site individually randomised controlled trial 
87 with a large sample size and a high follow up rate  for the primary outcome.
88  We used validated measurement tools; furthermore data analysis and primary outcome 
89 assessment were blinded, thereby limiting measurement bias. 
90  The study was underpowered  for secondary outcomes. TLowhe intervention uptake may 
91 have diluted any potential intervention effects.
92
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94 Tuberculosis (TB) is among the most common chronic infectious diseases in the world today. In 2019, 
95 1.4 million deaths worldwide were attributed to TB, and the majority of these occurred in low-
96 income and middle-income countries (LMICs).(1) South Africa not only has one of the highest TB 
97 burdens in the world; it is faced with high TB  treatment interruption and loss to follow-up rates. of 
98 the 30 high TB burden countries. It also has a high prevalence of human immunodeficiency virus 
99 (HIV) co-infection in patients with TB and a relatively high mortality in these co-infected patients.(1) 
100 Studies of interventions to advance the goal of ending the TB epidemic and improving treatment 
101 outcomes are therefore research priorities in South Africa and other LMICs.(2) 
102 Mortality and morbidity from TB is strongly associated with health risk behaviours, particularly 
103 smoking and hazardous or harmful alcohol use, both of which are prevalent and often co-occur in TB 
104 patients with TB.(3–10) Strategies are also required to improve TB medication adherence in patients 
105 with TB and adherence to TB medication and anti-retroviral therapy (ART) in TB-HIV co-infected 
106 patients co-infected with TB and HIV, both of which may be negatively influenced by excessive 
107 alcohol use.(1) There is very limited research on how to concurrently tackle these three risk 
108 behaviours - namely smoking, harmful alcohol use and poor medication adherence - in patients with 
109 TB, particularly in LMICs. 
110 Motivational Interviewing (MI) is a counselling technique known to facilitate behaviour change,(11) 
111 and has been shown toeffectively support reduced drinking, smoking cessation in TB patients and TB 
112 treatment and/or antiretroviral therapy (ART) medication adherence.(11–13) MI interventions can 
113 be effectively delivered by lay health workers (LHWs).(14) The more widespread use of LHWs and 
114 the increased use of mobile health (mHealth) digital technologies represent promising ways to 
115 increase the scalability of MI interventions. Indeed, the World Health Organisation (WHO) has called 
116 for researchers to capitalise on advances in mobile phone technology, network coverage and the 
117 increased use of common and widely available digital technologies (including the mobile phone short 
118 message service (SMS)) to improve TB care.(15) There is robust evidence that mHealth technologies 
119 can have modest beneficial effects on a range of health outcomes, including medication 
120 adherence..(16)(16,17) Mobile phone messaging also shows a modest effect in improving TB 
121 treatment success rates.(18,19) The evidence is however stronger for two-way messaging and 
122 interactive systems for which smart phones are required.(18) These are often not available to 
123 patients with TB in Africa.(20) An SMS intervention in co-infected TB/HIV patients demonstrated 
124 effectiveness in increasing adherence to ART,(17) although the existing evidence is not of sufficient 
125 quality to know if this consistently applies to medication adherence in TB patients.(18)
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127 A limitation of existing MI and mHealth interventions is that they have been studied in the context of 
128 modifying a single lifestyle factor. Integrated interventions are likely to be better accepted and more 
129 effective than multiple interventions targeting different health risk factors.(21,22) In the case of TB, 
130 there is a need for an intervention that has the flexibility to target multiple lifestyle factors as 
131 appropriate and in line with patient preferences. This could be achieved through increased 
132 integration of TB and non-communicable disease services.(23) 
133
134 Recent re-engineering of primary health care in South Africa has seen the introduction of municipal 
135 ward-based primary healthcare outreach teams of community health workers (CHWS). CHWs work 
136 in an integrated, team-based manner, supported by nurses, and take responsibility for health 
137 education and promotion, counselling and support for a range of health conditions.(24,25) Task 
138 shifting in this context has been shown to improve population health in LMICs (26) and these teams 
139 can be trained and supported to take responsibility for TB/HIV care.(27) Integrated interventions 
140 could be implemented within this framework in a feasible and scalable way to improve outcomes for 
141 patients with TB across South Africa and beyond. 
142
143 Building on previous successes with MI and mHealth interventions, we developed a complex 
144 behavioural intervention (ProLife) comprising MI-based counselling and SMS, targeting three 
145 lifestyle risk behaviours for poor TB outcomes (smoking, hazardous/harmful alcohol consumption 
146 and poor medication adherence), and delivered by LHWs. We then conducted a randomised 
147 controlled trial (RCT) to assess the effectiveness of the ProLife intervention on improving TB 
148 treatment outcomes, smoking abstinence, reducing alcohol consumption and improving adherence 
149 to TB and ART medication compared to usual care. The cost-effectiveness of the intervention was 




154 Study design and participants
155 This was a prospective, two-arm, multi-centre, individually randomised controlled trialRCT, which 
156 took place across 27 primary care clinics in 3 districts in South Africa (Lejweleputswa in the Free 
157 State province; Bojanala in the North West province; and Sedibeng in Gauteng province). Adult 
158 patients (18 years or older) were eligible for the study if they had drug-sensitive Pulmonary TB (PTB), 
159 and were initiating TB treatment or had been on TB treatment for less than a month for this 
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160 treatment episode (both “new” and “retreatment patients”). They had to be tobacco smokers 
161 (defined as smoking daily or non-daily in the last four weeks on the Global Adult Tobacco Survey 
162 questionnaire)(28) and/or hazardous/harmful drinkers who were not alcohol dependent (Alcohol 
163 Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20).(29) They also 
164 had to have access to a mobile phone and understand one of the 4 languages used for the trial 
165 (English, IisiZulu, SeSotho and Setswana). Potential participants were recruited consecutively at the 
166 participating clinics between 15 November 2018 and 31 August 2019. Trained field workers 
167 identified those interested in the study and screened them for eligibility. If eligible and willing to be 
168 enrolled into the trial, written informed consent was obtained. The RCT received ethics approval 
169 from the Research Ethics Committees of the five participating research institutions.(30)
170
171 Randomisation and blinding
172 Patients were centrally randomised (1:1) to the ProLife intervention or control group using a 
173 randomised sequence generator by the trial statistician (MK) who was blind to the arm allocation. 
174 We used block randomisation with varying block sizes stratified by clinic so as to achieve equal 
175 numbers in intervention and control groups within each clinic. Fieldworkers used sequentially 
176 numbered, sealed, opaque envelopes to allocate participants to intervention or control. ProLife 
177 involved a complex behavioural intervention therefore LHWs and participants could not be blinded 
178 to the intervention. However, the determination of the primary outcome was done by the TB nurses 
179 who were blinded to the intervention status of the participants, based on routinely collected data. 
180 The statistician (MK) was blinded to the intervention or control arm allocation of participants during 
181 the analysis. 
182
183 Intervention and procedures
184 The ProLife intervention was developed based on a conceptual framework, following a review of 
185 pre-existing evidence.(31) This framework assumed that smoking cessation, reducing harmful 
186 alcohol use and improved adherence to TB and HIV treatment would result in improved TB 
187 treatment outcomes.(30)  The intervention consisted of 3 brief MI counselling sessions, lasting 15-20 
188 minutes, one month apart, delivered by trained LHWs at their TB clinic. The first MI session took 
189 place immediately or shortly after the randomisation and involved prioritisation and agenda setting, 
190 wherein the participant determined which factor should be prioritised (either a plan to quit tobacco 
191 smoking, or reduce or quit drinking, or deal with barriers relating to ART or TB medication 
192 adherence). The second and third sessions built on the previous one until all relevant behavioural 
193 problems had been addressed. These sessions were reinforced with follow-up SMS text messages, 
194 twice a week over 12 weeks.(30) Study patients received 10 TB-related messages followed by seven 
195 alcohol reduction- and/or seven smoking cessation-related messages, as appropriate. Messages 
196 were aimed at giving information, and augmenting motivation or behavioural skills (we refer to the 
197 feasibility paper for more details).(31) Applicable SMS-messages were automatically activated after 
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198 the first MI had taken place. Thereafter the remaining messages were delivered even if the 




203 Participants randomised to the ProLife intervention also received the same “usual care” as those in 
204 the control group. The control group received the usual care and routine treatment and support 
205 offered to TB patients with TB in South Africa, which varies by district but includes: health education; 
206 dietetic input; social support; point of care biochemical testing; and HIV testing with pre- and post-
207 test HIV test counselling. 
208
209 Data were collected at baseline, 3- and 6-months and recorded by fieldworkers equipped with 
210 mobile phones with the ProLife mobile data collection application (built with CommCare)(32) 
211 installed. They used a standardised electronic case report form (CRF) and followed standard 
212 operating procedures (SOPs) to ensure quality. Details of data collection, protection and storage 
213 procedures have been reported elsewhere.(30)
214
215 Patient and public involvement
216 Patients or the public were not involved in the design, or conduct, or reporting, or dissemination 




221 The primary outcome of TB treatment success at 6 to 9 months follow-up (depending on when it was 
222 recorded) was as per the WHO definitions adopted in South Africa,(10) that is, either successful 
223 treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss 
224 to follow-up (defined as treatment interruption of more than 2 months), or outcome not evaluated. 
225 It was measured using the routinely collected TB treatment outcomes in patients’ individual files. 
226
227 Secondary Outcomes
228 For those participants with bacteriologically confirmed PTB at baseline (either sputum acid fast 
229 bacilli (AFB) positive, culture positive or GeneXpert positive PTB), sputum conversion at the end of 
230 treatment (“cure rate”) was measured as a secondary outcome.(10) Continuous smoking abstinence 
231 was assessed at 3- and 6-months follow-up in those participants who were current cigarette smokers 
232 at baseline. It was defined as having quit smoking completely and a self-report of not smoking more 
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233 than 5 cigarettes from the start of the study, in addition to a negative biochemical test (exhaled 
234 Carbon Monoxide (CO) < 7 ppm).(33,34) Changes in alcohol consumption were computed using the 
235 AUDIT questionnaire scores measured at 3- and 6-months follow-up in those participants who were 
236 hazardous/harmful drinkers at baseline. 
237 HIV positive participants were asked about ART status at baseline, 3- and 6-months using 
238 standardised questions on the CRF and change in ART status as measured at the 2 follow-up times. 
239 TB and ART medication adherence was measured using modified versions of the AIDS Clinical Trials 
240 Group Adherence Questionnaire, a validated tool for measuring adherence specifically to ART.(35) 
241 Adherence was measured using an adherence index calculated by the formula (using the 4-day 
242 recall): [Total number of doses taken/Total number of doses prescribed] x 100. Patients with at least 
243 95% adherence were classed as having optimal adherence and those with less than 95% were 
244 classed as having low (or suboptimal) adherence. This was assessed at 3- and 6-months. 
245 During COVID-19 lockdown (in the s cond term of 2020) we switched to telephonic follow-up of 
246 participants using a shortened questionnaire whereby only strictly needed information for the 
247 measurement of outcomes was inquired about.
248 Training and Intervention Fidelity Monitoring
249 The training and intervention fidelity monitoring is described in more detail in previous 
250 papers.(30,31) In brief, 18 LHWs, 3 district coordinators and 1 research assistant who focused on 
251 counselling supervision underwent MI training over 5 days. LHWs completed a post-session semi-
252 structured form onto which they indicated the extent to which they implemented each element of 
253 MI, as well as their general qualitative impressions of that particular session. In addition, we 
254 assessed MI intervention fidelity based on ratings of the counsellors’ recorded MI sessions, as 




259 The ProLife intervention costs consisted of the costs of training and the delivery of the ProLife 
260 intervention, including relevant personnel involvement (trainers and LHWs), materials used, travel, 
261 accommodation and refreshments, and digital infrastructure for the intervention. These were 
262 estimated based on research team records. Usual care costs consisted of TB medication costs, 
263 biochemical investigations, and ART costs if applicable. These were estimated based on information 
264 obtained through routine records. The country specific version of Euroqol with 5 dimensions and 
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265 with 3 levels of response categories (EQ-5D-3L) for South Africa was administered to participants at 
266 baseline, 3- and 6-months follow-up to measure health-related quality of life.(36,37)
267
268 Statistical analysis
269 The sample size was estimated at 696 in total (348 participants per arm), to detect a 10% difference 
270 in TB treatment success rates (0.86 vs. 0.76) in the ProLife arm (intervention) vs. the control arm 
271 with 80% power, a significance level of 0.05 and 25% attrition rate. The assumed success rates in the 
272 control group were based on actual success rates in TB patients with TB in the studied provinces 
273 obtained from TB managers at the time of the grant application for this study.
274 We summarised baseline data descriptively by trial arm. For the primary outcome, we conducted 
275 statistical analysis on an intention-to-treat basis. We used binary logistic regression to compare the 
276 main outcome (TB treatment succ ss rate) between the intervention and the usual care arm. Where 
277 treatment outcome data were missing, the outcome was coded as unsuccessful. TB treatment 
278 outcomes recorded by the TB nurse were taken on face value as inconsistencies in the dates of 
279 bacteriological results did not permit us to verify the correctness of the nurse assessment. We 
280 carried out similar statistical analyses for the secondary outcomes with appropriate regression 
281 techniques. For the reduction in harmful or hazardous drinking, we used linear regression to 
282 estimate the difference in total AUDIT score between control and intervention groups accounting for 
283 the baseline AUDIT score as covariate. Separate analyses at 3- and 6-months were performed. 
284 For our main analyses we adjusted for baseline characteristics if these differed between trial arms at 
285 baseline. The covariates that we controlled for in each model are specified when a model is 
286 presented. The statistical packages STATA (38) and R (39) were used to carry out the analyses, with a 
287 P-value < 0.05 considered statistically significant. 
288 The validated Motivational Interviewing Treatment Integrity (MITI) coding tool (version 4.2.1)  was 
289 used to assess MI intervention fidelity.(40) The coding entailed making ‘Global Ratings’ (on 4 
290 dimensions: Cultivating change talk, Softening sustain talk, Partnership and Empathy) and 
291 ‘Behaviour’ counts (with respect to the items: giving information, persuade, persuade with 
292 permission, question, simple reflection, complex reflection, affirm, seeking collaboration, 
293 emphasising autonomy and confront). A score was assigned to each of these items and the scores 
294 compared against the competency and proficiency thresholds that are specified in the MITI manual. 
295
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296 For the analysis of the costs, all costs were collected in South Africa Rand (ZAR) except for the data 
297 management system subscription. Results are presented in both ZAR and US dollar ($) using the 
298 2019 OECD exchange rate (1 USD = 14.448 Rand).(36) No South African specific valuation set was 
299 available for EQ-5D-3L. The valuation set of Argentina, based on a Visual Analogue Scale for EQ-5D-
300 3L, was used to derive utility values, because the GDP per capita in international dollars was the 
301 closest between the two countries at the time of analysis.(37,41) Quality-adjusted life years (QALYs) 
302 were derived from the utility values at the time points by calculating the area under the curve.(42) 





308 Participant enrolment and follow-up 
309 A total of 2099 TB patients with TB were screened for eligibility out of which 574 consenting and 
310 eligible participants were randomised: 291 to control and 283 to intervention. Trial recruitment was 
311 terminated on 31 August 2019 before the planned sample size was reached because of budget and 
312 time constraints. In the intervention arm, 227 (80.2%) participants completed the first MI (MI 1) 
313 session, 199 (70.3%) MI 2 and 150 (53.0%) MI 3. In the intervention arm, at least one message was 
314 delivered to 208 (73.5%) participants, while 99 (35.0%) received all messages. Of those randomised 
315 to the control and intervention groups, the primary outcome was recorded in 244 (83.8%) and 253 
316 (89.4%) participants, respectively. .(Figure 1)
317
318 Figure 1 Consort flow diagram
319
320 Baseline participant characteristics of the intervention and control arm
321 Socio-demographic; socio-economic and clinical characteristics  
322 Baseline characteristics were distributed similarly in the intervention and control arms for most 
323 variables but with some imbalances in educational level. A total of 513 (91.3%) participants were 
324 new TB patients with TB, 129 (22.5%) women, and nearly all had PTB (International Classification of 
325 Diseases-10 A15) without extrapulmonary TB manifestations (553 (98.9%)). About half of the 
326 participants were HIV positive (305 (53.2%)), of whom 204 (65.4%) were on cotrimoxazole and 257 
327 (82.4%) were on ART. (Table 1) Details of marital status, employment, wealth, depression status and 
328 co-morbidities are presented in Supplementary table 1.
329  
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Table 1 Baseline descriptive socio-economic statistics and clinical characteristics by study arm
Control (N = 291)
n (%)*




Age in years: mean (SD) 39.37 (12.60) 38.56 (11.15)
Female Sex 69 (23.7) 60 (21.2) 129 (22.5)
Education
No education 7 (2.4) 5 (1.8) 12 (2.1)
Grades 1-5 23 (7.9) 20 (7.1) 43 (7.5)
Grades 6-7 32 (11.0) 35 (12.4) 67 (11.7)
Grades 8-11 96 (33.0) 128 (45.2) 224 (39.0)
Grade 12 87 (29.9) 70 (24.7) 157 (27.4)
Higher 24 (8.2) 8 (2.8) 32 (5.6)
Declined to answer** 22 (7.6) 17 (6.0) 39 (6.8)
TB Patient category
New patient 264 (92.3) 249 (90.2) 513 (91.3)
Relapse 10 (3.5) 9 (3.3) 19 (3.4)
Re-treatment after default 9 (3.1) 14 (5.1) 23 (4.1)
Re-treatment after failure 1 (0.3) 2 (0.7) 3 (0.5)
Other 2 (0.7) 2 (0.7) 4 (0.7)
TB Site of disease Pulmonary only (ICD-10 A15) 281 (98.9) 272 (98.9) 553 (98.9)
TB Sputum smear, Gene XPert, or culture result available N= 236 227 463
At least one Sputum smear, Gene XPert, or culture result positive 208 (88.1) 195 (85.9) 403 (87.0)
HIV status
Negative 118 (40.7) 125 (44.2) 243 (42.4)
Positive 163 (56.2) 142 (50.2) 305 (53.2)
Unknown 9 (3.1) 16 (5.7) 25 (4.4)
HIV positive patients
Using Cotrimoxazole 104 (63.8) 100 (67.1) 204 (65.4)
Using anti-retroviral 139 (85.3) 118 (79.2) 257 (82.4)
Page 124 of 155
















































For peer review only
12
330 * Frequencies and (percentages) are presented unless otherwise stated
331 **More variables with the option “declined to answer” are listed in the Supplementary table 1
332







In the past month, smoked tobacco
Not at all** 110 (37.8) 92 (32.5) 202 (35.2)
Daily 149 (51.2) 149 (52.7) 298 (51.9)
Less than Daily 32 (11.0) 42 (14.8) 74 (12.9)
Had a drink in the past 12-months 208 (71.5) 223 (78.8) 431 (75.1)
AUDIT Score (males) : mean (SD) [max: 19]† 12.27 (3.98) 13.02 (3.78) 12.66 (3.89)
AUDIT Score (females): mean (SD) [max: 19]† 11.32 (4.02) 10.98 (4.02) 11.15 (4.0)
Hazardous/harmful drinking and Smoking Combined 
(Constructed)
Hazardous/harmful drinking Only‡ 110 (37.8) 92 (32.5) 202 (35.2)
Smoking Only 103 (35.4) 77 (27.2) 180 (31.4)
Smoking and hazardous/harmful drinking‡ 78 (26.8) 114 (40.3) 192 (33.4)
333 * Frequencies and (percentages) are presented unless otherwise stated
334 **Non-smokers were only included if they were harmful or hazardous drinkers
335 †Only hazardous/harmful drinkers and/or current smokers were included in the study. Therefore TB patients with TB  were excluded if they were non-current smokers and had an AUDIT 
336 score <7 (females) or <8 (males) or >19; however, they were included if they were smokers independent of whether they had a drink in the past year and therefore independent of the 
337 AUDIT score. These AUDIT scores are thus representative of the mean AUDIT scores in the entire study sample and differ from the AUDIT score in the harmful/hazardous drinkers whose 
338 change in AUDIT score was measured at 3 and 6-months follow-up (see Table 3) 
339 ‡Harmful/hazardous drinking is defined as Alcohol Use Disorders Identification Test (AUDIT) score ≥ 8 for men or ≥ 7 for women but <20
340
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341 There were 372 current smokers (298 daily, 74 less than daily). Seventy eight participants (26.8 %)   
342 in the control arm were dual smokers and drinkers compared to 114 (40.3 %) in the intervention 
343 arm. In the control arm, 110 (37.8%) were hazardous/harmful drinkers only and 103 (35.4%) were 
344 smokers only, compared to 92 (32.5%) and 77 (27.2) respectively, in the intervention arm. (Table 2) 
345 More details of smoking and drinking history, forms of tobacco use, addiction and quit attempts are 
346 presented in Supplementary Table 2.
347
348 Primary outcome 
349 Overall, 396 (70%) of participants were classified as treated successfully (treatment completed or 
350 cured). The remainder either interrupted treatment, failed treatment, developed drug resistance, 
351 wereas transferred out or had an unknown the treatment outcome.(Supplementary table 3) The 
352 percentage of successful TB treatment did not differ significantly between the control and 
353 intervention arm (70.1% vs. 67.8%), odds ratio (OR) for successful TB treatment 0.90 (95%CI: 
354 (0.64,1.27)) comparing the intervention arm to the control arm; and was similar to adjusted ORs. 
355 (Tables 3 and 4)  
356
357 Secondary outcomes
358 Cure rates 
359 Among the 403 participants who had at least one positive bacteriological result at baseline, 168 
360 (41.7%) were recorded as cured; of these, 83/205 (39.9%) were in the control arm compared to 
361 85/195 (43.6%) in the intervention arm. The OR of being cured was 1.16 (95% CI: 0.83,1.63) in the 
362 intervention versus the control arm; and was similar to the adjusted OR. (Tables 3 and 4)
363
364 Continuous smoking abstinence 
365 Among those who identified as cigarette smokers at baseline (345 (60.1%)), 27 had information (self-
366 report plus biochemical verification) to enable the identification of continuous abstinence at 6-
367 months of which 22 had continuously abstained from smoking. These were similarly distributed 
368 across the two study arms: 10 (5.59%) participants in the intervention arm compared to 12 (7.23%) 
369 in the control arm, OR 0.76 (95% CI: 0.35,1.63). (Tables 3 and 4) At the 3-month follow-up 20 (11.2%) 
370 participants in the intervention arm compared to 27 (16.3%) in the control arm continuously 
371 abstained from smoking, OR 0.65 (95% CI: 0.37,1.14). (Tables 3 and 5)
372
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Control Intervention Total Control Intervention Total Control Intervention Total
TB treatment statusa
Successful** 204 (70.1) 192 (67.8) 396 (69.0)
Not Successful 87 (29.9) 91 (32.16) 178 (31.01)
Cured a, ***
Yes 83 (39.9) 85 (43.6) 168 (41.7)
No 125 (60.1) 110 (56.4) 235 (58.3)
Continuous smoking 
abstinenceb 
Yes 27 (16.3) 20 (11.2) 47 (13.6) 12 (7.2) 10 (5.6) 22 (6.4)
No 139 (83.7) 159 (88.8) 298 (86.4) 154 (92.8) 169 (94.4) 323 (93.6)
Harmful/hazardous 
drinkers!: N =
188† 206† 394† 141† 130† 271† 112† 127† 239†










































122† 83† 205† 100† 83† 183†
Taking ART 








91 (74.6) 58 (69.9) 149 (72.7) 80 (80.0) 74 (89.2) 154 (84.2)
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Optimal adherence 101 (99.0) 64 (98.5) 165 (98.8) 75 (97.4) 64 (97.0) 139 (97.2)
Suboptimal 
adherence
1 (1.0) 1 (1.54) 2 (1.2) 2 (2.6) 2 (3.0) 4 (2.8)
TB medication 
adherence
Optimal adherence 181 (92.3) 138 (90.8) 319 (91.7) 61 (89.7) 59 (90.8) 120 (90.2)
Suboptimal 
adherence
15 (7.6) 14 (9.2) 29 (8.3) 7 (10.3) 6 (9.2) 13 (9.8)
a: only assessed at 6-months
b: assessed at 3 and 6-months; this table refers to cigarette smokers only (other forms of tobacco smoking are excluded)
* Frequencies and (percentages) are presented unless otherwise stated
**Primary Outcome: This is a binary variable defined as either successful treatment (cured or treatment completed) or failed treatment, death, acquired drug resistance, loss to follow-up or treatment interrupted 
for more than 2 months, or outcome not evaluated/unknown.
***Based on having a cured treatment outcome among those who were bacteriologically positive at baseline.
! hazardous/harmful drinkers who are not alcohol dependent= AUDIT score ≥ 8 for men or ≥ 7 for women but < 20; *! Important distinction at baseline for eligibility purposes.
†Denominator for the mean (SD) or denominator for % 
‡ Information on HIV-positivity was obtained from information from TB records combined with patient self-report at baseline. True HIV-positivity rates may have been higher.
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TABLE 4 Regression analysis results for the primary and secondary outcomes at 6-months
Crude Odds Ratio
(95% CI)*





TB treatment status: Successful (Ref: Not successful) 0.90 (0.64,1.27) 0.548 0.86‡ (0.60,1.24) 0.421
Secondary outcomes
Cured  (Ref: Not Cured) 1.16 (0.83,1.63) 0.374 1.07‡ (0.76,1.51) 0.684
Continuous smoking abstinence (Ref: No)*** 0.76 (0.35,1.63) 0.482
TB medication adherence (Ref: Optimal) 0.89 (0.26,3.07) 0.849
ART medication adherence (Ref: Optimal) 1.17 (0.14,9.94) 0.884
Taking ART medication (Ref: No) 2.05! (0.80,5.27) 0.136
AUDIT -0.04** (-2,1.91) 0.966 0.02!! (-1.55,1.6) 0.976
* Analyses accounted for potential clustering by centre.
‡ Adjusted for district, sex, and smoking/drinking status and HIV status at baseline. It is worth noting that of the variables in the adjusted model; the only statistically significant result is for the district variable.
! Adjusting for art status at baseline
**Controlling for the AUDIT baseline values.  The values represent the study arm regression coefficient.
!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.
***Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, 
type of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.73 
and 0.76 with similar confidence limits as for the crude estimate.
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TABLE 5 Regression analysis results for secondary outcomes measured at 3-months
Secondary outcome Crude Odds Ratio
(95% CI)*
P Value* Adjusted Odds Ratio
(95% CI)*
P Value*
Continuous smoking abstinence (Ref: No)** 0.65 (0.37,1.14) 0.135
TB medication adherence (Ref: Optimal) 1.22 (0.52,2.87) 0.641
ART medication adherence (Ref: Optimal) 1.58 (0.10,26.12) 0.750
Taking ART medication (Ref: No) 0.79! (0.38,1.65) 0.53 0.74‡ (0.35,1.58) 0.443
AUDIT 0.55† (-1.01,2.11) 0.474 0.74!! (-0.62,2.1) 0.273
*Analyses accounted for clustering.
! Adjusting for art status at baseline
‡ Adjusted for art status at baseline, district, sex, and smoking/drinking status and HIV status at baseline.
†Controlling for the AUDIT baseline values. The values represent the study arm regression coefficient.
!! Controlling for the AUDIT baseline values and adjusted for district, sex, and smoking/drinking status and HIV status at baseline. The values represent the study arm regression coefficient.
** Given the limited number of those who were identified as continually abstained, we were only able to adjust for one additional variable at a time. Adding one of the following variables: heaviness of smoking, type 
of drinker at baseline, age when started smoking, and the duration of smoking at baseline; the adjusted odds ratio of continuous abstinence comparing the intervention to the control arm ranged between 0.63 and 
0.66 with similar confidence limits as for the crude estimate.
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373 Change in harmful/hazardous drinking 
374 AUDIT scores were about 4 points lower at both follow-up times than at baseline, independent of 
375 the intervention.(Table 3) In the intervention arm, participants had, on average, a reduction of 0.04 
376 points (95% CI: -2,1.91) on the AUDIT score at 6-months, compared to those in the control arm 
377 controlling for baseline scores; whereas an average increase of 0.55 (95% CI: -1.01,2.11) was 
378 observed at 3-months. (Tables 4 and 5)
379
380 Medication adherence  and ART uptake
381 At 6-months, the OR of taking ART medication was 2.05 (95% CI: 0.80,5.27) comparing the 
382 intervention arm to the control arm and controlling for ART baseline medication status; whereas it 
383 was 0.79 (95% CI: 0.38,1.65) at 3-months. The proportion of participants who had optimal TB 
384 medication adherence was 90.2% (120/133) at 6-months and 91.7% (319/348) at 3-months. 
385 Suboptimal TB medication adherence ORs were 0.89 (95%CI: 0.26,3.07) and 1.22 (95%CI: 0.52,2.87) 
386 comparing intervention arm to the control arm at 6-months and 3-months, respectively. The 
387 proportions of participants on ART who had optimal ART medication adherence were high at both 3-
388 months (165/167, 98.8%) and 6-months follow-up (139/143, 97.2%). Suboptimal ART medication 
389 adherence ORs were 1.17 (95%CI: 0.14,9.94) and 1.58 (95%CI: 0.10,26.12) comparing the 
390 intervention arm to the control arm at 6-months and 3-months, respectively. (Tables 3, 4 and 5)
391
392 Intervention fidelity
393 Motivational interviewing fidelity
394 The recordings of 17 counsellors (one each) were transcribed verbatim and then assessed. In terms 
395 of the global ratings, the LHWs’ counselling sessions were above proficiency levels on all items, 
396 namely, cultivating change talk, softening sustain talk, partnership, and empathy (as the mean scores 
397 were all above 2). In terms of the summary measures, the LHWs’ counselling sessions did not 
398 achieve the basic proficiency threshold of 3.5 for the Relational component (Partnership + Empathy) 
399 as their mean score was 3.1 (SD=1.19). However, their mean score on the Technical component 
400 (Cultivating Change Talk + Softening Sustain Talk) of 3.3 (SD=0.97) was above the threshold of 3. For 
401 behavioural counts, “Asking Questions” had the highest mean score (24.2; SD=10.42), followed by 
402 “Affirm” with a mean score of 5.5 (SD=3.7). The counsellors were least likely to engage in the 
403 following: Persuade with permission and emphasising autonomy. The mean Reflections to Questions 
404 Ratio was 0.23 (SD=0.24). The LHWs made on average 9.3 (SD=4.74) MI adherent (Affirm, Emphasize 
405 Autonomy and Seek Collaboration) and 1.2 (SD=2.28) MI non-adherent (Confront and Persuade) 
406 statements per session. (Supplementary Ttable 4)
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409 Of the total number of Information-Motivation-Behaviour messages triggered, 3583 (80.4%) were 
410 delivered. All due SMS messages were delivered to 95 (41.9%) of the participants who completed 
411 the first MI, See Supplementary Table 5 for more details.
412
413 Costs and health related quality of life
414 Unit costs used to estimate the mean costs are presented in the Supplementary Table 6. Incremental 
415 cCost-utility ratios are not presented since the intervention was not clinically effective. The mean 
416 cost of the ProLife intervention was ZAR 2601 (SD 6) ($180.02 (SD $0.42)) per participant in the 
417 intervention arm (n=283). The mean cost of usual care was ZAR 681 (SD 357) ($47.13 (SD $24.71)) in 
418 the intervention arm (n=122) versus ZAR 706 (SD 302) ($48.86 (SD $20.90)) in the control arm 
419 (n=131). The total mean cost of care including the intervention was ZAR 3285 (SD R357) ($227.37 (SD 
420 24.71)) in the intervention arm (n=122). EQ-5D-3L data were available at the 3 time points for 137 
421 intervention and 159 control arm participants. The mean QALYs estimated over six months were 
422 0.442 (SD 0.061) in the intervention arm versus 0.430 (SD 0.074) in the control arm (adjusted mean 




427 This RCT did not finprovided evidence for improved TB treatment success rates in those receiving the 
428 ProLife intervention compared to those receiving usual care. We could also There was also not 
429 demonstrate significant beneficial effects on any of the secondary outcomes, i.e., smoking, alcohol 
430 consumption, medication adherence and ART initiation. To our knowledge there are no other 
431 published studies of similar complex interventions that aim to improve TB treatment outcomes in 
432 patients who smoke or drink to harmful or hazardous extent. Interventions evaluated by other 
433 studies were either complex interventions or complex SMS-based interventions aimed at improving 
434 TB outcomes through the pathway of increasing adherence, but without an alcohol or smoking 
435 intervention component (43,44) or  or focused on a single behaviour, namely smoking or 
436 drinking.(45,46).  Of the latter studies, a brief smoking cessation intervention was effective in 
437 inducing smoking cessation in TB patients with TB but did not improve TB outcomes.(45) Conversely, 
438 in another study in India, intensive counselling for alcohol disorders led to significantly better TB 
439 treatment outcomes in the intervention group compared to the control group.(46) Smoking 
440 cessation also led to better TB treatment outcomes in a secondary analysis of a large tobacco 
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441 cessation trial in TB patients with TB in Bangladesh and Pakistan.(47) Our non-significant result for 
442 smoking-related outcomes is not consistent with findings from our previous TB study, which used a 
443 single MI session and found that the chance of sustained smoking cessation was twice as high in the 
444 MI intervention group compared to the control group,(14) albeit with a less stringent exhaled CO 
445 cut-off point. Evidence on the effectiveness of MI for smoking abstinence in non-TB settings has 
446 been equivocal.(48) Self-reported alcohol consumption decreased with about 4 points in both 
447 intervention and control arms in our study at both follow-up times. Answering questions on drinking 
448 in brief intervention trials may alter subsequent self-reported behaviour.(51): eExposing non-
449 intervention control groups to an integral component of the intervention may therefore 
450 underestimate the effect of the intervention.(49) There have been few previous studies looking at 
451 MI and SMS interventions for the modification of hazardous/harmful drinking in the context of TB. A 
452 previous trial of a brief counselling intervention to reduce alcohol consumption in patients with TB 
453 did not find a significant effect on alcohol reduction.(50) Outside a TB setting, results have been 
454 mixed. A meta-analysis showed a small but significant improvement in outcomes when MI was used 
455 in conjunction with cognitive behavioural therapy for co-morbid alcohol use and depression.(51) 
456 Self-reported TB and ART medication adherence was high overall in ourthis study population, which 
457 is consistent with other studies conducted in South Africa.(52,53) It is possible that we did not find a 
458 difference in treatment adherence due to a ceiling effect.
459
460 There were several key strengths in this RCT. This was an individually RCT with a relatively large 
461 sample size and a high follow up rate (87%) for the primary outcome. Primary outcome assessment 
462 was blinded. This was a novel intervention, which built on previous successes with both MI and 
463 mHealth interventions and was aligned with the WHO’s call to increase the use of digital 
464 technologies to improve TB care.(15) We utilized a validated alcohol consumption questionnaire 
465 (AUDIT) (29) and a four-day timeline follow-back for medication adherence to reduce recall bias as 
466 self-reports tend to underreport drinking while overestimating adherence behaviour compared 
467 with.(54) (35) Smoking cessation was confirmed with exhaled CO using strict cut-off points. Overall, 
468 the quality of the counselling was acceptable. The results of our MI analyses suggest that the LHWs 
469 trained as counsellors were more proficient in MI than during the feasibility stage, as observed by 
470 their global rating scores on cultivating change talk, softening sustain talk, partnership and empathy. 
471 (Supplementary Table 4) These results were achieved by ongoing monitoring and training of LHWs 
472 during the trial and adapting the training based on feedback from the feasibility stage. Extra 
473 counsellors were also appointed to minimise travel distances to clinics. There were some limitations 
474 associated with this RCT. Trial recruitment had to be terminated before the planned sample size 
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475 because of funding and time constraints. Nevertheless the calculation of sample size was based  on 
476 an anticipated 25% LTFU for the primary outcome, while in reality only 13.4 %, of the TB outcomes 
477 were not available. As a result, we achieved a slightly higher power to detect the a 10% difference in 
478 primary outcomes, than we had aimed for (83% vs. 80%). The smaller sample size did however 
479 reduce the power to detect a difference for secondary outcomes for which the LTFU was much 
480 higher than 25%. Also, the calculated sample size was not powered for subgroup analysis which was 
481 the case for outcomes relating to smoking, drinking,  ART and cure rates. In addition, due to COVID-
482 19 lockdown in March 2020, we had to switch to telephonic follow-up of participants using a 
483 shortened questionnaire (22 participants) and could not access clinics to retrieve outstanding TB 
484 treatment outcomes. The low intervention uptake meant that half of the participants received only 
485 one or two MI sessions combined with SMS messages. SMS messages were only used for the first 
486 half of the study period, and one quarter of participants did not receive their messages, a commonly 
487 occurring problem in developing countries.(20,55) It could be argued that in the absence of ongoing 
488 text messages, the MI and associated text messages were not enough to keep participants focussed 
489 for the second three months of the trial. The 2-arm study design did not permit the untangling of the 
490 individual effects of SMS and MI. Understanding their separate effects could have important cost 





496 The lack of effectiveness of our intervention consisting of three sessions of MI combined with SMS 
497 on the primary outcome (TB treatment success) can have a number of possible explanations. 
498 Although intervention uptake was high (80.2%) for the first counselling session, many participants 
499 did not return for the second (29.7%) and third (47%) sessions. As a result of this only about half of 
500 the intervention arm participants received all three MI sessions. Furthermore, about one quarter of 
501 all participants did not receive any SMS-messages. Low intervention uptake leads to a dilution of any 
502 potential effects. There were a number of possible technical barriers to SMS delivery: invalid phone 
503 numbers, phones that are off for a long duration of time, numbers that are deactivated, and phones 
504 that are disconnected from the network leading.(41) The proportion of participants with TB 
505 treatment outcomes recorded was high, but follow-up rates at 3- and 6-months were low. Due to 
506 COVID-19 lockdown, we had to switch to telephonic follow-up of participants using a shortened 
507 questionnaire (22 participants) and could not access clinics to retrieve outstanding TB treatment 
508 outcomes.
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510 The lack of effectiveness on TB treatment success couldmay perhaps also be explained by the 
511 complexity of the ProLife intervention itself: counsellors had to address multiple behaviours, namely 
512 medication adherence, tobacco smoking and hazardous/harmful drinking. This integrated approach 
513 was nevertheless adopted to avoid the need for multiple vertical counselling services (in addition to 
514 TB treatment and HIV treatment), to allow the different elements of the programme to reinforce 
515 one another, and to improve the affordability, feasibility and acceptability for a future roll-out of the 
516 programme. Despite having established the feasibility and acceptability of this approach ,(31) and 
517 ongoing on site performance monitoring and feedback of counsellors, it is possible that MI for 
518 multiple behaviour change in the ProLife study was counterproductive as counsellors may have 
519 ended up not focusing on any of the behaviours at optimal levels. Similarly, patients might have 
520 found it difficult to change multiple behaviours simultaneously, especially because smoking and 
521 drinking are mutually reinforcing. This integrated approach was nevertheless adopted to avoid the 
522 need for multiple vertical counselling services (in addition to TB treatment and HIV treatment), to 
523 allow the different elements of the programme to reinforce one another, and to improve the 
524 affordability, feasibility and acceptability for a future roll-out of the programme. It is also possible 
525 There is some indirect evidence that sequential interventions may be better, at least for smoking 
526 cessation.(56) More intensive counselling (more sessions) or a modified counselling method with or 
527 without MI may have been more appropriate, even more so since a recent review of reviews of MI 
528 casts doubt on its efficacy.(48,57,58) For example, m, more emphasis on increasing patient 
529 knowledge in addition to increasing self-efficacy may have been more effective.(59) The cause of the 
530 mobile health message delivery problems (such as poor network coverage, no electricity to charge 
531 phones) (60) would need to be investigated in order to increase the effectiveness of future mHealth 
532 interventions. Messages may also have to be intensified or modified to be more interactive and/or 
533 tailored to specific circumstances of each individual. This would improve the personal value of the 
534 intervention to the individual, which is likely to increase the chances of their participation in the 
535 intervention.(61) Consistent with the normalisation process theory,(62) cognitive participation in the 
536 intervention might have been higher had we been deliberate in the implementation to ensure the TB 
537 nurse who would have routinely seen the participants, provided additional support and motivated 
538 participants to attend MI sessions with the counsellor. In this way, the intervention would have 
539 gained ‘legitimacy’ but this would have led to unblinding of the nurses to the intervention arm. 
540
541 In conclusion, Thwe could not demonstrate that the ProLife intervention was is RCT provided 
542 evidence that the ProLife intervention was not effective in modifying the primary o improving TB 
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543 treatment outcomes. This may be due to the lack of effect of the intervention, but r the study may 
544 also have been underpowered for the intermediary secondary outcomessecondary outcomes. 
545 Valuable lessons were learnt on challenges relating to training LHWs in MI counselling and delivery, 
546 the SMS-delivery in a challenging socio-economic context and the reasons for loss to follow-up of TB 
547 participants with multiple health problems. Further research is needed to provide answers on how 
548 to increase intervention uptake in poor resource settings and whether our complex intervention 
549 should have been more intensive (with several sessions for each behavioural problem). Other 
550 important questions are whether another counselling method would have been more effective. 
551 Lastly, in the light of the already existing evidence of SMS and the costs and implementation 
552 challenges relating to MI, intervention studies limited to an mHealth intervention but using different 
553 intensities, duration and type of interventions (oneway, twoway, interactive) are needed. 
554
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Abstract
Background: South Africa is among the seven highest tuberculosis (TB) burden countries. Harmful lifestyle behaviours,
such as smoking and alcohol, and poor adherence to medication can affect clinical outcomes. Modification of these
behaviours is likely to improve TB treatment outcomes and has proven possible using motivational interviewing (MI)
techniques or use of short message service (SMS) text messaging. There have been no studies assessing the effect of
combined MI and SMS interventions on multiple lifestyle factors and TB treatment outcomes.
Methods: This is a prospective, multicentre, two-arm individual randomised controlled trial looking at the effectiveness
and cost-effectiveness of a complex behavioural intervention (the ProLife programme) on improving TB and lifestyle-
related outcomes in three provinces of South Africa. The ProLife programme consists of an MI counselling strategy,
delivered by lay health workers, augmented with subsequent SMS. We aim to recruit 696 adult participants (aged 18
years and over) with drug-sensitive pulmonary TB who are current smokers and/or report harmful or hazardous alcohol
use. Patients will be consecutively enrolled at 27 clinics in three different health districts in South Africa. Participants
randomised individually to the intervention arm will receive three MI counselling sessions onemonth apart. Each MI
session will be followed by twice-weekly SMS messages targeting treatment adherence, alcohol use and tobacco
smoking, as appropriate. We will assess the effect on TB treatment success, using standard World Health Organization
(WHO) treatment outcome definitions (primary outcome), as well as on a range of secondary outcomes including
smoking cessation, reduction in alcohol use, and TB medication and anti-retroviral therapy adherence. Secondary
outcomes will be measured at the three-month and six-month follow-ups.
Discussion: This trial aligns with the WHO agenda of integrating TB care with the care for chronic diseases of lifestyle,
such as provision of smoking cessation treatments, and with the use of digital technologies. If the ProLife programme
is found to be effective and cost-effective, the programme could have significant implications for TB treatment globally
and could be successfully implemented in a wide range of TB treatment settings.
Trial registration: ISRCTN Registry, ISRCTN62728852. Registered on 13 April 2018.
Keywords: Tuberculosis, Smoking, Alcohol, Motivational interviewing, Anti-retroviral therapy, Adherence
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: andrewmoriarty1@doctors.org.uk
1Department of Health Sciences and the Hull York Medical School, University
of York, York, UK
Full list of author information is available at the end of the article
Moriarty et al. Trials          (2019) 20:457 
https://doi.org/10.1186/s13063-019-3551-9
Page 146 of 155

































































South Africa has the second highest incidence of tuber-
culosis (TB) and the sixth highest TB burden of the 30
high TB burden countries. It also has a high prevalence
of human immunodeficiency virus (HIV) co-infection in
patients with TB and a high mortality in these co-
infected patients relative to most other high-burden
countries [1]. In addition to HIV co-infection, a range of
social, psychological and economic factors influence
treatment success in TB. Of these, tobacco smoking and
hazardous or harmful alcohol use are specifically men-
tioned in the South Africa National TB Management
Guidelines [2]. Tobacco use and problem drinking are
prevalent in TB patients, often co-occur [3–5] and are
known to increase the risk of death and poor treatment
adherence and outcomes [6–9].
As well as increasing the risk of TB infection and pro-
gression of disease [10], smoking is also known to in-
crease the risk of treatment failure [11], relapse [12, 13]
and death [14], and is associated with resistance to iso-
niazid, one of the main antimicrobials used to treat TB
[15]. There is evidence that patients who stop smoking
have better TB treatment outcomes and, if co-infected,
better HIV treatment outcomes than current smokers
[16–18]. In addition, alcohol misuse is associated with
poorer TB outcomes through a range of mechanisms in-
cluding decreased effectiveness of medications used to
treat TB (including drug resistance), increased recur-
rence and treatment default rates and social marginalisa-
tion [3]. It has been estimated that 10% of the global
burden of TB is attributable to alcohol use [19, 20].
Poor adherence to TB medication and anti-retroviral
therapy (ART) significantly increases the risk of adverse
effects and death in TB patients. Strategies are needed to
improve medication adherence in TB-HIV co-infected
patients, in whom integration of TB and HIV care has
been shown to decrease mortality [21].
A number of studies have attempted to evaluate the
effectiveness of tobacco cessation, alcohol reduction
or TB treatment adherence interventions in TB pa-
tients [21, 22], but few have assessed the effect on
TB treatment outcomes [23, 24]. We know that brief
smoking cessation interventions, ranging from oppor-
tunistic advice and proactive telephone support
through to in-person behavioural support over mul-
tiple sessions, are effective and affordable in low-
income countries, in both TB patients and smokers in
the general population [25, 26]. We also know that
disease diagnosis could constitute a ‘teachable mo-
ment’, when people are more amenable to advice and
motivated to modify harmful lifestyle behaviours [27].
For this reason, it is likely that patients receiving a
TB diagnosis may be more successful in quitting
smoking and moderating alcohol use if offered
behavioural support, compared with smokers and
problem drinkers in the general population.
Motivational interviewing (MI) is a counselling tech-
nique known to facilitate behaviour change [28], which
has demonstrated effectiveness for the reduction of haz-
ardous drinking, tobacco cessation, and TB treatment
and/or ART adherence [19, 29, 30]. Our group has had
previous success in achieving sustained smoking abstin-
ence in TB patients through a brief MI intervention de-
livered by lay health workers (LHWs) [31]. There is also
evidence to suggest that adherence to ART [32] and pos-
sibly TB medication [33], as well as tobacco cessation,
can be enhanced with the use of short message service
(SMS) text messages on mobile phone technology [34].
To our knowledge, no study has used MI in combination
with SMS text messages to address multiple harmful be-
haviours that adversely impact TB outcomes.
The ProLife programme is a novel complex behav-
ioural intervention targeting tobacco smoking, problem
drinking, and TB and HIV medication adherence in pa-
tients with TB. This is the study protocol for the rando-
mised controlled trial (RCT) aiming to assess the
effectiveness and cost-effectiveness of the ProLife
programme in improving TB treatment outcomes in pri-
mary healthcare clinics located in high TB-burden com-
munities in three provinces in South Africa (Gauteng,
Free State and North West). The protocol has been writ-
ten in accordance with the Standard Protocol Items:




The primary objective is to assess the effectiveness and
cost-effectiveness of the ProLife programme compared
to usual care in improving pulmonary TB (PTB) treat-
ment outcomes. We also aim to assess the effectiveness
and cost-effectiveness of the programme in achieving ab-
stinence from smoking, reducing harmful and hazardous
drinking, and improving TB and ART medication
adherence.
Trial design and setting
This is a pragmatic, prospective, multicentre, two-arm,
parallel, individual RCT taking place in 27 purposively
selected primary care clinics with the highest TB case-
load in three districts in South Africa: Welkom in the
Free State; Bojanala in the North West province; and
Sedibeng in Gauteng province. To be eligible for inclu-
sion in the trial, TB clinics had to be under the control
of the provincial or local government (i.e. not a mining
TB clinic). The intervention will be delivered by LHWs
and three district coordinators who will each cover 1–2
clinics.
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Participants will be randomly allocated to one of two
arms:
Arm 1: Intervention arm – participants in the
interventions arm will receive the ProLife programme;
Arm 2: Control arm – participants will receive usual
treatment and support provided to TB patients in TB
treatment clinics in South Africa (‘usual care’).
Intervention
The ProLife programme is a complex behavioural inter-
vention aimed at improving treatment outcomes in TB
patients who smoke tobacco, drink alcohol at harmful or
hazardous levels, or do both. The ProLife programme
has been developed in line with the Medical Research
Council (MRC) guidance on developing and evaluating
complex interventions [35] and has undergone a period
of development and feasibility testing in South Africa.
The paper reporting the results of this evaluation has
not yet been published. The conceptual framework used
to develop the ProLife programme assumes that smok-
ing cessation, reducing harmful alcohol use and im-
proved adherence to TB and HIV treatment will result
in improved TB treatment outcomes.
Participants randomised to the intervention arm will re-
ceive three brief MI counselling sessions, lasting 15–20
min, each onemonth apart, from a trained LHW at their
TB clinic. In the initial MI session, occurring at the start
of TB treatment, the counsellor will establish the partici-
pant’s tobacco smoking habits and problem drinking; po-
tential obstacles and facilitators for medication adherence
or treatment initiation (both TB treatment and ART)
will be determined. The participant will determine
which factor should be prioritised (i.e. agenda setting),
which could be a plan either to quit tobacco smoking,
reduce or quit drinking or deal with barriers relating
to ART or TB medication adherence. For participants
who are HIV-infected and not yet on ART, beliefs
and attitudes regarding HIV-testing or ART will be
explored to facilitate ART initiation and adherence.
The second session will build on the previous one
and will focus on the previous agenda before moving
on to the next behavioural problem (tobacco, alcohol
or medication adherence) where applicable. The third
session will deal with the last identified problem.
The individual counselling sessions will be re-enforced
with SMS text messages regarding information, motiv-
ation and behaviours (IMB) supporting tobacco cessa-
tion, alcohol use and medication adherence. Text
messages will be delivered twice a week over 12 weeks.
All participants will first receive 10 TB-related messages.
These messages will be followed by seven alcohol or
smoking-related messages depending on whether the
participant smokes or drinks. Co-joint users will receive
all sets of messages (i.e. 24 in total).
Comparator
Participants in the second group are the controls and
will receive usual TB treatment and support offered to
TB patients. Control participants are seen by a TB nurse
and receive the same biochemical investigations and
medical treatments as the intervention arm. However,
they will not receive the MI and SMS package of care as
described above. Usual care also includes HIV testing
with pre- and post-test HIV test counselling by a lay
counsellor or a nurse (this varies by district).
In addition, health education is given on:
 nature of TB, treatment adherence, treatment side-
effects/complications, drug interactions, tobacco use,
alcohol use and other substance abuse. This is
mostly done by the TB nurses, is not intensive and
is educational in nature rather than a form of
counselling;
 healthy diet by a dietician where possible;
 social problems and family support for treatment by
a social worker as needed and depending on the
availability of social workers; and
 point of care blood glucose, haemoglobin and
pregnancy tests are performed. If co-infected with
HIV, a full blood count, liver function test and
creatinine are also carried out.
Participants
The inclusion criteria for participants are:
 adult patients (aged ≥ 18 years) with drug-sensitive
(bacteriologically or clinically confirmed) PTB;
 initiating TB treatment or on TB treatment for < 1
month (these include both ‘new’ and ‘retreatment’
patients);
 current smokers and/or hazardous/harmful drinkers
who are not alcohol dependent (Alcohol Use
Disorders Identification Test [AUDIT] score ≥ 8 for
men or ≥ 7 for women but < 20);
 access to a functional mobile phone; and
 understands one of the four languages used for the
trial (Sesotho, Setswana, Isizulu or English).
Exclusion criteria:
 alcohol-dependent participants (AUDIT score ≥ 20);
 Extrapulmonary TB without PTB; or
 Resistance to one or more TB drugs at baseline
(because drug-resistant TB needs further investigations
which take several months and is treated through
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a long, specialised treatment programme if
present).
Recruitment process
Participants will be recruited consecutively from the
starting date of the trial until the required sample size
for each clinic has been achieved. The sample size per
clinic will vary depending on the workload for each
clinic. TB patients who initiate treatment (or who have
been on treatment for < 1 month) will be asked if they
would like to participate. If they agree, they will then be
screened for eligibility by trained fieldworkers immedi-
ately after the TB nurse at the clinic has initiated TB
treatment and started the r utinely used TB treatment
record. Eligibility screening will involve being assessed in
line with the inclusion criteria listed above and being
asked about their:
 smoking status: using the Global Adult Tobacco
Survey [36] questionnaire, patients will be asked
whether they currently smoke daily, less than daily
or not at all, and in the past daily, less than daily or
not at all. As TB patients in South Africa often
smoke little or may not have smoked for a few days
because of ill-health and the word ‘current’ is open
to interpretation (particularly when translated);
‘current’ has been defined as smoking daily and non-
daily in the last four weeks for the purpose of this
study. Smoking habits will be further quantified at
baseline interview;
 current alcohol usage: AUDIT, a validated tool for
identifying problem alcohol behaviours [37], will be
used to quantify alcohol intake. Those with an
AUDIT score ≥ 8 for men or ≥ 7 for women but < 20
will be eligible for the trial.
If eligible, patients will be invited to join the trial. For
those who wish to be enrolled into the trial, written in-
formed consent will be obtained (Additional file 1).
Randomisation and allocation
Patients will be randomised using a randomised se-
quence generator performed by the trial statistician
(MK) who will remain blind to the arm allocation. We
will use block randomisation with varying block sizes
stratified by the clinic to achieve equal numbers in inter-
vention and control groups within each clinic (see the
‘Sample size’ section). Allocation concealment will be
done with consecutively numbered, sealed, opaque
envelopes.
Ethics and consent
Potential participants will be approached and given an
introduction to the study and basic eligibility criteria
required for participation. Participants who meet the eli-
gibility criteria for language, age, PTB, treatment dur-
ation and mobile phone access will be given a consent
form (Additional file 1) to sign before screening for alco-
hol and tobacco use eligibility as the alcohol-related
questions are sensitive and the fieldworkers must ac-
cess the patient treatment record. If recruited to the
trial, participants will be ask to consent to enter the
trial, including consent for audio recording of the MI
counselling sessions (Additional file 1). A witness sig-
nature will be required where the participant is un-
able to read or write.
The identity of participants will be protected by allo-
cating each participant a unique trial number, which will
be used on all research documents and will ensure ano-
nymity for the data analysis. Participation will be volun-
tary; participants will be informed of their right to
withdraw from the study at any time without giving a
reason for their withdrawal. The project is unlikely to be
directly harmful to TB patients with the exception of in-
convenience in terms of time spent on the counselling
sessions. Participants will receive ZAR 60 (US$4.19)
travel and other expenses reimbursement for each MI
counselling session and follow-up visit related to the
study.
Timeline and procedures
Figure 1 Additional file 4 outlines the overall participant
flow through the trial. Eligible and consenting patients
will be enrolled in the trial and the baseline interviewer-
administered questionnaire and record review com-
pleted. Participants will receive a baseline interview on
the same day as the recruitment or on the nearest avail-
able date suitable to both the participant and the LHW.
The initial part of the questionnaire covers socioeco-
nomic and demographic factors. We will also assess for
depression using the CES-D10 [38], a validated tool, as
depression may be a potentially moderating or mediating
factor affecting treatment outcome. See Additional file 2
for the full case report form (CRF).
The next part will cover medical history, particularly
TB and HIV history and current medications. Partici-
pants identified as current smokers at eligibility screen-
ing will be asked more in-depth about their smoking
habits and quit history. All participants will be asked
about their use of smokeless tobacco and exposure to
second-hand smoke. Participants will also be asked
about time and money spent on TB-related healthcare
visits in the past three months and health-related quality
of life (see the ‘Economic evaluation’ section). After ad-
ministering the baseline interviews, fieldworkers will
draw the allocation envelopes and organise the
follow-up sessions for the participants. Each of the in-
terviews on health status, tobacco and alcohol use at
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baseline, three months and six months is not expected
to last > 25 min.
Primary outcome
The primary outcome is TB treatment success at 6–9
months of follow-up, measured using the routinely col-
lected programmatic TB treatment outcomes as defined
by the World Health Organization (WHO) and adopted
in South Africa. This is a binary variable defined as
either successful treatment (cured or treatment com-
pleted) or failed treatment, death, acquired drug resist-
ance, loss to follow-up or ‘default’, or not outcome
evaluated. Table 1 defines the different treatment outcomes
according to the South African Department of Health
National Tuberculosis Management Guidelines [2].
Individual TB treatment records will be used as the
primary source of information. The TB treatment rec-
ord is the routinely used clinical document initiated
by the TB nurse when the patient first presents at the
TB clinic and includes demographic information as
well as a comprehensive overview of the patient’s
treatment over time. The TB treatment outcomes will
be obtained 6–9 months after the TB treatment start
dates. This is to allow for short periods of treatment
interruption and time needed to confirm the TB
treatment outcomes status. For example, the TB nurse
may have to wait for end of treatment TB sputum or
culture results or time may be required to determine
whether a participant died. In some cases, TB patients
may also undergo a longer TB treatment regimen.
Routinely reported outcomes will be verified for cor-
rectness by checking the actual individual diagnosis and
treatment records. For example: if the outcome is classi-
fied as cured, then the criteria for diagnosis and out-
come definitions should have been adhered to. Attempts
will be made to verify the information of patients classi-
fied as ‘defaulted’ or who are lost to follow-up by con-
tacting them telephonically or sending them a short text
message. Sputum cultures and smears will be performed
at baseline, twomonths, three months and six months
per routine care.
Secondary outcomes
The following outcome measures will also be recorded
at the six-month follow-up:
 sputum conversion at the end of treatment: this will
be measured by negative culture or smears in the
group of participants who had bacteriology
confirmed PTB at baseline, i.e. cure rates in
intervention group versus control group for
participants who initially had sputum AFB-positive,
culture-positive or GeneXpert-positive PTB;
 six-month continuous smoking abstinence: the
Russell Standard defines continuous abstinence as a
self-report of not smoking > 5 cigarettes from the
Fig. 1 CONSORT Flow diagram outlining randomisation and participant recruitment
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start of the abstinence period (in this case, six
months), supported by a negative biochemical test
(exhaled carbon monoxide [CO] < 10 ppm) at final
follow-up [39]. For the purpose of our study, we
will, however, use a more stringent criterion of
exhaled CO < 7 ppm, based on findings from our
previous study that some participants who
reported continued smoking had an exhaled CO
< 10 ppm [26]. This analysis will be performed on
the group of participants who were current to-
bacco smokers at baseline;
 reduction in harmful or hazardous drinking:
alcohol use will be measured using the AUDIT
questionnaire. The questionnaire will be
administered at screening (which will take place
on the same day or shortly after the baseline
assessment) and again at three months and six
months. Changes in the total AUDIT score will
be used to compare change in drinking behaviour
between control and intervention groups. This
analysis will be performed on the group of
participants who were harmful or hazardous
drinkers at baseline.
 TB and ART medication adherence: adherence to
both TB and ART medications will be measured
using a modified version of the AIDS Clinical Trials
Group (ACTG) Adherence Questionnaire. The
questionnaire is a validated tool for measuring
adherence specifically to ART and we will use an
adapted version to also measure TB medication
adherence [40]. Field workers will administer the
baseline part of this questionnaire as part of the
baseline CRF and adherence will be measured at
both three months and six months.
Adherence will be measured using an adherence index
calculated by the formula (using the four-day recall
table):
Total number of doses taken=Total number of doses prescribed½  x 100
ART patients with at least 95% of adherence will be
considered as having optimal adherence and those with
< 95% will be considered as having low (or suboptimal)
adherence. For the TB medication regimen, patients with
at least 95% of adherence will be considered as having
optimal adherence and those with < 95% will be consid-
ered as having low (or suboptimal) adherence:
 increase in proportion of HIV-positive participants
on ART: HIV status will be recorded in the TB
Treatment Record. HIV-positive participants will be
asked about ART status at baseline, three months
and six months using standardised questions on the
CRF.
The following outcomes will be measured at three
months:
 biochemically verified three-month sustained to-
bacco cessation;
 reduction in harmful or hazardous drinking;
 TB drug and ART adherence;





Cure Patient in whom baseline smear or culture was positive at beginning of treatment AND is smear/culture negative in the last
month of treatment and on at least one previous occasion at least 30 days prior




Patient whose baseline smear or culture was positive at the beginning and has completed treatment but does not have a
negative smear/culture in the last month of treatment and on at least one previous occasion > 30 days prior. Patients diagnosed
with PTB whose baseline smear (or culture) result was negative and who started treatment based on clinical and radiological
findings who have shown clinical improvement and completed the prescribed course of treatment.
N.B. The smear examination may not have been done or the results may not be available at the end of treatment.
Treatment failure Patient whose baseline smear or culture was positive and remains or becomes positive again at 5 months or later during
treatment.
Patients who were negative at baseline but were later found to be positive.
N.B. This definition excludes those patients who are diagnosed with RR-TB or MDR-TB during treatment.
Died Patient who dies for any reason during the course of TB treatment.
Treatment default Patient whose treatment was interrupted for two consecutive months or more during the treatment period.




Participants who are subsequently referred for MDR treatment.
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 increase in proportion of HIV-positive participants
on ART.
The schedule for enrolment, intervention and assess-
ments is presented in Fig. 2. Table 2 summarises the
methods of data collection and analysis for each of the
primary and secondary outcomes.
Data collection and management
Data will be collected and recorded by field workers
equipped with Android phones with a mobile data col-
lection application installed. MI counselling and data
collection will take place in a well-ventilated private area
inside or outside the clinic (but within the grounds of
the health facility); MI sessions will be audio-recorded
where consent has been obtained. Fieldworkers and
LHWs will be provided with high particulate respirator
masks to minimise the risk of infection.
Fieldworkers will follow-up all participants in both
arms at three and six months within a window period of
two weeks before and two weeks after the ideal three-
month and six-month visit. Participants will receive SMS
reminders three days before each planned visit. Partici-
pants will also be in a position to send ‘please call me’
messages to the district coordinators, who will then call
the participant to solve problems that may have arisen
with the appointment.
The electronic data captured will be stored on secured
and password-protected storage servers and mobile
phones which ensure data privacy through only allowing
authorised research staff access to the data. The elec-
tronic data collection system used for the study requires
an SMS gateway to send and receive messages to the re-
search participants. Consenting participants’ phone
numbers, participant IDs and associated SMS messages
will be stored on the SMS gateway’s secured and
password-protected server.
Data quality will be ensured by providing fieldworkers
with standard operating procedures (SOPs), training and
ongoing support on the importance of data quality, data
collection and data collection problem solving. Training
will consist of a four-day session before the commence-
ment of the pilot and a one-day training session focusing
on problems identified during the pilot preceded the
trial. The data manager will continuously monitor the
captured data for missing variables and inconsistencies
in order to resolve any data problems.
The data manager will export the data from the se-
cured server, conceal the participants study arm alloca-
tion and de-identify the data before sharing the data in
STATA and R compatible formats. The exported de-
identified data will be stored in Dropbox, a secure cloud
storage platform, for sharing with the lead trial statisti-
cian at the University of York for analysis.
All research data and documents referring to the
ProLife trial will be stored and maintained in a secured
storage space at SMU for a minimum of 15 years from
the end of the ProLife trial. Study materials will be
destroyed 15 years after the study.
Blinding and limitation of risk of bias
This is a complex behavioural intervention and the
team dynamics mean that all team members work
very closely with one another. As such, LHWs and
participants cannot be blinded to the intervention.
The determination of the primary outcome will be
done by the TB nurses who are blinded to the inter-
vention status of the participants based on routinely
collected data. Blinding of the field researchers col-
lecting other questionnaire data (Additional file 2)
Fig. 2 SPIRIT Figure outlining data collection throughout trial
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will not be possible. The statistician will be blinded
to the intervention or control arm allocation of par-
ticipants during the analysis stage.
There is a potential of biased outcome reporting on
self-reported tobacco smoking or alcohol consumption
favouring the intervention arm. This will be minimised
by training the fieldworkers in open communication and
standardised data collection. Tobacco cessation will also
be verified by exhaled CO monitoring. Given the use of
the TB treatment record as a primary source of informa-
tion pertaining to TB outcomes, there is a risk of non-
differential misclassification. However, this risk is equal
in both the treatment and control arms and therefore
the decision has been taken that the TB treatment rec-
ord can be used as a primary data source (i.e. bias would
be towards the null).
Sample size
The sample size has been set at 696 participants (348 par-
ticipants per arm). This sample size is sufficient to
detect a 10% difference in TB treatment success rates
(0.86 vs 0.76) in the ProLife group versus the control
group with 80% power, a significance level of 0.05
and 25% attrition. The sample size per clinic was in
the range of 14–74 participants per clinic with a me-
dian of 24. The assumed success rates in the control
group are based on actual success rates in TB pa-
tients in the studied provinces.
Statistical analysis
We will summarise baseline data descriptively by trial
arm; however, we will not undertake statistical compari-
sons. For continuous measures, we will report means
and standard deviations (SD); for skewed data, we will
also provide medians and interquartile ranges. For cat-
egorical data, we will report counts and percentages. For
the primary outcome, we will conduct analysis on an
intention-to-treat basis. We will use binary logistic re-
gression to compare the main outcome between the
intervention and the usual care arm.
We will carry out similar analyses for the secondary
outcomes with appropriate regression techniques: logis-
tic regression for categorical outcomes and linear regres-
sion for continuous outcomes. We will also adjust for
baseline characteristics and other covariates (HIV status,
sex, alcohol versus tobacco versus both, district) if these
differ between trial arms at baseline.
In case of missing data, we will employ a number of
methods including multiple imputations to assess the
sensitivity of the results. We will conduct subgroup ana-
lyses to determine whether TB treatment outcomes dif-
fer between subgroups, as follows: HIV-positive versus
HIV-negative participants; participants with an alcohol
problem only versus smokers only versus participants
who are conjoint smokers and drinkers; and participants
who were GeneXpert positive versus participants who
were GeneXpert negative at baseline.
Table 2 Summary of methods of data collection and analysis for primary and secondary outcomes
Variable Method of data collection Method of data analysis
Primary outcome: TB treatment outcome as
defined by WHO and the South Africa TB
Management Guidelines (see Table 1)
• CRF and TB treatment record
• Treatment outcome as recorded by TB nurses in TB
cards using the standard WHO definitions of cure,
completions, failure, death, TB treatment
interruption, drug resistance developed in course of
treatment (confirmed for correctness by checking
sputum culture/smear at baseline, at 5 and 6
months)
Binary outcome: successful (cured of
completed) vs not successful (died, failure,
treatment interruption, drug-resistant TB)
All participants, excluding those transferred out
Secondary outcome: sputum conversion • Sputum culture/smear at baseline, 5 and 6months
to determine cure rates for PTB patients who had a
positive smear or culture at baseline
• Sputum conversion at 2–3 months
Binary cured vs not cured for the subgroups of
participants who had a positive smear/culture
at baseline
Binary conversion vs not for the subgroups of
participants who had a positive smear/culture
at baseline
Secondary outcome: change in smoking
behaviour
• CRF – questions as per Russell’s Standard – baseline
smoking behaviours and then at 3 and 6months
• Exhaled carbon monoxide reading at 3 and 6
months
Binary outcome validated 3 and 6months
sustained smoking cessation for the subgroup
of participants who were smoking at baseline
Secondary outcome: percentage reduction
in harmful or hazardous drinking (change in
AUDIT score)
• AUDIT score at baseline and at 3 and 6months Change in AUDIT score (continuous) for
subgroups of participants who were hazardous
or harmful drinkers at baseline
Secondary outcome: HIV and TB medication
adherence
• CRF – questions modified from ACTG Binary outcome (% adherent vs non-adherent)
Secondary outcome: proportion of HIV-
positive participants on ART
• HIV status at baseline
• ART status at baseline, 3 months and 6 months
Binary on ART vs not on ART for the subgroup
of HIV-positive participants, taking into account
baseline % on ART
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We will follow the CONSORT statement guidelines
in reporting. We will use the statistical packages
STATA and R to carry out the analyses and a P value
< 0.05 will be considered as statistically significant.
The statistical analysis pertaining to cost-effectiveness
will be described in the section detailing the planned
economic evaluation.
Monitoring
Each centre will be responsible for its own data entry
and local trial management. Monitoring and site training
will be carried out at each site within specified intervals.
The project manager will visit each district every third
month with the counselling supervisor. The district co-
ordinators will visit each clinic bi-weekly; the site leads
and data manager will visit the sites when required.
The monitoring will adhere to the principles of Good
Clinical Practice and will follow an agreed monitoring
plan. During their bi-weekly visits, the district coordina-
tors will be guided by a checklist to confirm adherence
to protocol, review eligibility verification and consent
procedures, and provide additional training as needed.
Any adverse events will be formally recorded and re-
ported where appropriate.
The mobile data collection tool was improved based
on findings from the pilot phase and feedback from the
field staff capturing the data. Validation was added to
the mobile questionnaires to ensure that all questions
should be answered, participants only answer question
relevant to them and that no unusual values (range
checks) are entered. Coordinators can use the mobile
data collection tool on their phones to monitor incom-
plete data activities, outstanding and upcoming appoint-
ments with participants and basic project performance
indicators per clinic.
The data captured during the interviews with the par-
ticipants are only captured on the electronic mobile data
collection tool and can therefore not be verified by the
site coordinators. However, the district coordinators will
require access to all (enrolled TB) patient medical re-
cords including, but not limited to, laboratory test re-
sults and prescriptions. They will do spot checks by
comparing the captured data with the medical records
and look for missed outcomes reporting: verify com-
pleteness; consistency; and accuracy of data being en-
tered on CRFs. The site leads (or delegated personnel)
should work with the district coordinators to ensure that
any problems detected are resolved.
The data will also be checked by the data manager for
missing or unusual values (range checks) and checked
for consistency within participants over time. If any such
problems are identified, the individual centres will be
contacted and asked to verify or correct the entry.
Indicators related to enrolment, premature withdrawal,
motivational interviewing completion, CRF completion
and SMS delivery will be analysed and included in
monthly reports.
As the ProLife programme is a low-risk intervention,
the decision was taken not to appoint an external data
monitoring committee.
Training and intervention fidelity monitoring
Eighteen LHWs, three district coordinators and one per-
son who will be focusing on counselling supervision
underwent MI training over five days, which covered:
basic knowledge of TB; treatment adherence; tobacco
and alcohol use; overview of the overall spirit of MI and
communication style; core interviewing skills; evoking
change talk, hope and confidence; developing a change
plan; and strengthening commitment. The LHWs’ know-
ledge in terms of TB, alcohol use, tobacco smoking, TB
and ART treatment adherence, and motivational inter-
viewing was assessed before and after the training
To ensure that all the essential steps, techniques and
skills of an MI session are covered during each session,
the LHWs will be provided with a checklist to use dur-
ing each session (Additional file 3). At the end of each
session, they will also complete a post-session semi-
structured form onto which they will indicate the extent
to which they implemented each element of MI, as well
as their general qualitative impressions of that particular
session.
During the trial, the LHWs will receive regular super-
visory support from the district and national study coor-
dinators. In addition, an appointed supervisor with
proficiency in MI will be providing monthly counselling
supervision to the LHWs in each site, by travelling to
each of the three sites and then providing support to the
LHWs in a group, followed by individualised support to
each LHW separately. All lay counsellors completed
grade 12 and have at least one year of prior counselling
experience in TB and/or HIV.
In order to assess the fidelity of the counsellors’ deliv-
ery of motivational interviewing during the trial, the vali-
dated Motivational Interviewing Treatment Integrity
Coding Manual 4.2.1 (MITI) tool will be used [41]. We
will tape record each LHW’s counselling sessions and
then randomly select 5% of each counsellor’s patients
and then use the recordings of all three sessions with
those patients for the MITI task. Those selected record-
ings will be transcribed and translated into English. Two
independent raters who are Setswana/Sesotho speakers
will listen to the recordings and code a randomly se-
lected 20-min portion of the written transcript. In the
case of shorter counselling sessions, the entire recording
will be assessed. The coding will entail making ‘Global
Ratings’ (on four dimensions: Cultivating change talk;
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Softening sustain talk; Partnership; and Empathy) and
‘Behaviour Counts’ (with respect to the items: giving in-
formation; persuade; persuade with permission; question;
simple reflection; complex reflection; affirm; seeking col-
laboration; emphasising autonomy; and confront). A
score will be assigned to each of these items and the
scores compared against the competency and proficiency
thresholds that are specified in the MITI manual.
Economic evaluation
The economic evaluation will be a within-trial incre-
mental cost-effectiveness analysis of the ProLife package
over and above usual care conducted alongside the RCT.
In each arm of the trial, we will estimate the costs of de-
livering the intervention to participants. Costs consist of
the delivery of ProLife intervention (staff costs, over-
heads and consumables) in the intervention arm and the
costs of behavioural support and support (staff time,
overheads and consumables) in the control arm. Costs
will be calculated based on the length of time of contacts
and the unit cost of the healthcare worker delivering the
intervention. These costs should demonstrate some
within patient variability as cost will be partly dependent
upon the length of the recorded appointments.
We will also record contacts with health services for
TB by patients in each trial arm, using the question-
naires adapted from those used in a previous trial of TB
[42]. Applying unit costs of healthcare to quantities re-
corded in the service use questionnaire will produce a
healthcare cost profile for each patient at baseline,
three-month and six-month follow-ups. Healthcare cost
profiles based on TB contacts can then be used to inves-
tigate differences in total costs between the treatment
and control groups. The base case analysis will use
healthcare costs as the study perspective. This is justified
by presenting the cost implications of delivering the
ProLife intervention from a healthcare decision maker’s
perspective. However, we will also record participants’
travel costs associated with making the journey to the
intervention site. This will estimate the wider societal
cost to patients associated with receiving treatment.
We will estimate the cost per additional successful TB
outcome by computing an incremental cost-effectiveness
ratio (ICER) combining treatment and wider healthcare
costs with outcome data from the trial. The analysis will
also use measures of health utility. We have registered on
the EuroQol website to use the country specific version of
EQ-5D-3 L for South Africa to measure health-related
quality of life at baseline, three-month and six-month
follow-ups. We will use EQ-5D-3 L to estimate changes in
quality-adjusted life years (QALY) using the area under
the curve by using the utility score at each time point to
create a profile [41]. A cost utility analysis is then per-
formed by combining incremental health outcomes using
QALYs with the incremental cost. The cost utility analysis
will estimate the cost per QALY that estimates the value
for money afforded by administering the ProLife interven-
tion over and above usual care. We will plot incremental
cost against incremental outcome using a cost-
effectiveness plane. We will also conduct sensitivity ana-
lyses to assess the robustness of the ICER and use boot-
strapping techniques to calculate cost-effectiveness
acceptability curves. Supporting analysis will also present
the costs to patients incurred by making visits to both trial
arms to present the wider cost burden. However, these
costs will not be included in the base case scenario as the
objective is to present the value for money from the per-
spective of the purchaser or commissioner.
Discussion
Ending the TB epidemic is one of the Sustainable
Development Goals (SDG) established by the United
Nations. The WHO calls for a 90% reduction in TB
incidence by 2030 compared to 2015 and has
highlighted the need for intensified research and
innovation. The WHO has recently published guid-
ance advocating the use of digital technologies, spe-
cifically mobile text messaging campaigns, in the
treatment of TB as a means of improving the provision of
patient-centred care and supporting medication adherence
[43]. This publication highlights advances in mobile tech-
nologies and network coverage as opportunities to more
effectively support patients during what can be a long
period of treatment. This study is well-aligned with this
guidance and, to our knowledge, this is the first trial look-
ing at a complex behavioural intervention aiming to use
MI techniques, alongside SMS, to modify a range of
harmful lifestyle factors with the aim of improving TB
treatment outcomes.
Work already undertaken in the formative phase sug-
gests that the ProLife intervention is feasible and accept-
able to patients. However, we anticipate some potential
procedural challenges throughout the trial as we recog-
nise that patients with TB may feel unwell and have
taken steps to ensure that the MI and data collection are
as brief and comfortable for patients as possible. The
district coordinators will call participants to follow-up
with those who missed appointments.
Implementing complex interventions in the real world
can pose logistical challenges and careful process evalu-
ation will be required to fully understand the challenges
that may be presented. However, there is evidence to
suggest that using MI techniques can be cost-effective
when implemented in healthcare settings and the
ProLife programme could represent a scalable and feas-
ible approach to improving the care of patients with TB
globally. Its scalability is particularly relevant in South
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Africa as the government plans to formally introduce
community health workers as part of its health workforce.
Trial status
Protocol Version 1.2, 5 January 2018. Recruitment on-
going; piloting started at 30 clinics: 7 May 2018 and was
completed by 31 August. The actual trial enrolment
started on 13 November 2018. We expect to enrol the
target sample size by May 2019 and plan to continue
with follow-up until December 2019. The trial was
piloted internally from May 2018 until the end of August
2018; piloting results will be reported at a later stage, to-
gether with the trial results.
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